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ABSTRACT
Epithelial Ovarian Cancer (EGG) remains the most lethal o f gynaecological cancers with 
4295 deaths in 2010 in the UK. There is ongoing research for novel biomarkers as these are 
needed to improve the management o f this disease which is characterised by development 
of drug resistance. Previous work suggested that cell cycle dysregulation is associated with 
anticancer drug resistance. Both and cyclinE as key players in cell cycle, were
considered as potential markers of chemoresponse and disease progression in EGG in the 
present thesis.
In order to evaluate the utility o f biomarkers (p57^‘^  ^and Gyclin E), immunohistochemistry 
(IHG) was used to assess the expression levels in tissue sections from a cohort of 250 
women with a confirmed diagnosis o f EGG. This included the establishment o f a robust 
scoring system for the assessment of expression levels of either p57^'^^ or cyclin E. In 
addition, the study involved the setting up of an extensive database of clinico-pathological 
data for each patient. With appropriate statistical management of the data, associations 
between expression levels of p57^'^^ and cyclin E in relation to disease stage, histological 
type, prognosis and survival were made to enable the assessment o f each parameter as a 
potential biomarker in EGG.
The study observed that high cyclin E levels were associated with poor prognosis in 
agreement with the literature for other tumour types; however, this did not reach levels of 
statistical significance to enable predictive modelling. Importantly, the data obtained for 
p 5 7 kip2  j.gygaled that high expression was associated with lower grade, earlier FIGG stage and 
better prognosis, reaching high levels of statistical significance.
Predictive modelling using clinicopathological data and expression levels was used to 
compute survival and this model is currently being tested and validated (in further work 
beyond the scope of this thesis). In Stage I EGG where the role o f adjuvant chemotherapy on
survival remains unclear, expression may help to influence decision making and
larger studies are required to explore this further. This study encompassed the largest cohort 
o f EOC patients for the assessment o f either cyclin E or according to current
literature.
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This chapter offers a general overview of the anatomy and physiology of the ovary, 
details the epidemiology of ovarian cancer and discusses the management of ovarian 
cancer.
1.1. Background
Cancer is the second leading cause of death. Human cancer is probably as old as the 
human race. The world's oldest documented case of cancer hails from ancient Egypt, in 
3000 B.C. Earliest evidence is found in fossilized bones and Egyptian mummies. The 
ancient Egyptian physicians treated patients for several forms of cancer. Hieroglyphic 
inscriptions and papyri manuscripts suggest that these ancient physicians were able to 
distinguish between benign and malignant tumours. They suggested that surface tumours 
may be removed surgically much similar to the current medical practice. The word tumour 
is derived from the Latin word for ‘swelling’. In traditional medical terms, it meant 
abnormal swelling and was associated with the four cardinal signs of acute inflammation 
(calor, rubor, dolor and tumour) as described by Celsus the Roman medical encyclopaedist 
(30BC-38AD). Today it is used synonymously to cyst filled growths and cancerous or pre- 
cancerous neoplasms. Neoplasm is derived from Greek. Neo means ‘new’ and plasma 
means formation or creation and suggests growth o f an abnormal mass of tissue as a result 
of neoplasia which is abnormal cell proliferation. A neoplasm may be benign, pre- 
malignant (also known as carcinoma in-situ) or frankly malignant.
Hippocrates, the Greek physician and “Father of Medicine” (460-370 B.C), noticed that 
blood vessels around a malignant tumour looked like the claws of crab. He named the 
disease karkinos (the Greek name for crab) to describe tumours that may or may not 
progress to ulceration. In English, this term translates to carcinos or carcinoma. Later, 
Galen (130-200 AD) used the word oncos (Greek word for swelling) in describing 
tumours. The crab analogy of Hippocrates is to date used to describe malignant tumours
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and Galen’s description is reserved for physicians specializing in cancer treatment 
(oncologists).
During the Renaissance period beginning in the 15th century, autopsies were allowed 
which led to better understanding o f the anatomy and physiology of the human body. John 
Hunter (1728-1793) the famous Scottish surgeon recommended surgical removal of some 
cancers and described surgical techniques. He felt "If the tumour had not invaded nearby 
tissue and was ‘moveable’ -  there was no impropriety in removing it” recommending that 
surgery was reasonable treatment for non-metastatic tumours which had not yet invaded or 
fixed themselves to the underlying tissue. In the late 19th century, Rudolph Virchow 
recognized that cells, even cancerous cells, were derived from other cells.
This started an era, which has seen the advancement of surgery and development of 
rational therapies based on clinical observations (Imbault Huart 1984, Raven 1990 and 
Olson 2009).
1.2. Ovary
1.2.1 Anatomy of the Ovary
The ovaries are a pair o f small oval shaped female reproductive organs homologous to the 
testes in the male. They are greyish-pink in colour measuring 4x2x0.8 cms with an uneven 
surface and weigh 2-5gms. They normally enlarge in pregnancy and shrink after 
menopause. Each ovary is located in the lateral pelvic wall in a shallow depression known 
as the ovarian fossa (Figure 1.1).
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Figure 1.1: Female pelvic anatomy (Adapted from www.webmd.com - permission
requested)
In the newborn, ovaries are extrapelvic organs and gradually descend into the pelvis 
during the prepubertal period. They are attached to the uterus (womb) by the fallopian 
tubes or oviducts, which carry the eggs into the uterine cavity. In the erect posture the long 
axis of the ovary is vertical (Figure 1.2).
Figure 1.2: Attachments of the ovary in the female pelvis (Adapted from Grays 
Anatomy 2008- permission requested)
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1.2.2 Blood & Nervous Supply
Offshoots of the abdominal aorta, the ovarian arteries and the ovarian branch of the uterine 
artery meet and anastomose in the mesovarium and mesosalpinx supplying the ovaries and 
fallopian tubes with blood. Ovarian veins parallel the arterial route and form a tangled 
network in the broad ligament known as the pampiniform plexus (Figure 1.3).
Sympathetic nerves that supply the ovaries are branches of the inferior hypogastric nerve, 
the pelvic plexus (network), the ovarian plexus, and uterine nerves within the fallopian 
tubes.
Figure 1.3: Ovarian blood supply (Adapted from Grays Anatomy 2008- permission
requested)
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1.2.3 Embryology
Genetic sex is determined at fertilization. However, the gonads can be differentiated at 
week 7 and gender is not apparent until week 12 of embryonic life. By week 6 of 
embryonic development, both male and female embryos develop the same structures on 
either side of the midline (Figure 1.4).
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1. Genital ridge (proliferation of coelomic epithelium)
2. Mesonephric (Wolffian) duct (lateral to the genital ridge)
3. Paramesonephric (Mullerian) duct
Figure 1.4: Early embryonic development (Adapted from Grays Anatomy 2008)
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One of the critical events in sexual differentiation occurs in the seventh week. Embryos 
which contain the Y chromosome have a specific gene known as sex-determining region Y 
(SRY). This gene for a testes determining factor (TDF) determines the path of formation of 
testes. SRY is expressed in the mesenchyme and is expressed immediately. SRY will 
always cause a cascade of events leading to the formation of internal male organs. In the 
absence of SRY, a female embryo will develop though the ovaries are not identifiable until 
the twelfth week (Figure 1.5).
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Figure 1.5: Schematic representation of differentiation into the male and female
reproductive system
Formation of gonads -  5 weeks
Gonad
^    Mullerian duct
Mesonephros 
Wolffian duct
Urogenital sinus 
Ureter
Male genital system Female genital system
ProstatIc _
utricle
Testis
Ductus
deferens
Ovary
uterine tube
Uterovaginal
canal
Ureter
Solid vaginal plate
1.2.4 Histology of the Ovary
Ovarian epithelium or serosa is covered by a single layer of cells which is a highly
specialised mésothélial layer. The cells are cuboidal in young women flattening out once
menarche occurs due to the influence of the various hormones.
Figure 1.6: Histology of normal ovary (Adapted from 
http://siumed.edu/dking2/erg/RE007b.htm- Permission requested)
The germinal epithelium of Waldeyer is a layer o f columnar cells which covers the 
ovarian surface. (Figure 1.6, 1.7) A number of vesicular ovarian follicles imbedded in the
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meshes of a peculiar soft tissue stroma with rich vascular supply consisting mostly of
spindle shaped fibrocyte cells and small amount of connective tissue. Tunica albuginea is
the superficial cortex containing collagen.
Figure 1.7: Histology of a postmenopausal normal ovary with thinned out germinal 
epithelium (H & E stain at lOx magnification- JPEG size 574*429pixels)
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The cells of the ovarian follicle are the oocyte, granulosa cells and the cells o f the internal 
and external theca layers. An external fibrovascular coat surrounds the larger follicles 
(Figure 1.8). The membrana granulosa is the internal coat made up of layers of nucleated 
cells. At one area, the membrana granulosa cells project into the follicle cavity called 
discus proligerus embedding the ovum. The nucleus of such an oocyte is called a germinal 
vesicle.
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Figure 1.8: Ovarian follicle (Adapted from Grays Anatomy 2008)
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A mature Graafian follicle contains the secondary oocyte and is released each month. Only 
following successful sperm fertilisation, a zygote is formed. If unsuccessful, corpus luteum 
is formed and menstruation occurs.
In summary, the ovary consists of 3 types of cells:
• Epithelial cells, surrounding the ovary on the surface
• Germ cells responsible for eggs (ova) formation within the ovary
• Stromal cells holding the ovary together and responsible for female hormones
production.
1.3 Function of the ovary
1. Ovaries produce mature ova (eggs) which, when fertilized, will develop into a foetus
2. Secretion of steroid hormones
3. Stimulation and growth of reproductive hormones oestrogen and progesterone
4 . Development of secondary sexual characteristics
5. Maintenance of the implanted blastocyst
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1.4 Ovarian Cysts
Any fluid filled collection within or on the ovary is called an ovarian cyst. Ovarian cysts 
are common and affect women of all ages and are mostly benign functional cysts. Ovarian 
cysts are simplistically divided into functional and non-functional cysts.
Functional cysts comprising of Follicular cysts and Corpus luteum cysts 
Non-functional cysts vary from polycystic ovaries, endometriotic cysts (chocolate cysts), 
benign epithelial tumours (cystadenoma) and borderline epithelial tumours to epithelial 
ovarian cancer (cystadenocarcinoma) and are described in detail later on in this chapter on 
Page 42.
For a cell to become malignant it has to acquire several key properties and cell cycle 
dysregulation is the key phenomenon in cancer development and is discussed in the next 
section below.
1.5 The Hallmarks of Cancer
Hanahan and Weinberg in their landmark paper on the hallmarks of cancer in 2000 
suggested that six essential cell cycle physiological alterations led to cancer development 
as shown below (Figure 1.9). (Hanahan et al 2000)
Figure 1.9: Acquired capabilities of Cancer (Adapted from Hanahan et al 2000)
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Dysregulation o f the cell cycle as shown above are essential for the oncogenic process. Ten 
years on, they suggested that the constitution and signalling interactions o f the tumour 
microenvironment are two new hallmarks which enabled acquisition of the six hallmarks 
previously described crucial to oncogenesis. (Hanahan et al 2010)
1.6 Aetiology of Cancer
The cause of cancer has puzzled physicians over centuries. The Gods were blamed by the 
ancient Egyptians. Over the centuries, several other theories have been proposed and they 
include the following:
H um oral Theory: This theory was proposed by Hippocrates who felt that the body had 4 
types o f body fluids (humors). Disproportionate balances in any o f the 4 were considered to 
cause cancer and this theory was unchallenged through the Middle Ages for nearly 1300 
years.
Lym ph Theory: The lymph theory gained continuing support based on the theory that 
cancer was composed of fermenting and degenerating lymph in varying degrees o f density 
and pH.
Blastema Theory: Johannes Muller a German pathologist in 1838 showed that cancer was 
actually made of cells that were not normal rather than lymph fluid as previously thought 
proposing that cancer cells developed from blastema (budding elements) between normal 
tissues. His student Robert Virchow was instrumental in determining that cancer cells were 
derived from previously normal cells that had undergone some change within them to 
develop into a cancerous cell.
Chronic Irrita tion  Theory: Virchow incorrectly believed that cancer spread like a liquid 
and that métastasés occurred through the spread of malignant cells was first proposed by 
German surgeon Karl Thiersch in the 1860’s.
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T raum a Theory: Until late 1920’s trauma was considered to be the cause o f cancer though 
it was irreproducible in experiments.
Infectious Disease Theory: Following the diagnosis o f cancers in a household, Zacutus 
Lusitani and Nicholas Tulp from Holland proposed that cancer was contagious. Isolating 
cancer patients and moving cancer hospitals to city outskirts was part o f the contagion 
theory. (Olson 2009).
1.6.1 Aetiology of Epithelial Ovarian Cancer
Today, the aetiology of epithelial ovarian cancer (EOC) remains unknown and various 
hypotheses have been considered and are mentioned below. The most commonly accepted 
theory is that most o f these malignancies arise from the cells covering the ovarian surface. 
Malignant transformation of the surface epithelium explained by the “incessant ovulation 
theory” suggests that ovulation causes surface epithelium disruption leading to reparative 
proliferation. Being “generative” stem cells, the newly formed epithelial cells proliferate in 
response to any additional trauma caused by further ovulations. Continuous disruption and 
repair might trigger mutations and oncogene activation, inactivating tumour suppressor 
genes resulting in carcinogenesis which is invariably accompanied by cell differentiation 
change (Henderson et al 1982, Purdie et al 2003).
Embryologically, the Ovarian Surface Epithelium (OSE) is derived from the coelomic 
epithelium (which gives rise to Mullerian ducts). Progression of the OSE towards 
malignant change causes it to acquire the characteristics of Mullerian duct epithelium i.e. 
serous (like fallopian tube), endometrioid (endometrium like) and mucinous (endocervical 
like). Classification of ovarian cancer (OC) is based on this aberrant de-differentiation.
The incessant ovulation theory is supported epidemiologically by the risk factors for OC as 
summarised in Table 1.1.
1 2
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Uninterrupted ovulation increases risk (1.5-3.2) as seen with nulliparity and ovarian 
stimulation with drugs (e.g.clomiphene citrate) inducing ovulation but not subsequently 
leading to pregnancy for various reasons. Similarly, contrary to popular belief, decreased 
risk is noted with using oral contraceptives (OCP) (0.4-0.7) (Purdie et al 2003). Oestrogen 
taken in the premenopausal period as an OCP is protective while taken as post- menopausal 
hormone replacement therapy confers increased risk. This is attributed to maintenance of 
the ovarian surface epithelium by OCP by preventing ovulation.
Table 1.1 showing risk factors supporting incessant ovulation theory
Ovarian Cancer (aetiology) 
Incessant Ovulation 
Surface-epithelium ►Mullerian differentiation 
Nulliparity (1.5-3.2) |  
|Oral Contraceptives (0.4-0.7) 
t Ovulatory Drugs (nonpregnant) 
I Gonadotrophins
Progesterone Hypothesis
Progesterone or progestins confer protection and appear to reduce the risk of OC (Risch 
1998). Animal studies with hens showed that administration of progesterone reduces the 
rate of OC. Increased circulating levels o f progesterone during pregnancy, oral pill 
consumption and depot medroxyprogesterone acetate use are associated with reduced 
levels of OC in various case-control and epidemiological studies (Rosenberg et al 2001, 
Barnes et al 2002 and Pearce et al 2009).
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Androgen Receptor Hypothesis
Most OC display varied levels o f androgen receptor (AR) expression. The binding of 
androgen to AR results in the expression of target genes (Risch et al 1998 and Ligr et al
2011). Higher risk of OC is noted in the post-menopausal woman when the primary 
steroids secreted by the ovary are androgens such as testosterone and androstenidione 
(Ahonen et al 2000). Eighty-four percent o f OC expresses AR. Factors that increase 
androgen levels like PCOS are associated with higher risk o f OC as seen in 
epidemiological studies and the OCP by reducing the level of androgen confers protection. 
(Murphy et al 1990, Olsen et al 2008 and Schildkraut et al 1996).
Gonadotrophin Hypothesis
Studies in the early 1990s suggested an increased risk of OC following gonadotrophin use 
especially with fertility drugs (Cramer et al 1983 and Capen et al 1995). More recent 
epidemiological studies including the Danish population based cohort study by Jensen et al 
reassuringly did not find any increased risk (Jensen et al 2009).
1.6.2 Origins of OC and models of Carcinogenesis
1.6.2.1 Histogenesis (Table 1.2)
That OC may develop de novo (Bell et al 1994) was a concept that has been disproved. 
Pre-existing benign tumours can develop into OC (Kuhn et al 2012 and Nowak- Markitz 
2012). In favour of the latter are the higher average age of women with OC as compared to 
benign tumours and a finding of benign components on histology in a high number o f OC 
exhibiting the focal, abrupt transformation from benign to malignant epithelium 
(McCluggage 2011 and Kurman et al 2012).
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Table 1.2: Histogenic model of Ovarian Cancer 
Ovarian Cancer (histogenesis)______________________
De Novo 90%
From benign and borderline tumours (10%)
- OC in older women
- Benign and borderline components histologically
1.6.2.2 Somatic Genetics
Research continues into the role of oncogenes and tumour suppressor genes in ovarian 
carcinogenesis (Kuhn et al 2012 and Kurman et al 2012). Speculation exist that gene 
responsible for familial OC may be involved in sporadic cases of OC (Wysham et al 2012). 
OC appears to rise from the stepwise accumulation o f gene mutation controlling the 
epithelial-cell proliferation, differentiation and apoptosis. According to the “incessant 
ovulation theory” continuous repair can trigger mutation and Loss of Heterozygosity 
(LOH) in 17q and 13q may cause malignant transformation.
Table 1.3: Pathogenesis of Ovarian Cancer
Ovarian Cancer (pathogenesis)
LOH at 17q21 (BRCA-1) 75%
BRCA -1 promoter hypermethylation 30%
LOH at 13q (BRCA-2) 30%
c-erb B-“ (Her 2/neu) amplification/overexpression (22-61 %)
K-ras (codon 12) mutations in mucinous tumours, benign, borderline and malignant (68%) 
P53 LOH, mutations and overxpressions (68%)
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1.7 Epidemiology of Ovarian Cancer
1.7.1 Incidence
In 2008, ovarian cancer accounted for 225,000 new cases worldwide. Ovarian cancer is the 
fourth most common cancer overall in women after breast, bowel and lung cancer and the 
second common gynaecological cancer after uterine cancer. It appears to be a disease o f the 
western world with increased predominance in Europe and America and least incidence in 
Asia and Africa. The distribution for OC incidence and mortality in the EU is depicted in 
Figure 1.10 on the next page.
In the UK, there were 6955 new cases o f ovarian cancer diagnosed in 2009 and 4295 
women died o f ovarian cancer in 2010 (Cooper et al 2008, Jemal et al 2009, Office of 
National Statistics, ISD Online). Table 1.4
Table 1.4: Overall Ovarian Cancer statistics table
Ovarian cancer - UK Females
Number o f new cases (UK 2006) 6955
Rate per 100,000 population* 17.2
Number o f deaths (UK 2007) 4,295
Rate per 100,000 population* 9.1
1 year survival (for patients diagnosed 2005-2009) 72.3%
5 year survival (for patients diagnosed 2005-2009) 42.9%
10 year survival rate (for patients diagnosed in 2007, England & Wales) 35.4%
The crude incidence rate in 2008 per 100,000 women in the UK distributed by region is 
shown in Table 1.5.
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Table 1.5: No. of new cases, crude incidence rates per 100,000 in UK
England Wales Scotland Northern
Ireland
United
Kingdom
Cases 5304 400 648 185 6537
Crude Rate 20.3 26.1 24.3 20.5 20.9
Figure 1.10: showing incidence and mortality for OC in the EU. The arrow shows UK 
having high rates of incidence and mortality. (Adapted from Cancer Research UK
accessed 15^  ^October 2012)
Age-standardised (European) Incidence and mortality rate for ovarian cancer, EU-27,2008 estim ates
Age-standardised (European) incidence and mortality rates, ovarian cancer, EU-27,
2008 estim ates
HJ-27 Country M ortality ncldence
Cyprus 5,5 6,9
Portugal 4,7 7,3
H ie Netherlands 8,3 9,9
France 6,3 10,7
Spain 5,7 10,8
Italy 6,0 11,6
Austria 7,8 12,2
Finland 8,3 12,3
Sweden 8,9 12,3
Belgium 8,2 12,8
Romania 7,0 13,0
EU-27 7,6 13,5
Malta 9,5 13,6
rtjngary 8,3 13,7
Germany 7,5 13,7
Greece 6,3 13,8
Slovenia 8,7 14,0
Estonia 10,4 14,4
Slo\^kia 8,5 15,5
Denmark 10,1 15,7
Luxembourg 8,7 16,4
Poland 10,1 17,0
United Kingdom 9,6 17,5
Czech Republic 9,9 17,6
Ireland 12,2 18,2
Bulgaria 6,6 18,5
Lithuania 10,4 18,7
Latvia 10,1 19,3
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Epithelial ovarian cancer (EOC) accounts for more than 90% of all OC overall, germ cell 
tumours constitute the remaining 2-3% and sex-cord stromal tumours 5-6% in developed 
countries.
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1.7.2 Mortality
Ovarian cancer is a major cause of mortality and morbidity. Worldwide, there were 
140,100 deaths in 2008 from OC. Of these 29,000 deaths occurred in the EU alone. 4373 
deaths from OC were recorded in 2008 in the UK. Worldwide, more deaths occur from OC 
than any other gynaecological cancer.
OC tends to be predominantly a disease of older, postmenopausal women with more than 
85% of cases being diagnosed in women over 50 years and the highest incidence appears to 
be in women over 65 years.
Figure 1.10: Cases and deaths from gynaecological cancers in the UK
(Acknowledgement: CRUK accessed 15^  October 2012)
2007 incidence 2008 mortality
Site Number of cases
European age- 
s tandardised rate 
per 100,000 women
Number of 
deaths
European age- 
s tandardised  rate 
per 100,000 wo me
Ovary 6,719 17.0 4,373 " 9.7
Lite ms 7,536 19.3 1,741 3.5
Cervix . 2 J 2 8 .. . . . . . 8.4, 1 957 2.4 1
Vulva 1,120 2 4 400 0.7
Vagina 243 0.6 77 0.1
Table 1.6: Rapidly decreasing survival with increasing FIGO stage
(Acknowledgement: CRUK accessed 15^ *^  October 2012)
Stage at diagnosis Number of cases % of all cases 5-year relative survival (%)
Stage I 424 29 92.0
Stage II 62 4 55.1
Stage III 652 45 21.9
Stage IV 216 15 5.6
Unstaged 89 6 27.6
All stages 1,443 100* 43.5
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1.7.3 Survival
The most important factor determining survival is the stage at diagnosis. In women 
diagnosed with early [Stage I] OC, the 5 year survival rate is greater than 80%. This rapidly 
decreases to 15-20% for women diagnosed with advanced stage disease [Stage III & IV] 
(Table 1.6 and Figure 1.11)
Figure 1.11: Decreasing 5 year survival with stage.
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Improvements in survival have been noted since 1980s as shown in Figure 1.12 below 
which may be a result of increased awareness and referral, aggressive management and 
centralisation of cancer services.
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Figure 1.12: 5 year survival for OC by stage over time (Acknowledgement: CRUK
accessed 15^ *^  October 2012)
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As shown on the following page (Figure 1.13), age at diagnosis appears to play a role in
survival as well with older women having lower 5 year survival rates.
Figure 1.13: Worsening survival with age (Adapted from CRUK accessed 15‘*’ October
2012)
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The overall 5 year survival trends are much more encouraging with increased rates from 
20% in the 1970’s to nearly 40% for women diagnosed from 2001 onwards with
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centralisation of cancer services, improvements in the management and treatment of OC 
(Figure 1.14).
Figure 1.14: Improving 10 year UK survival rates (Adapted from CRUK accessed 15
October 2012)
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1.8 Risk Factors
There are no specific indications leading to OC but several risk factors have been linked 
and believed to exert an influence leading to the development of OC (Pieta et al 2012, Prat
2012). Environmental, dietary, genetic and lifestyle factors all seem to influence OC risk. 
Many determinants of OC are established at a young age- in the 2"  ^ and 3*^  ^decades o f life 
and appear to have long-lasting effects (Barnes et al 2012, Gajjar et al 2012).
The commonest risks as summarised by the American Cancer Society are tabulated in 
(Table 1.7).
Table 1.7: Risk factors for OC as classified by the American Cancer Society
Age OC tends to occur in the post-menopausal period.
Obesity Studies suggest that higher rate of death occurred in 
overweight women (rising by 50% in the heaviest women)
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Menstrual Periods Early menarche and late menopause is associated with 
increased risk
Smoking & Alcohol Use Associated with increased risk of a certain OC (mucinous)
Fertility Drugs Appear to increase risk o f EMP tumours
Family History OC risk higher in women whose first degree relatives have 
suffered from the same
Breast Cancer Genetic association leading to increased risk (BRCA gene 
mutation)
The risks are further divided by the strength o f association and direction o f association as 
shown in Table 1.8.
Table 1.8: R isk factors for OC by direction of association
Increases Risk Decreases Risk
Probable risk Family history of OC Tubal ligation or hysterectomy 
with ovarian conservationNulliparity
HRT
Height/tallness Oral contraceptives
Tobacco
Asbestos
Possible risk Fertility drugs 
Obesity
Breastfeeding
Diet/ Physical Activity
Reproductive Variables
Decreased OC risk is strongly linked with parity. Risk reduction (RR) of 40-60% occurs 
with a single pregnancy. Each additional pregnancy further decreases the RR by 10-15% as 
pregnancy has a protective effect (Chiaffarino et al 2005, Danforth et al 2007, Titus- 
Ernstoff L et al 2009). Nulligravid women due to infertility, subfertility or reproductive 
choice are at a higher risk. Higher risk among infertile women supports the possible role o f
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abnormal endocrine factors (Fathalla et al 1971, Salehi et al 2008 and Sueblinvong et al 
2009).
Oral contraceptives also lower the risk of OC by decreasing the number o f lifetime 
ovulations. Frequent ovulation contributes to increased risk as every rupture and repair of 
the OSE at the ovulation sites provides an opportunity for the development o f genetic 
aberrations. All o f these reproductive variables may coalesce as the total number o f lifetime 
menstrual cycles (Tworoger et al 2007, Beral et al 2008).
Increasing androgen levels through drugs (Danazol) appear to increase OC risk (Beral et al 
2007).
Hormone Replacement Therapy (HRT) and OC risk is still a controversial subject. The 
Million Women Study concluded that women using HRT are at an increased risk o f OC. 
Higher risk appears to be associated with oestrogen only HRT as compared to a slightly 
lower risk with combined oestrogen and progesterone HRT (Beral et al 2007, Pearce et al 
2009, Parkin et al 2011).
(Whittemore et al 1992 Stratton et al 1998, Ness et al 2002, Olsen et al 2007, Pearce et al 
2009, Cibula et al 2010 and Eahmann et al 2010)
Gynaecologic surgery
Simple hysterectomy or tubal ligation appears to reduce the RR of developing OC by 30- 
40%. The reason is unknown however; reduced ovarian blood flow may be a possibility 
leading to alteration of the hormonal environment (Finch et al 2006, Tworoger et al 2007) 
or by reducing the passage of environmental initiatiors of inflammation (Auesperg et al 
2001).
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Age
OC is uncommon in women younger than 40 years of age. OC risk increases with age and 
most OC develop after the menopause. Half of all OC are found in women over the age of 
63 (Purdie et al 2003, Salehi et al 2008).
Diet
Some studies have shown a reduced rate of OC in women, who ate a diet high in 
vegetables, but other studies disagree and the evidence is somewhat equivocal (Kaushik et 
al 2005, Schulz et al 2005, Foschi et al 2010).
Obesity
Various studies suggest that overall, obese women with Body Mass Index (BMI>/= 30) are 
at a higher risk of developing OC (Schouten et al 2008). The Million women and EPIC 
study also found a higher rate of death from OC in obese women with the risk increased by 
50% in the heaviest women (Reeves et al 2007, Eahmann et al 2010). This is likely to be 
associated with the increased circulating oestrogen levels from the adipose tissue which 
have been known to be a source of oestrogen as evidenced by the association between 
adiposity and endometrial cancer.
1.8.1 Host Factors for developing OC
Family history ofOC is a strong risk factor for developing OC. Women with first degree 
relative are at a 3 times increased risk (Granstrom et al 2008 and Gayther et al 2010). 
Women with relatives diagnosed before the age o f 50 are at a particularly higher risk.
BRCA 1 and BRCA 2are the commonest breast cancer susceptibility genes known to us. 
Women inheriting a mutation in the autosomal dominant BRCA 1 or BRCA 2 are at a 15- 
40% absolute risk o f developing OC with the increased risk being for BRCA 1. Both BRCA 
1 and BRCA 2 are tumour-suppressor genes appearing to preserve the ability of cells to 
efficiently repair double stranded (ds) DNA breaks. Although expressed in many tissues,
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mutations are highly associated with ovarian, fallopian tube, primary peritoneal and breast 
cancers (Gayther et al 2008, Tan et al 2008 and Alsop et al 2012).
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch Syndrome represents 10% 
of hereditary OC. The lifetime risk of OC in women with HNPCC is 8-15% (Engel et al 
2012 and Win et al 2012).
There is ongoing research into genetic counselling, genetic testing, and strategies for 
preventing OC in women with an increased familial risk and the approximate lifetime risk 
of developing EOC is shown in Table 1.9 (Taylor et al 2012).
Table 1.9: Approximate lifetime % risk o f developing OC
General Population 1.6%
1 first degree relative affected < 55yrs 5.2%
1 first degree relative affected > 55yrs 3.4%
2 first degree relatives affected 7%
BRCA 1 carrier 28-44%
BRCA 2 carrier 27%&
HNPCC carrier 12%
Talcum powder
Talcum powder applied directly to the genital area may be carcinogenic to the ovaries. 
Some studies including a meta-analysis in 2003 suggest a slight increase in risk o f OC in 
such women. In the past, talcum powder was sometimes contaminated with asbestos, a 
known cancer-causing mineral which may explain the association with OC in some studies 
(Ness et al 2000, Huncharek et al 2003). However, it is likely that this might be a result o f 
chronic irritation.
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Smoking and alcohol use
These do not increase the risk for most OC, but some studies have found they increase the 
risk for the mucinous subtype (Jordan et al 2006, Olsen et al 2007, Secretan et al 2009, 
Parkin et al 2011 and Barry et al 2012).
1.9 Diagnosis of Ovarian Cancer
1.9.1 Symptoms and Signs
Ovarian cancer symptoms are typically vague and non-specific often resulting in 
misdiagnosis and late presentation resulting in poor prognosis. OC has been called a ‘silent 
killer’ for this reason however, most patients do present with some symptoms prior to 
diagnosis (Goff et al 2004, Bankhead et al 2008 and Hamilton et al 2009). Because the 
symptoms are not obviously gynaecological the women with OC are often initially 
misdiagnosed as gastrointestinal disturbances such as irritable bowel syndrome (IBS). 
There is an awareness drive by various charities to improve awareness o f OC among the 
general public in the hope that the diagnosis may be made earlier in more women as the 
majority of women are diagnosed with advanced stage disease at presentation (Goff et al 
2007, Eve appeal 2008, DoH 2009 and Gajjar et al 2012).
In early stage disease, often in premenopausal women, irregular menstrual cycles may 
occur. The commonest symptoms tend to be pressure symptoms secondary to a pelvic mass 
compressing the bladder or rectum. Rarely acute pain secondary to ovarian torsion or 
rupture of a cystic tumour may occur.
The presentation o f advanced disease is related to spread o f the disease causing pleural 
effusion, ascites, and omental or bowel métastasés. The symptoms may include shortness 
of breath, abdominal distension, bloating, loss of weight or appetite, nausea, vomiting or 
constipation. The non-specific nature of these symptoms unsurprisingly tends to be put
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down to irritable bowel syndrome until more obvious clinical signs occur. Goff et al 
showed that in a survey o f women with OC, 70% reported gastrointestinal (GI) symptoms, 
58% reported pain, 34% urinary symptoms and 26% reported some form o f pelvic 
discomfort (Goff et al 2000 and Goff et al 2007).
Clinical signs include a palpable pelvic mass, which may be fixed within the pelvis, with 
ascites present on abdominal palpable and sometimes breathing difficulty due to pleural 
effusion with poor air entry and dullness on percussion of the chest wall. A cake o f omental 
tumour resulting in abdominal fullness may also be palpated in the upper abdomen.
1.9.2 Investigations
Surgery via laparotomy remains the gold standard for diagnosis and staging o f OC. 
However, this is associated with significant morbidity if undertaken for every pelvic mass. 
This is carried out along with pre-operative investigations including serum markers, 
imaging and biopsies to triage pelvic masses.
Serum tumour markers are commonly employed when a pelvic mass is found on clinical 
examination or imaging. The commonest used such marker is CA-125 whichis an antigen 
that is derived from the coelomic epithelium (Jacobs et al 2000). CA-125 is not a very 
specific tumour marker, however, and many benign ovarian as well as non-ovarian 
conditions may cause elevated marker levels including fibroids, pregnancy, rheumatoid 
arthritis and heart failure (Dauod et al 1991, Sturgeon 2002). Other malignancies such as 
metastatic colorectal as well as breast cancers may also produce an elevated CA-125 level 
(Cartel et al 2012 and Pinksy et al 2012). Bast et al demonstrated elevated serum CA-125 
levels more commonly in women with EOC (82%) as compared to the general population 
(1%), in women with benign disease (6%) or in 28% of cases with non-gynaecological 
malignancies (Bast et al 1983). Other tumour markers that can help to distinguish primary 
ovarian tumours from potential metastasis from another site are CEA (colorectal), CA 15-3
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(breast) and CA 19-9 (pancreatic) (Duffy et al 2006 and Goonetilleke et al 2007). In EOC, 
serum tumour markers are useful in assessing response to treatment as well as monitoring 
disease progression, and may be used as part o f an algorithm to attempt to differentiate 
between benign and malignant ovarian masses (RMI) at presentation (Davies et al 1993, 
Tingulstad 1996, Menon et al 2009 and Hâkansson et al 2012). This index may be useful 
to help guide clinicians as to which patients would benefit most from referral to a cancer 
centre for appropriate surgery by sub-specialist surgeons, and which may safely be 
managed in a smaller unit by their general gynaecologist.
Another marker currently being investigated is the Human Epididymal protein {HE 4}. 
(Langmar et al 2011, He et al 2012 and Karlsen et al 2012).
Ultrasound scan (USS), preferably in the form o f transvaginal scanning, is the first line 
imaging modality for OC and the most sensitive with which to assess suspicious ovarian 
masses. USS may help to determine the origin of the pelvic mass and its nature (Veyer et al 
2010 and Fleischer et al 2012). In difficult cases magnetic resonance imaging (MRI) scans 
may be complementary (Dodge et al 2012.). Computed tomography (CT) scans are 
commonly employed to assess the anatomical extent of disease spread (Chi et al 2007 and 
Lakhman et al 2012). Various features on the USS increase the index of suspicion for OC 
(see Risk o f Malignancy Index below).
Image-guided biopsies are more commonly being used to confirm OC diagnosis especially 
when extensive disease has already been noted on imaging. These are performed either 
with ultrasound or CT guidance with aspiration of ascitic fluid or biopsies o f the pelvic 
mass or omental cake. A tissue diagnosis confirmation is preferable prior to commencing 
neoadjuvant chemotherapy (NACT) or embarking on primary debulking (PD). Recruitment 
to therapeutic clinical trials in OC necessitates a histological confirmation.
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1.9.3 Risk of Malignancy Index
Risk of Malignancy Index (RMI) is currently the best available tool for stratifying patients 
into high and low risk groups. Jacobs et al first proposed this in the early 1990s and it has 
been in use since (Jacobs et al 1996 and Hakansson et al 2012). RMI is calculated as a 
product of the ultrasound scan score (U), the menopausal status (M) and the serum CA125 
level (lU/ml). RMI = U x M x CAI25. Two scoring systems RMI 1 and RMI 2 use the 
same features; however, the RMI 2 score gives greater weight to the USS findings and 
menopausal status than the RMI 1 score.
Table 1.10: The risk of malignancy index (RMI) scoring system
Feature RMI 1 Score RMI 2 Score
Ultrasound features: 
multilocular cyst 
solid areas 
bilateral lesions 
ascites
intra-abdominal métastasés
0= none
1= one abnormality 
3= two or more 
abnormalities
0= none
1= one abnormality 
4= two or more 
abnormalities
Premenopausal 1 1
Postmenopausal 3 4
CA-125 U/ml U/ml
RMI score = ultrasound score * menopausal score * CA-125 level in U/ml.
Several cohort studies explored the role of RMI and found RMI 2 score to be more 
sensitive and this is now routinely used with sensitivity of 80% and specificity of 92% and 
a positive predictive value around 80%. (Jacobs et al 1990, Morgan te et al 1999 and Bailey 
et al 2006).
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The single most important advantage of the RMI is that it helps triage women based on the 
score and effective planning. RMI >200 raises the index o f suspicion for malignancy and it 
is recommended that such women should have their surgery performed at a cancer centre 
under the auspices of a Gynaecological Oncologist. This is based on observational data that 
has shown improved outcome from OC when the initial surgery is performed by a 
Gynaecological Oncologist at a cancer centre and is the basis o f the referral system in the 
NHS from peripheral units to the cancer centres (Kehoe et al 1994, Bailey et al 2006 and 
NICE guidelines 2011).
Moore et al recently developed Risk of ovarian malignancy algorithm (ROMA) which uses 
serum HE 4, CA-125 and menopausal status. This is currently being investigated in various 
studies (Karlsen et al 2012, Plebani 2012 and Van Gorp et al 2012).
1.9.4 Screening
OC screening aims to detect cases at early stages with the aim o f improving survival. 
Currently 2 large clinical trials have closed to recruitment and early data is now available. 
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial o f different 
screening strategies in a low-risk population has closed to recruitment and results are 
expected shortly. However, early data appears to suggest that screening for OC is not 
effective (Menon et al 2009 and Sharma et al 2012). The UK Familial Ovarian Cancer 
Screening Study (UKFOCSS) recruited more than 5000 women at high risk o f OC and 
report that screening is of unproven efficacy and risk reducing salpingo-oopherectomy 
remains the standard of care in high risk women (Rosenthal et al 2012).
1.10 staging of Ovarian Cancer
Staging of OC has traditionally been surgical based on the intra-operative findings. The 
International Federation of Gynecology and Obstetrics (FIGO) staging is used
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internationally based on the extent of spread of disease and currently surgery is the gold 
standard for staging o f OC. It was adapted in 1988 and is included in APPENDIX A.
OC spreads principally through the peritoneal cavity. Lymphatic spread has also been 
noted in some instances. Besides microscopic examination o f tissues, cytological 
examination of ascites or peritoneal washings is also performed.
Essentially, Stage I disease is confined to the ovaries. Stage II limited to the pelvis. Stage 
III extends into the abdomen and Stage IV includes distant métastasés. Accurate staging is 
crucial for treatment planning and affects prognosis. Each stage is subdivided as shown in 
the Figure 1.16.
FIGO staging is included in the APPENDIX A as adapted from the FIGO Committee on 
gynaecologic oncology (FIGO Committee 2009). For Stage Ic as well as IIIC, in order to 
evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or 
lie, it would be o f value to know if  rupture of the capsule was spontaneous, or caused by 
the surgeon; and if the source of malignant cells detected was peritoneal washings, or 
ascites.
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Figure 1.15: FIGO Staging of Ovarian Cancer
FIGO Stage I Ovarian Cancer
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Stage Ic: C ancer on the surface of the ovary
(Adapted from American Society of Clinical Oncology 2005, Permissions requested)
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FIGO Stage II Ovarian Cancer
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Stage Ila: Extension and/or métastasés to the uterus and/or tubes
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Stage lib: Extension to other pelvic tissues
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Stage lie: Tumour either stage Ila or Ilb, but with tumour on surface of one or both ovaries, 
or with capsule(s) ruptured, or with ascites present containing malignant cells, or with 
positive peritoneal washings.
(Adapted from American Society of Clinical Oncology 2005. Permissions requested)
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FIGO Stage III Ovarian Cancer
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(Adapted from American Society of Clinical Oncology 2005. Permissions requested)
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FIGO Stage III Ovarian Cancer (Contd)
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Stage IIIC : Peritoneal metastasis beyond the pelvis >2 cm in diam eter and/or positive 
regional lymph nodes.
Stage IV Ovarian Cancer
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Stage IV :Growth involving one or both ovaries with distant métastasés. I f  pleural effusion is 
present, there must be positive cytology to allot a case to stage IV. Parenchym al liver 
metastasis equals stage IV.
(Adapted from American Society of Clinical Oncology 2005. Permissions requested)
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1.11 Treatment of Ovarian Cancer
Depending on the stage o f disease, treatment of OC includes surgery +/- chemotherapy and 
a flowchart for both suspected pelvic mass and for advanced ovarian cancer is included in 
Appendix A.
1.11.1 Surgery
Surgery for OC consists o f surgical staging and debulking of tumour volume. In early stage 
disease, the focus is on taking adequate and appropriate staging biopsies, while in advanced 
disease, staging is more straightforward and the majority o f surgical effort is directed 
toward surgical debulking (Young et al 1983, Hand et al 1993, Trimbos et al 2003 and 
Vergote et al 2010).
1.11.2 Early Stage disease
Early stage OC can only be confirmed following thorough staging (Benedet 2000 et al). 
This includes removal of the suspicious mass as well as a full pelvic clearance including a 
total abdominal hysterectomy and bilateral salpingo-oopherectomy. It also involves, 
peritoneal cytology, supracolic omentectomy, lymph node dissection and biopsies from 
other surfaces including but not limited to bowel, diaphragm, peritoneum etc.
Following careful assessment and counselling, fertility sparing treatment in the form of 
unilateral oopherectomy may be performed followed by close surveillance till child bearing 
and completion surgery (Zanetta et al 1997 and Fotopolou et al 2012). A recent Cochrane 
review evaluated the type of incision (laparoscopy vs laparotomy) for FIGO Stage I OC 
and did not find laparoscopy to be superior (Medeiros et al 2010) though there appears to 
be a selective role to reduce morbidity from a midline incision (Madhuri et al 2009).
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Figure 1.16: Surgical staging of OC. (Adapted from American Cancer Society 2005.
Permission requested)
PRO CEDURES REQUIRED FOR SURGICAL  
STAGING OF OVARIAN CANCER
Scraping of the 
underside of the 
right diaphragm
Liver.
Removal of 
the om entum -
Peritoneal 
washing
Removal of 
the para-aortic 
lymph nodes
Removal of 
the pelvic 
lymph nodes
Ovarian tumor
Uterus 
Cervix
Vagina
1.11.3 Advanced Stage Disease
The majority of women with a new diagnosis of OC present with advanced stage disease. 
The goal of surgery at this stage is surgical removal of the tumour masses including 
metastatic deposits. Griffiths, in 1975, suggested the concept of maximal cytoreduction 
(Griffiths 1975). Since then, the definition of optimal surgery has been constantly evolving. 
In 1994, Hoskins et al demonstrated that women with residual disease< 2 cm had a 
significant survival advantage (Hoskins et al 1994).
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Figure 1.17 (a) and (b) show large ovarian cancers removed at surgery. (Patient 
consent obtained for use of photographs in both cases)
(a)
(b)
In 2001 Chi et al found no survival benefit unless cytoreduction to <1 cm had been 
achievedFigure 1.18 (Chi et al 2001). Radical surgery and optimal cytoreduction has been 
shown to be associated with improved survival (Bristow et al 2002 and Elattar et al 2011). 
Recent European Organisation for the Research and Treatment of cancer (EGRTC) study 
suggested that the ability to achieve nil macroscopic residual is associated with maximal
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survival and the extent of debulking is the single most important prognostic factor (Vergote 
et al 2011).
Figure 1.18: showing im provem ent in cyto red active surgery over the years and 
consequently survival benefit (Adapated from Chi et al 2001)
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Figure 1.19 showing significantly improved survival w ith nil residual disease 
(Adapted from Polteaurer et al 2012)
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1.12 Chemotherapy
1.12.1 Early Stage Disease
Use of adjuvant treatment for early stage OC depends on the stage and grade of tumour and 
the presence of any patient co-morbidity. The International Collaborative Neoplasm trial 
(ICON 1) and Adjuvant Chemotherapy in Ovarian Neoplasm (ACTION) trials showed that 
adjuvant chemotherapy was o f benefit in Stage I OC and concluded that adjuvant platinum 
based chemotherapy was effective in prolonging survival in early stage OC (Colombo et al 
2003 and Trimbos et al 2003 and Winter-Raoch et al 2012).
1.12.2 Advanced Disease
Platinum based chemotherapy (carboplatin) is the cornerstone o f OC chemotherapy and 
Paclitaxel was incorporated as an adjunct in the 1990s. There are now several studies 
comparing various regimens of chemotherapy dosing, frequency and drugs. Vascular 
endothelial growth factor inhibitors (VEGF inhibitors) are also being used (Stewart et al 
2010 and Gaitskell et al 2011).
1.12.3 Novel Chemotherapy Regimens
The role of NACT has been investigated in 2 large trials. Results of the UK Chemotherapy 
versus upfront surgery (CHORUS) trial are still awaited. The EGRTC 55971 trial 
suggested that there was no difference in survival between the PD and NACT arm and the 
single most important prognostic factor was the extent o f disease remaining following 
maximal cytoreduction. (Vergote et al 2010).
A recent Cochrane review of intra-peritoneal chemotherapy (IPC) suggested that IPC with 
cisplatin improved both DFS and OS from OC (Jaaback et al 2011). Since the current 
standard of care is carboplatin +/- taxane (du Bois 2003 and Ozols 2003), ongoing trials 
have incorporated IP carboplatin in their ongoing studies.
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Worldwide, dose dense studies including the Japanese Gynaecology Oncology Group trial 
showed improved overall survival (OS) with weekly paclitaxel (Katsumata et al 2009). It 
was also noted that this weekly paclitaxel regimen was well tolerated. This has formed the 
basis for the ICON 8 trial which is currently recruiting.
Addition of anti-angiogenic factors: ICON 7 trial and other clinical trials (AGOOVAR 11 
and GOG-0218) which compared standard carbotaxol chemotherapy versus standard 
treatment and Bevacizumab for first line treatment reported an improvement in progression 
free survival (Heitz et al 2012). This survival advantage has also been noted in relapsed 
EOC in both platinum sensitive (OCEANS trial) as well as the platinum resistant 
(AURELIA) states of OC (Aghajanian et al 2012 and Heitz et al 2012). Bevacizumab is a 
mAb that binds and inactivates VEGF- A and inhibits angiogenesis.
Several other novel drugs like Poly ADP-ribose polymerase (PARP) inhibitors, epidermal 
growth factor (EGFR) inhibitors and potential vaccines are being investigated (Yap et al 
2009, Mukophadyay et al 2012).
1.13 Management of Recurrent Disease
Once OC relapses, it is incurable and recurrent OC is principally treated with 
chemotherapy. Surgery is sometimes used in selected cases for resectable disease or for 
palliative reasons in conjunction with chemotherapy (Galaal et al 2010). Current practice is 
principally guided by the duration of disease free survival (DFS). If DFS >12 months, re- 
challenging with agents from the primary treatment is offered. If recurrence occurs 
between 6-12 months, re-challenge may be considered depending on response originally 
possibly together with the addition of another agent. If relapse occurs <6 months second 
line chemotherapy is offered (Galaal et al 2010).
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1.14 Classification of Ovarian Tumours
Ovarian tumours may be benign, malignant or o f low malignant potential, often called 
borderline tumours. Ovarian tumours are a heterogenous group and are classified based on 
their morphology and clinical features. Other recently described phenomenon is borderline 
tumour (tumours of low malignant potential).
Since ovarian epithelium is derived from the coelomic epithelium which also gives rise to 
the Mullerian ducts from which the epithelium of the tube, endocervix and endometrium 
are derived, dedifferentiation o f neoplastic cells can produce several different histological 
subtypes. Hence, ovarian tumours tend to mimic normal genital tract epithelium.
Serous tumours are produced from cells differentiating along the fallopian tube pathway, 
the endocervical cells producing the mucinous subtype and the endometrial pathway cells 
producing endometrioid and clear cell subtypes of EOC.
A benign tumour has no abnormal cytological or proliferative features and no evidence o f 
stromal invasion. There is no significant malignant potential.
A borderline (low malignant potential or atypically proliferating) tumour is a lesion which 
has abnormal cytological and proliferative features within its epithelium but which has no 
evidence of invasion into the stromal supporting tissues. Extraovarian disease can occur 
and these tumour deposits are referred to as implants. Non-invasive implants are associated 
with a good prognosis. Invasive implants are associated with a prognosis that is 
intermediate between those of benign and malignant tumours. Most borderline tumours 
present as stage I lesions and are cured by surgery. Stage by stage the overall survival of 
women with borderline tumours is superior to women with EOC.
A malignant tumour is present when there is evidence of invasion into the stromal tissues 
of the ovary. This is usually associated with cytological atypia and increased proliferative 
activity. Invasion is best defined as the presence o f irregular spiculated or ragged epithelial
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islands with individual cells extending into the stromal tissues. These stromal tissues can 
display reactive changes such as necrosis or an immature fibroblastic response. These 
cytological and proliferative changes can occur locally within the ovarian mass. An ovarian 
tumour must be adequately sampled. EOC can metastasize through lymphatics and blood 
vessels to other viscera and lymph nodes. It also spreads through the abdominal cavity by 
forming nodules on the the peritoneal surface as well as the omentum.
Prim ary peritoneal cancer fallopian tube cancer (Piek et al 2008) is a tumour which 
shows similar morphological characteristics to EOC with minimal or no ovarian 
involvement. It is increasingly believed that many of these cases are due to metastasis from 
an occult primary.
Prim ary Fallopian Tube Carcinom a (PFTC) was previously thought to be an uncommon 
tumour with worse prognosis than EOC. Recent evidence suggests that tumour previously 
thought to be arising from the ovary were found to be o f tubal origin (Piek et al 2008). 
Ovarian tumour classification based on histogenesis would be the most logical way of 
classification. However, the pitfalls to this are:
• gonadal embryology is unclear
• tumours may have diverse or unknown origin
• overlapping histological features
To facilitate standardisation of treatment and uniform terminology, in 1999 a collaboration 
between the World Health Organisation (WHO) and International Society o f Gynecological 
Pathologists drew up a classification based on cell type and patterns of growth (Appendix 
A). Ovarian tumours ultimately arise from one o f the three ovarian components:
• surface epithelium and underlying stroma embryologically giving rise to the mullerian 
ducts- Surface epithelial stromal tumours
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• specialised ovarian stroma including the sex-cord and precursors of endocrine cells of 
post-natal ovary- Sex-cord tumours
• germ cells which have migrated to the ovary from the yolk sac and are totipotent- Germ 
cell tumours
A group of tumours that defy this classification always exist along with secondary and 
metastatic tumours.
The majority o f ovarian tumours are epithelial. Based on their histology, they can be
further subdivided as shown in Appendix A. The heterogeneity of the disease is
demonstrated by the classification of over 120 subtypes overall and atleast 30 malignant
subtypes (Serov et al 1973, Scully et al 1987, Chen et al 2003).
Figure 1.20: Schematic representation of classification of ovarian tumours based on 
cell of origin. (Adapted from Scully et al 1987 showing ovarian tumours classification)
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Clinically, histologically and at a molecular level, OC can be subdivided into two major 
groups. Type 1 cancers are low grade serous, mucinous, endometrioid or clear cell
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histology. They are usually of early stage (Stage I & II), often grow slowly, respond more 
frequently to hormonal treatment and appear to be resistant to conventional chemotherapy. 
The Type II tumours on the other hand are high grade tumours of serous, endometrioid or 
undifferentiated type. They often present at an advanced stage (Stage III & IV), grow 
rapidly and aggressively invade other sites but respond more to conventional chemotherapy 
and remain unresponsive to hormonal manipulation (Romero et al 2012).
Figure 1.21: Classification of ovarian tumours into Type I and II
(Adapted from Bast et al 2012)
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Understanding of this distinction and further evaluation of the molecular heterogeneity can 
be applied to personalised medicine.
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Serous cystadenocarcinoma
Two distinct entities o f serous ovarian carcinoma exist (Heitz et al 2001, Malpica et al 
2004 and Els et al 2012).Low and high grade serous represent two different tumours. The 
underlying pathogenesis is different and evidence now suggests that they are not variants of 
the same neoplastic process. High grade serous OC are the commonest subtype o f EOC. 
Endometrioid cystadenocarcinoma
Endometrioid type EOC has a strong association with pelvic endometrioisis and may 
represent malignant transformation of endometriosis (De Priest et al 1992, Zorn et al 2005, 
Jones et al 2010 and Weigand et al 2010). Synchronous endometrial tumours may be 
present in >20% of cases (Yamanoi et al 2012).
Mucinous cystadenocarcinoma
Typically, mucinous cancers of the ovary present as large pelvic masses often with low 
CA-125. They often tend to be resistant to chemotherapy (Garrett et al 2001 and Hess et al 
2004). Diagnosis may present a challenge due to its similarity with tumours of the lower 
gastrointestinal tract.
Clear cell carcinoma
Represent approximately 5% of EOC. They are strongly associated with endometriosis. 
Tend to present early however, show poor sensitivity to platinum chemotherapy as well as 
aggressive behaviour (Kennedy et al 1989 and Itamochi et al 2008).
1.15 Molecular Heterogeneity
Molecular alterations of OC are also distinct between the Type I & II tumours as tabulated 
below (Bast et al 2012).
The genetic heterogeneity demonstrated above suggests that OC arises from different 
molecular pathways and accordingly different histological subtypes may contain
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different alterations in the cell cycle regulatory proteins (Bamias et al 2012, Bast et al 
2012 and Gaudett et al 2012).
Table 1.11: Molecular heterogeneity of EOC
Molecular
Type
Histology Precursor Molecular features
I Low grade 
serous carcinoma
Borderline- carcinoma 
sequence
KRAS & BRAF 
mutations
I Low grade
Endometrioid
carcinoma
Endometrioisis Mutations CTNNBl, 
PTEN&
Microsatellite instability
I Mucinous carcinoma Cystadenoma- borderline 
sequence
KRAS mutations
I Clear cell carcinoma Possibly
Endometrioisis
PTEN mutations & loss of 
Heterozygosity, PIK3CA 
mutations
II High grade serous 
carcinoma
De Novo from inclusion 
cysts
p53 mutations, BRCA 1/2 
Mutations & BRCA 1 
méthylation
II High grade
endometrioid
carcinoma
Epithelial inclusion 
cysts
p53 mutations, BRCA 1/2 
Mutations & BRCA 1 
méthylation
II Undifferentiated,
carcinosarcoma
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1.16 Challenges in Cancer Management
As mentioned previously, imaging plays a crucial role in EOC management. Screening 
programmes often rely on imaging as do diagnostic tests to identify early stage disease. 
Responses to chemotherapy as well as identifying areas o f recurrence are some o f the 
commonest indications for the use o f imaging in women with EOC. Imaging is not without 
its risks (dye anaphylaxis, radiation risks) and development o f markers to monitor disease 
states, treatment responses as well relapses would be hugely advantageous since repeated 
analysis can be undertaken in comparison to less frequent imaging.
Translational Research
Translational research (TR) helps bridge the science from bench to bedside drawing 
clinical research and basic science closer. TR offers clues regarding disease mechanisms, 
rationale behind the development of new biomarkers and integration of laboratory science 
into clinical trials and practice once successfully tested.
The development o f robust biomarkers would be highly significant in cancer management 
from screening to prognosis and the role of biomarkers is discussed in detail in Chapter 2.
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2.1 Biomarkers
Use of various clinical and pathological markers to predict individual tumour behaviour is 
extremely useful especially in a heterogeneous disease, such as OC.Biomarkers are defined 
as molecules that exist naturally in the body and are expressed in certain disease states 
and can help predict or reflect the presence o f  a disease, the risk o f  relapse o f  the 
disease, and/or response to treatment. Ideal biomarkers should have high sensitivity and 
specificity for the individual diseases, levels should reflect disease state and treatment 
response and should be easily measurable as well as reproducible (Aebersold et al 2005 and 
Srivastava et al 2005). Biomarkers can be diagnostic, prognostic (survival related) or 
predictive (predicting response to chemotherapy, platinum sensitivity etc). Biomarkers are 
commonly defined as a laboratory measurement that reflects the activity o f a disease 
process. In contrast, a “surrogate marker” is defined as “...a laboratory measurement or 
physical sign that is used in therapeutic trials as a substitute for a clinically meaningful 
endpoint that is a direct measure of how a patient feels, functions, or survives and is 
expected to predict the effect o f the therapy.” (Katz R 2004) The primary difference 
between a biomarker and a surrogate marker is that a biomarker is a “candidate” surrogate 
marker, whereas a surrogate marker is a test used, and taken, as a measure o f the effects of 
a specific treatment.
Cancer biomarkers are those that are either produced by the tumour itself or by the 
surrounding tissues in response to the cancerous change.
2.2 Classes of Biomarkers in Cancer
2.2.1 Screening markers
Ideally biomarkers for cancer screening in populations should have >99.9% sensitivity 
and specificity (sensitivity implies that the test is positive in people with disease and
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specificity refers to negative results in people without disease} (Aberosold 2005). 
Screening biomarkers should be able to detect early stage disease. This is particularly 
useful in cancers where identification of early stage disease leads to improved survival like 
in EOC and translational research has now become a key component o f all clinical trials in 
HOC (Darcy et al 2010).
2.2.2 Diagnostic Biomarkers
These markers are frequently used in histopathology for accurate tumour diagnosis and 
classification and hence help in providing optimal treatment choices to patients (Aaliya 
2005 and LaBaer 2005). In EOC, this is particularly helpful to differentiate EOC from 
breast cancers using oestrogen and progesterone receptors and cancers o f the alimentary 
tract using CK 7, CK 20, CEA, C A -125 (McCluggage 2007 and Rekhi et al 2008).
2.2.3 Prognostic Biomarkers
These markers provide information regarding patient survival and relapse helping to 
facilitate treatment options. In EOC, the role o f VEGF as a marker o f angiogenesis is being 
investigated. (Aaliya et al 2005).
2.2.4 Predictive Biomarkers
These markers can help predict response to particular treatments. For ex. HER 2 expression 
in breast cancers can help clinicians decide about offering monoclonal antibody Herceptin 
(trastuzumab) (Dowsett et al 2000). Thus, these biomarkers can help offer targeted 
treatments to patients likely to derive maximal benefit while sparing others unlikely to 
respond the side-effects of toxicity.
2.2.5 Biomarkers of response to treatment
In EOC, CA-125 levels are measured throughout treatment. In CA-125 sensitive tumours, 
quantitative biomarker concentration measurement helps track response to treatment
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however its poor sensitivity makes in unreliable (Quaranta 1991, Gadducci et al 2004 and 
Duffy 2012). However, this relies on the disease severity and serum biomarker 
concentration being correlated.
2.3 Phases of Biomarker Research
Biomarkers were formally defined in 1999 (Biomarkers definition working group 2001). 
Successfully translating research on biomarkers from the laboratory to patients involves 
five phases (Scaros et al 2005).
Discovery phase is Phase 1 which includes exploratory studies to identify potentially 
useful biomarkers.
Validation Phase is Phase 2 studies to determine biomarker capacity for distinguishing 
between people with and without cancer.
Phase 3 determines the capacity of a biomarker to detect pre-clinical disease by testing the 
marker against tissues collected longitudinally from research cohorts.
Phase 4 includes prospective screening studies.
Phase 5 involves large-scale population studies to evaluate the overall impact o f the 
biomarker screening on population and whether this screening impacts survival.
The above steps in the bench to bedside biomarker pipeline are filled with bottlenecks and 
biomarker failure remains the norm and success is very minimal. There are several reasons 
for biomarker failure and some of the common reasons are listed below:
A clinical reversal (Type A failure) is considered when an existing biomarker being used in 
clinical practice is found to be o f little use and indeed in some cases harmful. Ex: PSA 
(prostate specific antigen) where following recent studies recommendations does not 
support routine screening with this marker (loannidis et al 2013).
Validation failure (Type B failure) results when biomarkers of great promise in early, small 
studies fail validation in robust studies. Ex: discovery o f proteomics patterns for EOC
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where suggestions of strong discriminating ability to enable screening and management 
failed in bigger studies (Petricoin et al 2002, Ransohoff et al 2007).
Non-optimized clinical translation (Type C failure) results when promising biomarkers are 
not followed through systematically towards clinical implementation (Dupuy et al 2007). 
Ex: Gene profiles for cancer outcomes wherein despite potential to modify cancer 
management, few signatures move to clinical development due to lack of rigorous clinical 
evaluation.
Promotion despite poor evidence (Type D failure) occurs when biomarkers are promoted 
extensively despite being o f little or no value.
Ex: Personal genomics with genetic prediction models have been commercialised despite 
limited information (Janssens et al 2008, Ransohof et al 2010).
My research revolves primarily around Phase I and Phase II and the aim of my 
research is to identify potential biomarkers and evaluate the utility of these 
biomarkers at the protein level to assess their role as new prognostic indicators and/or 
new drug targets to assist in the treatment and management of ovarian cancers.
2.4 Biomarkers and Ovarian Cancer
EOC commonly presents in advanced stages with high case/fatality ratio. Diagnosed early, 
survival is greatly improved. Over the years, there have been several studies evaluating 
many potential biomarkers. Ongoing microarray analyses and proteomics technologies hold 
promise in identifying signature molecular biomarkers for screening, early detection and 
prognosis in EOC.
Despite this, for several years, there has only been one biomarker in clinical practice which 
is extensively used- CA-125 and is discussed below. Another biomarker that is currently 
being investigated is HE4 and is discussed later.
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2.4.1 CA- 125’ (Cancer Antigen 125) also known as mucin 16 or MUC16 is a
protein that in humans is encoded by the MUC16 gene and is a widely used tumour 
biomarker. CA-125 was initially detected using the murine monoclonal antibody 
designated OC125 in 1981. (Bast et al 1981) Often considered the gold standard in EOC 
management, it is high molecular weight glycoprotein normally expressed in tissues 
derived from the Mullerian and coelomic epithelium (Rein et al 2011) with increased 
expression noted in more than 90% of EOC and is the most frequently used biomarker.
The use of CA-125 in EOC incorporates the following:
Triagingwomen with pelvic masses to gynaecological oncologists: There are several 
studies reporting better outcomes in women with EOC when referred to gynaecological 
oncologists for their management. Using the popular ‘RMT tool helps triage women more 
likely to benefit from subspecialised care (Jacobs et al 1990)
Early Detection: The 5 year survival for EOC has improved over the years however; long 
term survival rates remain unchanged as diagnosis continues to be at an advanced stage 
(Bast et al 2012). The Prostate, Lung and Ovarian Cancer Screening trial (PECO) in the 
US found no improvement in survival after screening post-menopausal women with CA- 
125 and TVS (Buys et al 2011). The trial concluded that a single measurement of CA-125 
is unlikely to have the required sensitivity however a greater PPV is noted in performing 
TVS in women with elevated CA-125. CA-125 notably increases in EOC while remaining 
static in women with benign disease. Results from the UKCTOCS trial are expected in 
2015 and the report from the prevalence phase o f the trial observed a ‘stage shift’ in the 
cases of EOC detected with early stage (I & II) cases doubling (Menon et al 2009). 
M onitoring treatm ent response: In women with elevated CA-125, it is used to assess 
biochemical response to chemotherapy and is known to track the progression or regression 
of EOC with significant accuracy (Bast et al 2012). Unfortunately, CA-125 is not
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sensitised to detect persistent disease and its concentrations can return to the normal range 
during treatment despite residual disease.
Correlation with prognosis: There are several studies ongoing to detect if  the rate at 
which CA-125 drops during treatment can be correlated with survival. Persistently elevated 
levels following chemotherapy indicate a poor prognosis.
Recurrence Detection: The role of sequential monitoring o f CA-125 in women following 
completion of treatment is the subject of extensive debate. Rustin et al queried this in their 
trial which produced negative results due to heterogeneity in the recruited participants. 
Early detection of disease may on one hand lead to more investigations and increased 
anxiety however may offer the lead time required for potential recruitment into various 
clinical trials. (Rustin et al 2010)
Pitfalls with CA-125 m easurem ent: Studies indicate limited specificity of CA-125 for 
EOC as it is elevated in endometrial, lung, breast and gastrointestinal cancers. (Bast et al 
1998) It is also elevated in some benign conditions such as endometriosis, pregnancy and 
menstruation and often results in false positives. (Sarandakou et al 2007,Bagan et al 2008, 
Nossov et al 2008). CA-125 elevations are also seen in non-gynaecological states such as 
cirrhosis and diabetes mellitus. (Faulkner et al 2012)
Sensitivity of CA-125 in EOC is also varied and reported to be around 79% with some 
subtypes not expressing the antigen at all. (Rosen et al 2005) In early stage EOC, 
approximately 50% of patients do not have elevated CA-125 levels and hence cannot be 
used in all cases of EOC for diagnosis especially prior to the onset o f symptoms. (Sasaroli 
et al 2009).
Due to the poor sensitivity and specificity of CA-125 the search for novel biomarkers is 
ongoing and one other biomarker showing promise in early studies is HE 4 and is discussed 
next.
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2.4.2 HE4- H um an Epididym al protein 4 has been found to be over expressed
in EOC. Though there is ongoing work to understand its role, HE4 offers hope as a serum 
marker in EOC in early detection (Hellstrom et al 2008). Studies suggest that HE4 
combined with CA-125 improved sensitivity and led to the development of the risk of 
malignancy algorithm (ROMA) (Li et al 2012). Though ROMA demonstrates high 
diagnostic accuracy in differentiating between EOC and other adnexal masses, its role in 
early detection of EOC is being studied.
Following several studies, the FDA has approved HE4 for monitoring relapse o f EOC 
(Montagnana et al 2011).
There are several serum biomarkers that are being studied including Kallikreins, 
mesothelin as well as tissue and epigenetic biomarkers including miRNA however are still 
experimental in various trials (sarojini et al 2012).
2.5 Previous Work
Besides serum biomarkers, there are several other immunohistochemical markers being 
studied as in this thesis and the background for this thesis and choice o f markers is 
described below.
Extensive previous work in our laboratory has involved the generation of novel drug 
resistant cell line models of EOC as part of an ongoing program to understand the basis for 
chemoresistance in EOC (Syed et al 2011, Coley et al 2012). Gene expression profiles were 
studied using DNA microarray technology. It is likely that there are several genes 
implicated in the drug resistance mechanism o f OC. Genes identified to date have not 
resulted in significant therapeutic advances or led to the identification o f new targets or 
prognostic markers. Extensive DNA méthylation at specific sites within genes gives rise to 
a process called gene silencing. An initial microarray analysis of the human PEOl human 
EOC line and novel drug resistant variants using a 30,000 oligo platform revealed low
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levels of the gene as a consequence of carboplatin resistance. Further, méthylation
reversal using demethylating agents (treatment of cells with 5’aza-cytidine and zebularine) 
“unmasked” the gene thereby suggesting a mechanism of gene silencing underlying the 
reduced expression of p57^'^" seen in carboplatin resistant cells. We have further examined 
this initial finding using qPCR analysis, western immunoblotting (Figure 2.1) of the same 
cell lines, chemosensitivity testing and analysis of freshly extracted ovarian cancer tissue 
for mRNA levels of p57^'^^ with assessment of clinico-pathological features which 
revealed high levels of p57 '^*^  ^in complete responders (Coley et al 2011).
Figure 2.1: Western blot showing methylated DNA in the promoter area where there 
is heavy méthylation which results in gene silencing
Unmasking of gene silencing 
with 5’aza-cytidine treatment
P E01 P E O IC arboR  PE O IcarboR  P E O IC isR  P E O IC isR
+ déméthylation + déméthylation
P57 kip2
Actln
(loading control)
WESTERN IMMUNOBLOTTING DATA FOR DETECTION OF 
P57KIP2 p r o te in  le v e ls  IN PLATINUM SENSITIVE AND RESISTANT 
HUMAN OVARIAN CANCER CELL LINES
Cyclin E-CDK2 is essential for pRb phosphorylation and subsequent gene transcription by 
E2F (Figure 2.5). The influence of p57’^ ‘^ “ on the Cyclin E-CDK2 complex promotes cell 
cycle exit and cell differentiation.
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As a result o f  the above work, I  became interested in understanding the cell cycle and in 
investigating the immunohistochemical expression o f  and Cyclin E and began
exploring the literature.
Despite relatively high frequency of EOC and its lethality, little is known of the 
pathobiology of the commencement and progression of the disease. Hanahan and 
Weinberg suggested that cell physiology alterations led to cancer development and 
breakdown of the homeostatic balance ensuring integrity of cell cycle progression is a 
hallmark of cancer (Hanahan et al 2000).
2.6 Cell Cycle
Mammalian cell cycle is divided into 4 main phases: Gi, S, Gi and M. (Figure 2.2)
Figure 2.2: Cell Cycle with the 4 phases 
Gi checkpoint
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M
M checkpoint ^
G2 checkpoint
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Orderly progression through the cell cycle is monitored by safety mechanisms commonly 
referred to as cell cycle checkpoints. When activated, they halt cell division. The cyclins, 
cyclin- dependent kinases (CDKs) and cyclin dependent kinase inhibitors (CDKIs) are all 
regulatory proteins acting at various points in the cell cycle instrumental in advancing cells 
through the different cell cycle phases (Figure 2.3).
Figure 2.3: Various cell cycle checkpoints and regulatory proteins
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Changes in cell cycle regulation can lead to uncontrolled cell proliferation and 
oncogenesis. The progression of the cell cycle through the various phases is tightly 
regulated by cyclins and CDKs and simultaneously counterbalanced by CDKIs. The 
transition from the Gi to the S phase is regulated by the CDKIs. This group of proteins are 
further subdivided into the INK4 family, consisting of pl6ink4a, pl5ink4b, pl8ink4c and
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pl9ink4d and the CIP/KIP family, consisting o f p 21^^ , p27’^ ‘^ * and The focus of
this thesis is on p57"^ '^  ^and how its expression may influence the pathogenesis o f EOC.
The CIP/KIP family regulate the cell cycle both positively and negatively by interacting 
with Cyclins A, D & E. Hence p57^'^^ levels are highest in the Go& Gi cell cycle phases in 
keeping with its role as a CDKI. Its levels also steadily decrease while progressing from Gi 
through the S cell cycle phase and overexpression of p57'^‘^  ^ induces Gi arrest in cultured 
cells.
2.7
In humans, the p57^‘^  ^ encoding gene (correctly called the CDKNIC  gene) is located on 
chromosome I lp l5 .5  and is maternally expressed and paternally imprinted (Kavanagh et al 
2011). p57^'^^ is distributed in the nucleus however distribution within the cytoplasm has 
been reported in cancer tissue (Kavanagh et al 2011). p57^'^^ is an important negative 
regulator and was previously considered to be a tumour suppressor (Figure 2.3). Recent 
findings of its involvement throughout the regulation o f cell cycle processes suggest a 
multifaceted existence o f the p57^'^^ protein (Figure 2.4) (Guo et al 2010).
Abnormal p57^'^^ function includes its participation in cancer initiation and progression. 
Since p57'^‘^  ^was discovered as a CDKI, research revolved around describing its ability to 
inhibit proliferation hence rendering it a tumour suppressor gene status (Coley et al 2012). 
Currently available data is limited and conflicting and the role o f p57'^‘^  ^ as an 
immunohistochemical (IHC) marker in EOC requires clarification.
Based on the above considerations, we conducted a systematic review of the literature with 
subsequent meta-analysis to clarify this association. In the meta-analysis, we examine all 
studies including IHC data following p57’^‘^  ^use. Furthermore, any correlation with clinical 
outcome was also evaluated to assess the efficacy and usefulness of p57' '^^  ^ as a potential 
prognostic marker. (Appendix D)
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Figure 2.4: Cell Cycle with various regulatory proteins at different phases
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2.8 as potential prognostic and therapeutic marker
Originally discovered as a CDKI, and considered as having only tumour suppressor 
function, it is becoming obvious that the role of p5?'^‘^  ^ has expanded beyond cell 
regulation. The studies described in the literature review, show that low p57'^‘‘^  ^ function is 
associated with high grade, advanced clinical stage and overall poor performance. This 
association may become crucial in target oriented cancer therapy by modulating 
levels. Several clinical trials including some Phase I & II clinical trials in haematological 
malignancies and some solid tumours are currently looking at reactivation of p5?'^'’’" in 
cancer cells as a therapeutic strategy. This is based on the principle that downregulation of
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in the majority of cancers makes it an obvious tumour suppressor candidate 
(B’Andrilli et al 2004).As shown in various studies, suppression o f the protein expression 
is due to the loss of p57""^^activity in cancer. Reactivation of p57^'^^ expression can be a 
useful mechanism and some therapies (HDAC inhibitors and demethylating agents) that 
cause reactivation are already being used successfully. (B’Andrilli et al 2004)
The involvement of p57'^‘*^  ^ is certainly more than just inhibition of cell growth as was 
previously thought. It is now known that its function includes promotion of cell 
differentiation and apoptosis and metastasis inhibition. In trying to unravel the mystery of 
p 5 7 kip2 , as a diagnostic marker in the differential diagnosis of early hydatidiform
mole has emerged. The four studies discussed above have suggested a role for p57'"'^^ as a 
prognostic marker at various levels and this needs further clarification. With more radical 
surgery being advocated for EOC including secondary debulking surgery, serial IHC work 
in conjunction with cell line and serum work from women at varying stages o f treatment 
for EOC (both chemo-naiVe and post treatment) may help to elucidate its role better. Serial 
IHC studies may also help to clarify its role in the development of drug resistance in 
women following first line platinum chemotherapy, both to assess potential response to 
treatment and to further explore if up-regulation helps prevent development of resistance. 
Larger numbers of cases of each individual histological subtype are required for 
meaningful data to emerge, and this might necessitate collaboration between different 
centres. p57' '^^  ^ is a protein that appears to regulate various functions in the “cancer 
hallmarks cycle”; resolving the enigma o f its function might provide interesting results in 
terms of prognosis and therapy for EOC.
2.9 Cyclins
Cyclins were first discovered in marine invertebrates (Evans et al 1983). Cyclins and CDKs 
are proteins are key regulators of the cell cycle in a stage specific manner (Stamatakos et al
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2010). Cyclins bind to CDKs and form complexes regulating different stages o f transition 
in the cell cycle. Screening o f human cDNA libraries for genes analogous to the cell cycle 
regulation in yeast Saccharomyces cerevisiae led to identification o f Cyclin E and 
discovery of its biochemical and physiological properties (Koff et al 1991 and Lew et al 
1991).
2.10 Cell Cycle and Cyclin E
In humans, Cyclin E encoding gene (correctly called the CCNEl gene) is located on 
chromosome 1 9 q l2 ^ q l3  (Hwang et al 2005 and Davidson 2010). Cyclin E is a 50kD 
nuclear protein and its maximal expression level is seen both in cells that are stimulated to 
re-enter the cell cycle as well as in mitotically proliferating cells (Dulic et al 1992 and Koff 
et al 1992). Cyclin E is an activating partner o f CDK2. This activation allows for the cells 
to travel through the G l/S  checkpoint. (Figure 2.5)
63
Chapter 2 - Biomarkers in Ovarian Cancer
Figure 2.5: Activation of Cyclin E and cell cycle check
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2.11 Altered Cyclin E and cancer
Previously, the carcinogenic effect o f Cyclin E was thought to be due to acceleration o f the 
cell cycle, unscheduled re-entry into the cell cycle as well continued proliferation. It is now 
understood that dysregulated Cyclin E induces genomic instability (Spruck et al 1999). 
Shortening of the Gi phase of the cell cycle occurs as a result o f overexpression o f Cyclin 
E (Bedrosian et al 2007).
Table 2.1: Role of Cyclin E in various malignancies
Cancer organ type Role o f Cyclin E
Breast
Poor DFS and OS 
High tumour grade and stage 
Lack of steroid receptors 
HER 2/Ki67 expression 
BRCA 1 germline mutations
Ovarian Cancer Controversial correlation with prognosis
High tumour grade
Advanced Stage
Suboptimal cytoreduction
No correlation with chemotherapy response
Marker o f aggressive disease
Serous, clear cell ovarian carcinomas
Gastric Cancer Poor histological grade 
Serosa invasion 
Advanced stage
Colorectal Increased recurrence risk 
Worse outcome
Melanomas Histological type 
Tumour stage
Non small cell lung 
cancer
Poor prognosis
Distant metastasis
Poor survival among Stage I-IIIa
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Other events that are also linked are reduced growth factor requirement, increased cell 
proliferation, induction o f chromosomal instability and polyploidy (Bedrosian et al 2007). 
Put together all these features contribute towards the oncogenic potential of cyclin E 
(Keyomarsi et al 1997). High Cyclin E expression also correlates with oncogenic viruses 
like HPV (Human Papilloma virus) and CMV (cytomegalo virus) implicated in cervical 
and CMV infection respectively (Bresnahan et al 1996 and Ruesch et al 1997). Increased 
levels of Cyclin E have been associated with more aggressive tumours as well as adverse 
prognosis in breast (Porter et al 1997), gastric, non-small cell (Mishina et al 2000) Non- 
Hodgkins lymphoma and EOC (Bedrosian et al 2007). Its role in these various cancers is 
shown in (Table 2.1) above.
2.12 Cyclin E and Ovarian Cancer
There have been studies reporting on Cyclin E expression in EOC (Farley et al 2003, 
Bedrosian et al 2007, Davidson et al 2007 and Schildkraut et al 2008). Farley et al in 2003 
reported that while there was no association found between Cyclin E expression and age 
race, grade, stage, cell type or amount of residual disease, but was associated with survival. 
Other authors showed common findings amongst these studies are that overexpression of 
Cyclin E is related to higher grade, more advanced stage EOC and was summarized by 
Nam et al in 2008 (Rosenberg et al 2001, Sui et al 2001 and Rosen et al 2003, Kawauchi et 
al 2006 and Nam et al 2008). Schildkraut et al performed a population based study to 
assess the relationship between Cyclin E and epidemiological risk factors for EOC and 
found that Cyclin E overexpression is associated with increased number of lifetime 
ovulatory cycles (Schildkraut et al 2008). Using Western blot analysis, Bedrosian et al 
reported in 2007 that Cyclin E may have a role in predicting response to chemotherapy 
(Bedrosian et al 2007).
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There is currently no clear consensus on the role of Cyclin E in EOC and a more recent 
Danish study (MALOVA) suggested that Cyclin E did not offer any independent 
prognostic information (Heeran et al 2012).
Given the previous work carried out by our group, the above lacunae in the literature and 
the paucity of data relating cell cycle to the problem of EOC, the idea of exploring the 
immunohistochemical expression of p57^‘^  ^and Cyclin E in EOC was undertaken in this 
thesis.
A schematic to explain our previous and ongoing work is shown below (Figure 2.6). The 
work in this thesis (lower half) is based on previous work as shown in the top half of the 
figure.
Figure 2.6: Schematic of previous work and my work within our group
Drug sensitive + drug resistant 
ovarian cancer cell lines
DNA microarray: 
assessment of up-regulated and 
down-regulated genes
Derivation of gene list: 
Genes down-regulated in drug- 
resistant cells (unmasking with 
de-methylating agents)
 ^ * ïwwi»-
. ftwse»
Assessment of methylated 
DNA in tumour tissue and 
Serum and protein 
expression in archived 
paraffin blocks
epithelial ovarian cancer
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The aims of this thesis were to evaluate:
1. If the immunohistochemical expression of and 
Cyclin E from tumour specimens correlates with other clinical 
or pathological variables in each case?
2. Does the level of immunohistochemical expression of above 
mentioned biomarkers correlate with prognosis in women with 
advanced epithelial ovarian cancer?
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Chapter Introduction
This chapter is divided as follows:
The first section (Section 3.1-3.2) focuses on the clinical methods including recruitment, 
sample collection and database creation. (Pages 71-75)
The next section (Section 3.3-3.6) describes the laboratory methods used, methodology of 
staining and scoring of slides. (Pages 76-94)
The final section (Section 3.7) explains the statistical methods used for data analysis.
3.1 Clinical Methods
This section focuses on patient recruitment, sample collection and clinical database set­
up. This study (sample collection) was undertaken at a single site (Royal Surrey County 
Hospital NHS Foundation Trust). All sample collection and laboratory techniques were 
undertaken in accordance with Good Clinical Practice (GCP).The patients in this study 
were divided into 2 distinct cohorts as described below:
3.1.1 Patients
Patient population within the study comprised o f 2 distinct groups.
Cohort 1
In this group we used retrospective patients who underwent surgery for EOC from January 
2004 to December 2006 for sample and data collection. The patients in this group 
underwent surgery between January 2004 and December 2006. Archived paraffin blocks of 
tissue taken at the time o f surgery in 74 patients were obtained. Retrospective data 
collection was performed from review of the patient medical records.
Cohort 2
This cohort included prospective sample collection. Women in this group underwent 
surgery between January 2007 and December 2009. Study Information leaflets were
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offered to patients at the time o f consultation when discussing the surgical management. 
Consent in this group was sought prospectively prior to surgery and sections were prepared 
from the surgical specimens submitted.
3.1.2 Ethics
The documents submitted to the Surrey Research Ethics Committee for ethical approval 
included the study proposal, patient information sheet and consent form (Appendix B). 
Approval for the proteomics study was obtained with study reference number (Study 
approval no: 07/Q1909/14- Appendix C). An amendment was granted to undertake IHC 
work 3 months later. Approval for this study was obtained from the Surrey Research Ethics 
Committee (Appendix C).
The methodology and IHC performed is described later in this chapter.
3.1.3 Database
An extensive clinical database (EOC IHC database) has been set up to enable complete 
data collection. Following consultation with statisticians, a standalone database was agreed 
upon rather than a complex system. This discussion revolved around the type of database 
required for this project, anonymity, ethical and legal issues, database design, type of 
software to be used and finally data coding.
The advantage of a standalone database is the easy creation and setup. Data is directly 
entered onto the database and in our case multiuser was not an issue. The disadvantage is 
the time taken to manually key in data for every field since the standalone database is not 
linked to other data sources.
Linked anonymisation was the method chosen, whereby patient identifiable data and 
anonymised research data are linked by a key rather than complete anonymisation (static 
data). The design of the datafields was based on the SCOTROC trial database, (personal 
communication from Helen Coley via Hani Gabra, Imperial College, London) Data were
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collated from various sources including the patient medical notes, Telepath & WinPath 
(Hospital biochemistry laboratory results checking systems) for results, the gynaecological 
oncology database and patient chemotherapy records. Attempts were made to contact the 
patients’ GP and other hospitals to minimise missing fields. The fields collected have been 
described in Section 3.2.3 of this chapter. The database was updated on a quarterly basis 
with relevant clinical information on recurrence, further treatment, last follow-up/ date of 
death and cause of death.
3.2 Data Collection
Following a review of the histopathological database, a cohort of 256 patients were 
considered suitable for inclusion in this study.
3.2.1 Inclusion Criteria
To be included in this study, all women should have undergone debulking surgery 
(laparotomy) for histologically confirmed epithelial ovarian cancer at some stage during 
their treatment pathway (i.e. either primary debulking {PD} or interval debulking surgery 
{IDS}).
3.2.2 Exclusion Criteria
Women with EOC who did not undergo definitive surgery despite other forms o f treatment 
(laparoscopy and biopsies).
3.2.3 Data Collected
Following identification of suitable cases, complete corresponding clinical data for the 
cohort was collected. This included the following:
• Age at diagnosis
• Any other cancers
• CA-125, CEA, CA19-9 and CA15-3 at diagnosis
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• Eastern Cooperation Oncology Group(ECOG) Performance Status
• Participation in ongoing national and local clinical trials if any
• Primary Treatment: If  surgery (date of operation); If chemotherapy (type of 
chemotherapy prior to and after IDS, number of cycles prior to and after IDS, date of 
cycle and date of IDS)
• Adjuvant Treatment: If PD performed then type o f adjuvant chemotherapy, number 
of cycles and date of completion of chemotherapy to calculate disease free survival (DFS). 
If neo-adjuvant chemotherapy (NACT) then post IDS type o f chemotherapy, number of 
cycles and date of completion of chemotherapy.
• Date o f completion o f all treatment to calculate DFS
• Per-operative information included volume o f ascites at surgery and bulk of 
residual disease following surgical resection.
• Histological and cytological data include type, FIGO stage and grade o f tumour
• Date of relapse and CA-125 level at relapse as recorded in either the MDT 
summary or medical notes following clinical review.
• Subsequent management till either last follow-up or death
• Date of death (DOD) and cause of death or survival date last seen
• Data were also collected about any previous malignancies (cancers prior to EOC 
diagnosis), synchronous tumours (at the same time as EOC diagnosis) and any cancers 
diagnosed during the follow-up period. Figure 3.1 shows a snapshot of the database.
3.2.4 Data Maturity
The master database contains mature data and patient follow-up until August 2012. From 
this database, only fields pertaining to the aims o f the study were collated separately for 
analysis below. This enabled calculation of the disease free survival (DFS) and overall 
survival (OS) for the cohort.
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Many o f the 256 women were recruited into several ongoing national clinical trials 
(CHORUS, ICON 7) as well as local trials which are mentioned in the next chapter in 
Section 4.1.1.
Generosity and willingness to participate was demonstrated by this cohort of patients who 
also consented to ongoing local trials and research.
Figure 3.1: Screenshot of study database showing some of the collected fields
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3.3 Laboratory Methods
3.3.1 Standard Operating Procedures
All laboratory activities were undertaken in accordance with the standard operating 
procedures (SOP) of the Histopathology Department at the Royal Surrey County Hospital 
in keeping with the principles of GCP.The student underwent GCP training annually during 
the study period.
3.3.2 Block Retrieval
In Cohort 1 where retrospective samples were collected, the archival paraffin blocks were 
retrieved by the student.
Figure.3.2: retrieved archival blocks
Figure3.3: Showing multiple blocks from a case
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Figure3.4: showing suitable block for sectioning selected from multiple blocks
This was then discussed with the pathologist to identify the right blocks to obtain sections 
from. In Cohort 2 where samples were collected prospectively and following reporting of 
the case by the pathologist, the sections were cut from the relevant paraffin blocks.
3.3.3 Microtomy
Microtomy is the process of taking sections from 10% formalin fixed paraffin embedded 
tissue (FFPE). It utilises a microtome which is a piece o f equipment that at the turn of a 
handle will take sections of a pre-determined thickness. These 4pm sections are then 
mounted onto glass microscope slides and the wax melted in a hot oven prior to staining 
the slides using various techniques. This was performed by the student in accordance with 
the SOP.
3.3.3.1 Immunohistochemistry (IHC)
IFIC is a well established histological technique to detect antigens by using the principle of 
antibodies binding to specific antigens in tissue. IHC is widely used in the diagnosis of 
malignancies for the visual detection of antigens in tissue. It provides crucial information
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not only on diagnosis and site of origin but additional information about tumour behaviour 
and likely prognosis. In EOC IHC, the commonly used antibodies are Cytokeratin 7 and 20 
(CK 7 and CK 20). Other antibodies that are also used are carcinoembryonic antigen 
(CEA) and CA-I25. EOC are CK7 positive and CK 20 negative except for mucinous 
ovarian tumours which may be CK20 positive closely resembling colorectal cancers 
(McCIuggage et al 2005). The use of markers such are oestrogen (ER) and progesterone 
receptors (PR) helps to distinguish from other tumours of the female genital tract and breast 
tumours (Monteagudo et al 1991). Wilms tumour I (W TI) helps distinguish between 
pancreatic and EOC with the former being negative. In basic research, IHC is used to 
understand the localization as well as the distribution of biomarkers and differentially 
expressed protein. The antigens are localized by use of labelled antibodies as specific 
reagents through antigen-antibody interactions which are then visualized by a marker 
which may be a fluorescent dye, an enzyme or a radioactive product. A secondary antibody 
is used to amplify the antigen antibody binding.
Quality control is important to ensure that IHC staining performed is of highest standard. It 
is particularly important with batch staining as in this study. Both positive and negative 
controls were employed and are discussed in the next section. (Section 3.3.4; Page 84)
3.3.3.2 Antigens
An antigen is a protein molecule or polysaccharides within or on the cell surface and bear 
one or more antibody binding sites known as epitopes.
IHC is a well-established histological technique to detect antigens by using the principle o f 
antibodies binding to those specific antigens in tissue. IHC is widely used in the diagnosis 
of malignancies. In basic research, IHC is used to understand the localization as well as the 
distribution of biomarkers and differentially expressed protein. The antigens are localized 
by use of labelled antibodies as specific reagents through antigen-antibody interactions
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which are then visualized by a marker which may be a fluorescent dye, an enzyme or a 
radioactive product. A secondary antibody is used to amplify the antigen antibody binding.
3.3.3 3 Antibody
Antibodies belong to a group o f proteins called immunoglobulins (Ig). They are formed by 
plasma cells. Following recognition o f the foreign antigen, B-cell lymphocytes undergo 
transformation forming plasma cells. Antibodies are the pivotal reagents common to all 
IHC techniques. There are five classes o f Ig and when listed in order o f decreasing amounts 
in serum or plasma are as follows: IgG > IgA> IgM > IgD > IgE. Each Ig is composed o f 2 
identical heavy chains which differ from other Ig in antigenic and structural properties 
determining the molecule class and 2 identical light chains. Ig G and Ig M are the most 
commonly used antibodies in IHC. The two heavy and light chains form a Y shaped 
structure and the arms varying in amino acid sequence (Figure3.5). This variable domain of 
the Ig is specific to a particular antigen epitope and hence facilitates binding.
FigureB.S: showing structure of Ig with 2 heavy and 2 light chains
Fab fragment
Fc region
■Antigen binding site
Light chain
Heavy chain
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3.3.3.4 Enzymes
IHC employing immunoenzymatic staining methods use enzyme substrate reactions to 
convert colourless chromogens into coloured end products. Enzymes are proteinaceous 
catalysts essential for chemical reactions. Selecting an enzyme for IHC reactions is often 
tricky however, ‘Horseradish peroxidase’ (HRP) meets this criteria and has been used for 
the IHC work during this study.
3.3.3.5 Horseradish Peroxidase (HRP)
HRP is isolated from the root of the horseradish plant. HRP oxidizes many substances and 
in the presence of an electron donor its activity results in the enzyme substrate complex 
formation and then electron donor oxidation.
3.3.3.6 Chromogens
Electron donors upon being oxidized become coloured products and are refeired to as 
chromogens. Once oxidized the chromogens become insoluble which makes the 
chromogens useful in IHC. 3,3’-diaminobenzidine tetrachloride (DAB) is a chromogen that 
has been used in our IHC protocol and produces a brown coloured end product which is 
highly insoluble. DAB oxidation caused polymerization increasing its staining intensity as 
well as electron density and can be easily visualized by light microscopy. To avoid false 
positive results with DAB as a result o f its interaction with peroxidase, this enzyme activity 
endogenous to our tissue is blocked. In all our protocols, endogenous peroxidase activity is 
blocked prior to staining.
3.3.3.7 Wash Buffer
These are used to remove excess reagents from any given specimen following each 
incubation step in the assay. We used Tris- buffered saline (TBS).
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3.3.3.8 Fixation
To enable consistent, reproducible diagnostic information the ‘art form’ of fixation needs 
to be standardized. Many steps in the IHC process destroy the antigen and the challenge of 
the fixation process is to retain the position of the antigen (nuclear or cytoplasmic), the 
antigenic structure to enable maximal surface for the antibody. The critical step o f tissue 
fixation needs to retain antigenic properties while changing the protein structure to preserve 
it from elution and degradation. Fixation in 10% neutral buffered formalin runs the risk of 
certain epitope destruction against which monoclonal antibodies may react. There are 
several fixatives that have been developed. For this IHC work, 10% neutral buffered 
formaldehyde (formalin) has been used. Due to its cross-linking behaviour it is well suited 
as a fixative for small molecules such as hormones. However, this can also cause masking 
of certain antigenic sites due to the protein cross-linkage and hence antigen retrieval 
technique has been employed for this work for the antibodies. Various methods include:
• Water bath methods
• Pressure cooker heating
• Autoclave heating
• Microwave oven heating
• Proteolytic pretreatment
•  Combined Proteolytic pretreatment and heat induced epitope retrieval
We have used the microwave oven and pressure cooker heating method for antigen 
retrieval during the course of this study.
IHC Reagents
All reagents were o f the purest grade available commercially and used routinely in the 
hospital laboratory. A list o f the IHC Reagents used has been recorded in Appendix D.
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3.3.4 Controls
Variations in IHC can be easily introduced which can affect results. This is especially 
significant when using the autostainer to ‘batch stain’ slides. Once the antibody has been 
optimised, batch staining is a process whereby IHC autostainers produce multiple slides 
with consistent staining for that batch. Therefore use of controls is imperative to test the 
specificity and sensitivity of the involved antibodies. The criteria for specificity are that, 
firstly, no staining occurs in the absence o f the primary antibody, and that, secondly, 
staining is abolished by adsorption o f the primary antibody with the relevant antigen prior 
to its use.Tissue controls can be negative, positive or internal and each serves a purpose. 
Positive tissue controls are indicative of proper staining and gauge the accuracy o f the 
antigen retrieval procedure. They are also indicative of properly prepared tissue. Should 
positive controls not perform as expected we planned to discard and repeat the IHC 
process. When negative controls show positive staining this may indicate lack of antibody 
specificity and in such instances we agreed to discard and repeat the IHC process. For each 
case, at least one negative control slide was performed.
A positive control slide was used in every single run performed based on the plan that 
absence of staining in a test section is likely to imply that our technique had not been 
‘optimised’ rather than assuming absence of the antigen. Hence, positive controls 
recommended by the manufacturers of the antibodies for the antigen tested were used. We 
agreed that lack of staining in a positive control obviated the need for restaining using the 
spare sections cut.
3.3.5 Positive and Negative Controls
Since this study was aimed at differences in the protein expression o f biomarkers in 
cancerous tissue and how this variation in expression affected prognosis, non-cancerous 
ovarian tumours and in normal ovaries was not explored. Quality control was significant
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with the batch staining and sectioned paraffin-embedded samples o f cell lines with known 
positivity for each antibody were included in each IHC run. Tissues used are indicated in 
Table 3.1. Also included in each run was a negative control cell line slide to which primary 
antibody was not added. This was to ensure no residual endogenous peroxidase activity, 
which should have been removed during the step of O.I % hydrogen peroxidase use. On 
completion of the immunostaining run, the slide should stain blue (negative). If  it did not, 
then the run was repeated. The antibody concentration chosen was the one, which gave the 
best definition between positive (brown) and negative (blue) controls but minimal 
background staining. Optimization involves using a range of antibody dilutions to obtain 
maximal staining.
Table 3.1: Immunohistochemistry controls
POSITIVE
CONTROL
NEGATIVE CONTROL
pS7"P^ Colon Carcinoma Tissue section used in method minus the 
primary antibody
Cyclin E Breast
adenocarcinoma
Tissue section used in method minus the 
primary antibody
3.4 Methodology for Immunohistochemistry
The histopathology department developed and validated the use o f an automated IHC 
staining technique (DAKO Autostainer®) and this technique was used for all the IHC 
performed in this project as per the department SOP. The protocol was developed using 
known IHC scores to comply with reliability and result reproducibility.
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3.4.1 IHC Technique
A new generation of IHC methods emerged in 1981 using avidin-biotin methods and has 
been used in this project. This relies on the strong affinity that avidin/streptavidin has for 
biotin since both possess four binding sites for biotin (Figure 3.6).
As seen below, the first step is the binding of the primary unlabelled antibody to the tissue 
antigen. The next step is the binding of this antigen-antibody complex to a preformed 
avidin and biotinylated horseradish peroxidise macromolecular complex. Under the light 
microscope the bound complex appears brown in colouration after oxidation and hence is 
clearly visible against the background counterstaining. Addition of DAB as substrate 
results in the colour change. Conversely, if the primary antibody does not bind to the 
antigen (due to its absence), no peroxidase activity will ensue and hence no brown 
colouration will occur. These negatively staining samples are counterstained with 
haematoxylin which produces a blue colour. Use of hydrogen peroxide removes the 
endogenous peroxidase which may have resulted in a false positive result.
Figure3.6: Avidin Biotin complex
Indirect M ethod-A vid in  Biotin co m p lex  (ABC) M ethod
Avidin- Biotin 
C om p lex
Biotinylated S eco n d a ry  Antibod
Primary A ntibody-^!
T is su e  A ntigen
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Antibody optimization was first performed by testing various dilutions on positive controls. 
Hence, optimum antibody concentration was available at the outset, prior to proceeding 
with IHC resulting in maximal positive staining and minimal background staining. 
Microwaving and pressure cooker antigen retrieval techniques are used to expose the
antigens to antibodies. The heat energy disrupts the protein-protein crosslinkage resulting
from formaldehyde fixation and paraffin embedded tissues. The procedure is summarised
below:
3.4.2 DAKO® Autostainer protocol
3.4.2.1 Dewaxing of slides (in a laminar flow hood)
1. Slides were placed in a metal rack and immersed in Xylene® for 2x5 minutes.
2. Slides were then rinsed in a bath of 100 % industrial methylated spirit (IMS) for I 
minute.
3. Slides were then rinsed in tap water for 1 minute.
5. Slides were then washed in a bath of PBS for 5 minutes.
3.4.2.2 Antigen retrieval
1. Slides were placed in a plastic rack and then into a microwave box with 750mls citrate 
buffer. The box was covered with cling film and the cling film then pierced.
2. The box was microwaved at 750-Watt power for 15 minutes.
3. The box was then left to cool for 20 minutes and the slides then transferred to PBS prior 
to loading onto the autostainer.
3.4.2.3 Setting up the autostainer run and preparing reagents
1. The software instructions were followed to enter the number and identification of each 
slide. This also calculated the volume of each reagent required.
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2. The reagents were prepared as per the autostainer instructions and stored on ice until 
ready.
3. The slides were loaded in order, the reagents were inserted into the correct position and 
the autostainer run commenced.
3.5 Immunohistochemistry scoring
Numerous methods exist for evaluation o f immunohistochemical expression, with most 
studies designing novel scoring systems (McClelland et al 1990, Detre et al 1995, 
Macdonald et al 2004). The most frequently used scoring methods include the following:
1. Simple 2 way scoring o f high and low expression with an arbitary cutoff point.
2. Semiquantitative method or Staining Index: This is performed by randomly 
selecting an area showing positive staining, counting 1000 nuclei and 
expressing the proportion o f positive cells as a percentage.
3. Quickscore: This is a qualitative score and involves grading each cell by both
intensity and quantity.
4. ‘H ’ Score: Used frequently in breast cancer incorporates the staining intensity 
and % of cells staining positively.
In consequence, adoption of an established system o f intensity and scoring was deemed an 
appropriate system and the Quickscore was used to grade the intensity o f staning in each 
cell. This system incorporates both the intensity and proportion of tumour cells staining. To 
then obtain the ‘H ’ score, the number of cells in a field was counted to a 100 to determine 
the % o f positively stained cells o f varying intensity. All data analysis was performed using 
the ‘H ’score and is calculated as shown on page 93. Slides in this study were scored using 
the multiplicative ‘quickscore’ (Macdonald et al. 2004) and the ‘H ’ scoring system. The 
amount of staining in each slide was determined by the number o f cells stained and a 
qualitative method to determine the extent of staining the Quickscore. The intensity of
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staining (staining index) was established by randomly selecting an area showing positive 
staining, counting 100 cells and expressing the proportion o f positive cells as a percentage. 
Each slide was given a unique study number to maintain confidentiality. A training set was 
initially prepared by TKM under the supervision o f (BH) a Consultant in Histopathology at 
RSCH with special interest in gynaecological malignancies. This comprised o f positive and 
negative controls as well as slides with various levels of staining. This was referred to in 
cases o f query. Slides were scored by two observers independently and blinded to all 
clinical information. The first scorer, TKM is the author of the thesis, who received 
specific training in ovarian cancer pathology and IHC scoring. The second scorer HC is a 
scientist at the University with an interest in Ovarian Cancer IHC. All slides were 
independently scored by TKM who was blinded to the clinical outcome when the scoring 
was undertaken. BH assessed a random selection of 30. A slide per 10 cases was selected at 
random and independently scored by BH. If there was difference between the scoring o f 
TKM and BH by 5% or greater, a discussion and consensus was reached. Difficult cases 
were also scored by both. Of the 30 slides scored by both, there was a high concordance 
between both BH & TKM with less than 4% of slides requiring reassessment. An initial 
inspection of the entire slide was carried out under low power settings at I Ox 
magnification. Random selections of 3 fields were scored at 40x magnification. A semi­
quantitative staining was used and incorporated both the intensity of staining and the 
number o f cells stained as a percentage as this was considered to be the most accurate 
method o f demonstrating protein expression. Relevant positive and negative controls 
(Table 19) were checked for each run prior to scoring to try to minimise variability.
The intensity of staining was as follows:
Cells with no staining = 0; Cells with staining intensity <25% = 1+ (Weakly positive); 
Cells with staining intensity >25% and < 50% =2+ (Positive); Cells with staining intensity
86
Chapter 3 -  Materials and Methods
>50% = 3+ (Strongly positive). The training slide used to determine the intensity of scoring 
is shown in Figure 3.7.
Figure 3.7: Training slide at 40x magnification showing all levels of staining intensity 
for p57'^‘P^  (JPEG 492*370 pixels) ‘H ’ score=233
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Figure 3.8: A case of a 72 year old patient with grade 3 mixed serous and clear cell 
ovarian carcinoma showing complete absence of p57‘^ ‘’^  staining (0 staining). Slide at 
40x magnification (JPEG 492*370 pixels) ‘H ’ score =0
A
» * *
#
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Figure 3.9: A case of a 56 year old patient with grade 2 endometrioid ovarian 
carcinoma showing a staining intensity of 2+ for pSV'^^l Slide at 40x magnification 
(JPEG 492*370 pixels) ‘H ’ score= 178
%»
%
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-► intensity of 
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Figure 3.10: A case of a 67 year old patient with grade 1 serous ovarian carcinoma 
showing a staining intensity of 3+ for p57‘^ '’^  Slide at 40x magnification (JPEG
492*370 pixels). H score= 235
%
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The same scoring technique was used for Cyclin E and representative figures are shown 
below.
Figure 3.11: A case of a 65 year old patient with grade 1 serous ovarian carcinoma 
showing negative intensity (0 staining) for Cyclin E. Slide at 40x magnification (JPEG
492*370 pixels) ‘H ’ score= 0
Figure 3.12: A case of a 78 year old patient with grade 2 endometrioid ovarian 
carcinoma showing staining intensity of 1+ for Cyclin E. Slide at 40x magnification 
(JPEG 492*370 pixels). ‘H ’ score =77
% %
^  Staining 
intensity of
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Figure 3.13: A case of a 78 year old patient with grade 3 endometrioid ovarian 
carcinoma showing staining intensity of 2+ for Cyclin E. Slide at 40x magnification 
(JPEG 492*370 pixels). ‘H ’ score= 137
r: "
Staining 
-► intensity of
2+
Figure 3.14: A case of a 85 year old patient with grade 3 clear cell ovarian carcinoma 
showing staining intensity of both 2+ and 3+ for Cyclin E. Slide at 40x magnification 
(JPEG 492*370 pixels). ‘H ’ score = 269
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The index was calculated for atleast 3 random positively staining areas on each slide. 
Counting was performed using the cell counter (Figure 3.15).
Figure 3.15: Cell counter used for IHC scoring
___
When the total on the cell counter reached 100, counting was stopped and the data recorded 
in the laboratory notebook. This was then transcribed regularly onto an excel spreadsheet 
and verified with the source document by the supervisor (Figure 3.16). This method 
provided a clear indication of the number and intensity of staining.
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Figure 3.16: Screenshot of IHC database showing IHC scoring over 3 fields
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‘H ’ score calculation
A validated too was used for the assessment o f ‘H ’ score and 3 fields were chosen at 
random at 40x magnification and staining intensity in the nuclei scored as 0, 1+, 2+ & 3+ 
corresponding to negative, weak, intermediate and strong brown nuclear staining 
respectively. (Macdonald et al 2004).
The total number of cells in each field along with the number of cells stained at the 
different intensities are counted and calculated as a percentage and the following formula 
applied:
IHA- H score= (% of cells stained at intensity category 1x1) + (% of cells stained at 
intensity category 2x2) + (% of cells stained at intensity category 3x3)
This results in a H score between 0 and 300 with 300 implied 100% staining of tumour 
cells at 3+.
3.6 Validation of IHC scoring
Variability in staining due to differences o f the protein expression is noted on IHC. 
However, variation in results may occur for other reasons including the staining 
methodology used, inter-observer variability, intra-observer variability and the variation in 
protein expression within a heterogeneous tissue section.
The variability of the IHC scoring was investigated by the author along with the pathologist 
by calculating kappa scores. Kappa scores allow assessment of differences in scoring by 
giving weighting to the differences in each score. This precision pertaining to agreement 
between observers (interobserver agreement) is the Kappa statistic (Viera et al 2005). It 
offers readers a quantitative measure of the extent of interobserver agreement in a study. 
When analysed in this study, the IHC quickscore method was highly reproducible 
(unpublished observations).
93
Chapter 3 -  Materials and Methods
3.7 Statistical Analyses
All data were recorded on Microsoft Excel® during various stages o f data collection and 
immunohistochemistry (IHC) scoring in a raw form. Extensive data cleaning was then 
performed by the author and discussed with the statistician Mr Peter Williams from the 
Department of Statistics, University o f Surrey. All statistical analyses were performed 
using SPSS® Version 18 & 19 along with Mr. Williams. Microsoft Excel® was also used to 
obtain relevant graphs and for some descriptive statistics.
The various statistical tests used are described in detail in the relevant sections below.
Data checks were carried out to identify “outliers” and “missing data”. In such instances 
the source data was rechecked to confirm the absence o f a mistake. Outliers have not been 
removed during the data analysis except when explicitly mentioned. Attempts have been 
made to minimise missing data unless unavailable historically (ex CA-125 at diagnosis or 
ascites at surgery etc).
To examine the association between two categorical variables within a single group, cross 
tabulation of data is presented. This has helped provide insight into the sub-group structure 
within the presented data.
Statistical analyses invariably involve comparisons either between subject groups, 
treatments or tests. “Effect” is the numerical value corresponding to the comparison. 
Hypothesis testing is about the difference between parameters. The “null” hypothesis when 
accepted states that there are no difference between the groups being compared and the 
effect of interest is zero. When the null hypothesis is rejected, suggesting there is a 
difference between the groups and the effect of interest is not zero, the alternative 
hypothesis is accepted.
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3.7.1 p value”
The p value is the probability o f observing the result/data assuming the null hypothesis is 
true. The p value is expressed between 0 and 1. An arbitrary accepted cut off for statistical 
significance is usually 0.05 (i.e. less than 5% probability that the observed difference is 
likely to be the result of chance) and any result below this has been considered significant 
in this study in keeping with the medical literature.
Different hypothesis tests are suitable for the various parameters collected. Normally 
distributed data in this study have been analysed using parametric tests described later. 
Non-parametric tests have been used for data with no distributional requirements.
The data in this study consists essentially o f clinicopathological variables and univariate 
analysis has been undertaken. A significant proportion o f the data is o f a qualitative nature. 
The staining results were analysed using Mann Whitney U Test (MWU) which is a non- 
parametric test to compare data from two independent groups. The Chi (%2) square and 
Fisher exact test were used to test whether the proportions across a number of independent 
groups or in two categories respectively are the same.
3.7.2 Correlation
To study any possible association between variables and the degree o f association should 
one exist, correlation analysis is performed and the correlation coefficient is calculated. 
Two correlation coefficients are used (Pearson’s & Speaiman’s) and we have used both in 
this study.
The Pearson’s (r) is used in a linear relationship. This varies from -1 indicating a negative 
association to +1 suggesting a positive association.
The Spearman’s (rg rho) is a non parametric measure of correlation coefficient assessing the 
existence of a monotonie non-linear relationship.
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3.7.3 Survival Data Analysis
This data is concerned with the time it takes an individual to reach a certain endpoint of 
interest such as relapse or death. The simplest way to express survival data is calculating 
the mean in normally distributed data and the median in non-parametric datasets. In this 
study, I have used both; however, the median may not always be relevant especially at 
certain points in the study when there may not be sufficient number of subjects in a certain 
group. In calculating survival data, two factors are taken into consideration. Firstly, it is the 
length o f time that an individual takes to reach an endpoint rather than whether it is reached 
and secondly whether the end point is actually reached when last followed up in the study 
(right censored data). In real time as in this study it is nearly impossible to obtain a 
complete dataset with no patients lost to follow up and having reached the endpoint (in this 
study either relapse or death). While it would be ideal to have mature data on all study 
individuals this is not feasible. The Kaplan-M eier method is a statistical technique 
allowing for right censored observations and making use o f the information at the time 
when they were censored. To perform this analysis a “life table” is first constructed. This 
consists of a table listing the individuals and their survival times from shortest to longest 
period. Considering the time in several small intervals, the probability of surviving a 
certain length of time is calculated. The survival curve is presented as a “step function” and 
censored data is removed from subsequent analyses. The resulting data is plotted as a 
survival probability against time and censored cases are usually denoted by the symbol “+”. 
The assumption made during this analysis is twofold. Firstly censoring is considered to be 
a random event and we assume that the censored cases would behave no differently to the 
other individuals within the original group. In this study, if a death is unknown since last 
follow up, the data is incorrectly censored thus introducing bias. The cause o f death was 
recorded and if death resulted from another cause, the data has been treated as right
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censored. However, statistically, this is only valid if  the cause of death is completely 
unrelated to EOC. Another assumption is that irrespective o f the time patients enter the 
study survival prospects are the same. The Kaplan-Meier plot graphically displays 
differences in survival between groups. It does not, however, estimate statistical 
significance.
3.7.4 Log rank statistic
When comparing survival between two independent groups or to compare several groups 
of subjects (ex. in this study between the NACT and PD group) the log rank test is 
preferred. This is a non-parametric method for null hypothesis testing and deduces if 
statistically significant differences exist. The working principle is division o f survival 
timescales into intervals that are distinctly observed survival times and ignores censored 
data allowing for interpretation of survival differences across the whole study duration 
rather than specific time points. A 2x2 table o f observed (O) and expected (E) events (ex. 
death) is constructed and comparison performed by using the formula below: 
x2 = I [ E - 0 f / E .
To reach the p value, the degree o f freedom is used relating to the number of comparison 
factors. This was computed using SPSS throughout. The assumptions made for Kaplan- 
Meier will also hold true for log rank test and this test should not be used if  the Kaplan- 
Meier is not significant, as this suggests variation in the relative proportions o f events 
between the groups being studied.
3.7.5 Multivariate Analysis & Statistical Modelling
Mathematical models best describe the relationship between an outcome and one or many 
variables to provide description of observed data and is known as statistical modelling. It 
does not describe the underlying mechanism o f relation however, offers a more simplistic
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explanation of the data. As mentioned above, the log rank test compares survival between 
two or more groups but does not allow for the confounding effect (potential influence of 
associated factors) and does not explore the effects of multiple variables on survival.
In 1972, Cox introduced a semi-parametric regression method to investigate the 
simultaneous effects o f several variables. It is known as the Cox regression model or 
proportional hazards regression analysis. In this study, the Cox model has been used to 
establish the interrelationship between various variables and survival. This is then used to 
test the independent effects of variables on the hazard (the risk of an individual at any 
given point in time o f reaching the endpoint) and the exponential o f this is estimated as the 
hazard ratio (HR). The Cox model produces a baseline survival curve and provides an 
estimate of the effects on survival after adjusting for other explanatory variables. This is 
undertaken by backwards stepwise regression which involves removing each variable from 
the model and measuring the effect resulting in an estimate o f the independence and size of 
effect for each variable on the overall HR.
A HR of one for any given variable indicates that variable as having no influence on 
survival. The HR produced for each variable reflects the increased or decreased likelihood 
of death at any time point due to this factor. The backwards stepwise process continues 
until the only variables remaining in the model are all statistically significant. In this final 
model, a HR of greater than one means the factor is associated with increased likelihood of 
death, and less than one with a reduced likelihood of death. Greater effect on survival is 
noted by a variable the further away the HR is from one. It involves complex modelling or 
regressing the survival times (HR) on variables. Confidence Intervals (Cl) have also been 
generated representing the plausible range of values in the parameters collected. In 
normally distributed variables, 95% of values will lie in the interval between mean +/- 2 
SD and hence 95% Cl are most commonly used in medical research. A variable is only
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capable o f having an independent effect on survival if  its Cl range is on either side of one. 
Any variable with a 95% Cl straddling one is capable of either a positive or negative effect 
and is not an independent prognostic factor. Apparent statistical significance o f a variable 
on univariate analysis is put to test by using the Cox model and may fail if 95% Cl 
straddles one suggesting that the variable is confounded by other truly prognostic variables. 
Similarly to Kaplan-Meier and log rank testing, the Cox model assumes that a variable’s 
effect on prognosis remains constant throughout the study. Therefore, variables with 
crossing Kaplan-Meier curves should not be included in this model since the assumption is 
then invalid and, variables not statistically significant prognostic factors on univariate 
analysis should certainly not be included in a Cox model.
Development of a predictive model for overall survival (OS) to predict the lyr, 2yr and 3yr 
OS was attempted. This was then tested against the data since the true OS had already been 
calculated. The model while assisting in predicting also exhibited some variation between 
the true survival and the predicted survival. In some cases, the model predicted a better 
survival than the actual OS and these cases have been marked as ‘underperformers’. In 
other instances, the model predicted a much poorer survival percentage. However, the 
actual OS was much higher in these cases and they have been defined as ‘overperformers’. 
The final model was tested for the assumption o f proportional hazards underlying the Cox 
regression to ensure that the application o f the technique was valid.
Following IHC scoring and compilation of the database, data analysis was undertaken and 
the results from the IHC and statistical analyses are discussed in the next chapter.
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Chapter Introduction
This chapter encompasses all the results generated as part o f this thesis incorporating 
results o f analysis of the cohort, the IHC scoring data for both p57^‘^  ^and Cyclin E as well 
as the survival data correlating them. This chapter is divided into the following sections. 
Section 4.1 provides a brief overview of the collected data and clinical trial 
recruitment. (Pages 102-103)
Section 4.2- 4.5 analyses the data from the cohort to provide information prior to 
incorporating the laboratory work and is explained below. (Pages 103-136)
Section 4.2 analyses the cohort for demographic data such as age, performance status, 
tumour marker (CA 125), primary treatment and other cancers present in this cohort.
Section 4.3 analyses data collected at the time o f surgery including volume o f ascites and 
bulk o f residual disease following surgery.
Section 4.4 provides analyses of data collected following surgery in the same cohort 
including the grade, stage, histological subtype, cytology of collected fluid, cause o f death 
and the duration of follow-up in the cohort.
In Section 4.5 survival data analyses including disease free survival (DPS) and overall 
survival (OS) for the cohort is analysed with various parameters such as the primary 
treatment, type o f chemotherapy, bulk of residual disease following surgery, grade and 
FIGO stage.
Section 4.6-4.9 analyses the data with regards to p57^^  ^(Pages 137-165) 
p 5 7 kip2  expression is compared and cross-tabulated with age at diagnosis, primary 
treatment, residual disease, stage, grade and histology in Section 4.6. (Pages 137-149) 
Subsequently analysis of the IHC scores previously obtained for p57^^  ^ from this 
cohort with various parameters is described. (Pages 149-163)
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In Section 4.7 survival analyses (DFS and OS) o f various parameters against the 
p57kip2expression is shown. (Pages 151-157)
The final section o f p57'^‘^ ^data analyses in Section 4.8 uses Cox modelling incorporating 
all o f the above described data into a Cox model separately for DFS and OS to allow 
factors of statistical significance to emerge. (Pages 157-164)
In Section 4.9 some o f the outliers in the data are discussed providing examples o f the 
cases they represent. (Pages 164-165)
The next few sections focuses on Cyclin E as described below. (Pages 165-184)
In Section 4.10 Cyclin E expression is compared and cross-tabulated with age at diagnosis, 
primary treatment, bulk of residual disease, stage, grade and histology. (Pages 165-175)
In Section 4.11 survival analyses (DFS and OS) o f various parameters against the Cyclin E 
expression is shown. (Pages 175-184)
The last section of the data analyses in Section 4.12 uses multivariate (Cox modelling) 
incorporating all the previously analysed parameters to allow factors o f statistical 
significance to emerge for both DFS and OS. (Pages 185-187)
Attem pts a t predictive statistical modelling are  described in Section 4.13. (Page 188) 
Section 4.13 is the last section in this chapter and sum marizes the main findings from 
the extensive data analyses. (Pages 189-190)
4.1 Data Collection
As mentioned in the previous chapter, cohorts o f 256 patients were considered suitable for 
inclusion in this study based on the inclusion and exclusion criteria mentioned in the 
previous chapter (Section 3.2).
4.1.1 Clinical Trial Recruitment
During the period of recruitment to this study, the unit was also recruiting to other clinical 
trials and many of the 256 women were recruited into several ongoing national clinical
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trials such as (CHORUS, ICON 7 etc) as well as local trials as mentioned below along with 
the number o f women recruited into each:
CHORUS: Randomised two-arm, multicentre trial to determine the impact o f timing of 
surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, 
primary peritoneal or fallopian tube carcinoma. N=42
ICON 6: Randomised three-arm, three stage, double-blind, placebo-controlled multi-centre 
Gynaecologic Cancer InterGroup (GCIG) phase III trial. N= 32
ICON 7: Randomised (1:1 ratio), two arm, multi-centre, (GCIG) open-label phase III trial 
designed to evaluate the safety and efficacy of adding bevacizumab, to standard 
chemotherapy (carboplatin and paclitaxel), in patients with advanced EOC or PPC. N= 20 
BIBF: Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of 
BIBF 1120 in Combination with Carboplatin and Paclitaxel Compared to Placebo plus 
Carboplatin and Paclitaxel in Patients with Advanced EOC. N=10
4.2 Cohort Demographics
4.2.1 Age
The age at the time of diagnosis of the patients in this cohort ranged from 17-90 years as 
shown in (Figure 4.1) with a median age o f 65 years and a mean of 63 years (SD 12.8) and 
subdivided by primary treatment as shown in the Table below.
Table 4.1: Distribution of age by primary treatment
Age in years All patients 
n=256
NACT n=96 PD n=160
<30 5(1.9%0 0 5(3.1% )
30-49 33 (12.8%) 7 (7.2%) 26 (16.2%)
50-69 131 (51.1%) 51 (53.1%) 80(50%)
70-90 87 (33.9%) 38 (39.5%) 49 (30.6%)
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Figure 4.1: Age range of women recruited to study with the biggest group between
50-69 years of age
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4.2.2 Eastern Cooperative Oncology Group Performance Status
The Eastern Cooperative Oncology group (ECOG) was setup in 1955 with the aim of co­
operation to launch multicenter clinical trials. The ECOG performance status (ECOG PS) 
is a functional scale very widely used by medical professionals and researchers to 
determine symptom status, disease prognosis as well as effect of the malignancy on the 
patient in relation to daily living, self-care and mobility. It is divided from 0 to 5 with 0 
indicating a fully active person with the ability to carry on all pre-disease activity without 
restriction and 5 indicating death as shown in Table 4.2.
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Table 4.2 showing classification of ECO G  perform ance status
Grade I ECOG
0 1 Fully active, able to carry on all pre-disease performance without 
restriction
I Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work
2 Ambulatory and capable of all self care but unable to carry out any work 
activities. Up and about more than 50% of waking hours
3 Capable of only limited self care, confined to bed/ chair more than 50% 
o f waking hours
4 1 Completely disabled. Cannot carry on any self care. Totally confined to 
1 bed or chair
5 1 Dead
In the above cohort, the patients were assessed upon presentation to the gynaecological 
oncology team and the ECOG status was recorded in all cases as shown in the graph in 
Figure 4.2.
To assist in modelling survival, the ECOG status was recoded into 2 groups only. PS of ‘0’ 
and ‘1’ were grouped together as PS o f ‘0’ and compared with the other groups from ‘2’ till 
‘4 ’ as PS of ‘r .  This recoding was based on the former group being able to carry out self 
care and other work (office/house work) and the latter group only being able to undertake 
varying proportions of self care and is shown in the graph (Figure 4.2 and Table 4.4). 
Figures 4.2 and 4.3 are shown below each other to demonstrate the redistribution when 
recoding of PS was done as are the Tables 4.3 and 4.4.
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Figure 4.2: Distribution of patients by ECOG status 
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Figure 4.3: Recoded ECOG performance status 
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Table 4.3: Patient ECOG performance status classified by their primary treatment
ECOG PS All patients n=256 NACT 
n=96 (37.5%)
PD
n=160 (62.5%)
PS=0 47(18.4%) 17(17.7%) 30 (18.7%)
PS=1 137 (53.5%) 47 (48.9%) 90 (56.2%)
PS=2 68 (26.6%) 31 (32.2%) 37(23.1%)
PS=3 4(1.6%0 1(1%)) 3(1.8% )
Table 4.4: Recoded ECOG performance status further divided by primary treatment
ECOG PS All patients n=256 NACT n=96 PDn=160
PS=0 184 (71.8%) 64 (66.6%) 120 (75%)
PS=I 72 (28.2%) 32(33JH4) 40 (25%)
4.2.3 Other Cancers
In this cohort, there were 183 women with a diagnosis of OC only with no other previously 
diagnosed malignancy. However, the remaining women were diagnosed with another 
cancer either prior to the OC diagnosis, a synchronous tumour at this diagnosis or 
diagnosed during the course of the study during follow-up. They are demonstrated on the 
pie chart (Figure 4.4) with breast cancer being the commonest in 55 women followed by 
corpus cancer which is diagnosed as a synchronous tumour at the time o f surgery in this 
cohort in 11 cases.
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Figure 4.4: Synchronous tumours diagnosis while on treatment for EOC
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4.2.4 CA-125
The CA-125 was available at diagnosis in 254 cases. It was unavailable in 2 cases despite 
extensive searching with the GP practice, hospital notes and the biochemistry laboratory. 
The exhibited median CA-125 was 476 with a range o f (7-19000).
The CA-125 was also documented in the notes just prior to surgery. This had been 
performed either following consultation in clinic with a member of the surgical team or by 
pre-operative assessment while assessing fitness of the patient for surgery. This data was 
available in 253 cases. The median CA-125 was 275 with a range of 2-12982 (Table 4.5). I 
have not reported the mean in the above situation as there is one outlier and the mean is 
compromised by outlier values in a skewed distribution. The mean CA-125 prior to surgery
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has nearly halved from the mean CA-125 at diagnosis from (1270+/-2397) to (720 +/- 
1465) with a mean drop in CA-125 o f 549 +/-1875. (two sample t-test, p < 0.005). This 
may be explained by the fact that in 37.5% of cases, chemotherapy was the primary 
treatment and surgery was performed after 3-4 cycles. In 4 women who received NACT, 
the CA-125 prior to surgery was higher than the CA-125 at diagnosis indicating a 
worsening biochemical response to treatment.
Table 4.5: CA-125 distributed by primary treatment
Primary
Treatment
CA-125 Range at 
diagnosis
CA-125
Range prior to 
surgery
Median 
CA-125 at 
diagnosis
Median 
CA-125 prior 
to surgery
NACT=96 46-19000 13-2117 857 197
PD= 160 7-16000 7-12982 314 309
4.2.5 Primary Treatment
Following diagnosis, primary treatment depended on various factors including ECOG PS, 
tumour volume, ability to commence treatment, patient choice and availability o f operating 
slots for surgery. The cohort was subdivided by primary treatment into either NACT 
(n=96; 37.5%) or PD (n=160; 62.5%) as shown in Table 4.5.
O f the 160 who had surgery first, 25 had primary surgery as part of a study randomising 
primary treatment into either upfront surgery or neo-adjuvant chemotherapy.
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The 96 women who received chemotherapy as their primary treatment were further 
subdivided into women receiving only single agent carboplatin (C) chemotherapy and 
those receiving combination chemotherapy of carboplatin (C) and paclitaxel (CP) as shown 
in the (Figure 4.6) below. 12 (12.5%) women received single agent C alone and 83 (86.5%) 
received both CP chemotherapy. 1 patient received 3 weekly epirubicin and C with 5FU 
Figure 4.6.
Figure 4.6: Distribution by type of chemotherapy in the primary chemotherapy group
Type of Chemotherapy
90
80
70
1 60
'5 50
8.
*5 40
i 30
20
10
0
. ■
12
f e t i c J  ... . Ï-.  ^ ---------
Carboplatin only Carobplatin +Paclitaxel 
Chemotherapy type
Other
11 0
Chapter 4: Results
In the NACT group, the number of cycles prior to surgery varied from 1 to 6 with 
62(64.6%) receiving 3 cycles and 25 (26%) receiving 4 cycles. The distribution of the 
number of cycles is shown in Figure 4.7.
Figure 4.7: Showing no. of cycles of primary chemotherapy prior to surgery
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Following primary surgery in the 160 women, 23 (14.4%) women declined adjuvant 
chemotherapy due to various reasons including worsening quality o f life (QoL). The 
distribution of type of treatment is shown below (Figure 4.8). 25 (15.6%) had single agent 
carboplatin only, 108 (67.5%) had combination CP chemotherapy while 4 (2.5%) had other 
types of chemotherapy.
I l l
Chapter 4: Results
120
100
c 80
Qi
Eo
^ 60
Figure 4.8: Adjuvant treatments following primary debulking 
Adjuvant chem otherapy  post su rgery
40
20
0
108
25
. . . .  1
4
Declined Carboplatin only Carobplatin
+Paclitaxel
Type of chem o
Other
In the NACT eohort of n=96, the median decrease in the 494.5 with a range o f (698 to 
18402). The negative value implies that in 4/96 cases the CA-125 increased despite NACT 
suggestive of a poor bioehemical response and possible progression while on treatment. In 
all 4 of these cases the patients were noted to be BRCA earriers.
In the next section, data collected at the time of surgery including volume of ascites 
and bulk of residual disease following surgery is described.
4.3 Per-operative Data
Intraoperatively, the following data has been colleeted: 
o Any ascites, free fluid 
o Bulk of residual disease following surgery
1 1 2
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4.3.1 Ascites
The volume of aseites or free fluid present at the time of surgery was recorded in all cases 
in the operation notes and grouped as shown below in Figure 4.9. Further subdivision by 
primary treatment is shown in Table 4.6 below:
Table 4.6 showing volume of ascites at surgery by primary treatment
Volume of ascites All patients NACT PD
n=256 n=96 n=160
No ascites 100 (39%) 55 (57.394) 45 (28J94)
<500mls 80 (31.2%) 28 (29.2%) 52 (32.5%)
>500mls 79 (30.8%) 13(13.5%) 63 (39.4%)
A Mann Whitney U Test with p <0.0005 indicated a statistically significant difference
between the two treatment groups with the PD group having a higher volume of ascites.
Figure 4.9: Distribution by volume of ascites at surgery 
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4.3.2 Residual Disease
The bulk of residual disease was not recorded in 4 cases (3 in the NACT group and 1 in the 
PD group). A three way score was used to indicate extent of cytoreduction with ‘O’, ‘ T and 
‘2’ indicating nil macroscopic residual disease, disease volume less than 0.5cm and disease 
volume greater than 0.5cm respectively following surgical debulking effort and is shown in 
Figure 4.10. A Mann Whitney U Test with p <0.01 indicated a statistically significant 
difference between the two treatment groups with the NACT group having a higher 
residual disease following IDS.
Table 4.7: Residual disease by primary treatment
Bulk of residual 
disease
All patients 
n=256
NACT
n=96
PD
n=160
Nil visible 112(43.75%) 29(31.2%) 83(52.2%)
<0.5 cm 48(18 /^4 ) 25 (26.9%) 23(14.5%)
>0.5 cm 92 (35.9%) 39(41.9%) 53(33.3%)
Missing 4(L5%0 3 (3.194) 1 (0.6%)
Figure 4.10: Distribution of residual disease 
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This section analyses data collected following surgery including histological data, 
clinical staging and follow-up
4.4 Post Surgery
Following surgery, the histology was discussed at MDT and covered grade, stage, 
histological subtype and if  cytology was positive for metastatic disease.
4.4.1 Grade
The grade was classified using the FIGO classification into grade 1 (01), grade 2 (02) and 
grade 3 (03) or low, intermediate and high grade respectively and is shown in the Figure 
4.11 and Table 4.8.
Figure 4.11: Distribution of cohort across tumour grade
Division by Grade
G1 Low G2 Intermediate G3 High 
Grade of Ovarian Malignancy
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Table 4.8 below shows the tumour grade by primary treatment
All patients 
n=256
NACT
n=96
PD
n=160
Low grade (G l) 11 0 11 (6.9%)
Intermediate 
grade (G2)
3:» 9 (9.4%) 23 (14.4%)
High grade (G3) 213 87 (90.6%) 126 (78.8%)
4.4.2 FIGO Stage
The stage of disease in both groups shows a classical distribution with Stage 3c being the 
commonest stage of presentation. Advanced stage (Stage 3 & 4) was diagnosed in 92.9% of 
cases (Figure 4.12) and did not differ by primary treatment (Table 4.9).
Table 4.9 showing FIGO stage distribution by primary treatment
FIGO Stage All patients n=256 NACT 96 PD=160
Stage 1 8 0 8(5% )
Stage 11 9 1 (194) 8(5% )
Stage 111 186 61 (63.5%) 125 (78.1%)
Stage IV 53 34 (35.5%) 19(11.9%)
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Figure 4.12: Distribution of patient cohort by FIGO stage 
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4.4.3 Cytology
At surgery, free fluid (ascites) was collected for cytological examination. If no free fluid
was present, 50mls of normal saline was flushed into the pelvis and collected as shown in
Figure 4.13below:
Figure 4.13: Results of cytological analysis of ascites/washings 
Cytology of Peritoneal Washings
Negative Positive Not sampled
Results of cytology
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When subdivided by primary treatment (Table 4.10), women receiving NACT had 64.5% 
positive cytology as compared to 83.3% in the PD group which may be explained by 
response to chemotherapy.
Table 4.10 showing distribution of cytology by primary treatment
Cytology NACT n=96 PDn=160
Negative 33(34.4%) 26(16.3%)
Positive 60(62.5%) 130(81.3%)
Not sampled 3 (3.194) 4 (2.594)
4.4.4 Histology
The 256 cases included in the EOC IHC database were mostly EOC with low numbers of 
non-epithelial OC as shown in Table 4.11
Table 4.11: Histological subtype subdivided by primary treatment
Histological subtype Total
n=256
NACT
n=96
PD
n=160
Epithelial
Serous 151 77 (80.2%) 74(46.3%)
Endometrioid 29 4 (4.2%) 25 (15.6%)
Mucinous 22 4 (4.2%) 18(11.3%)
Clear cell 28 5(5.2%0 23 (14.4%)
MMMT 19 6(&3%0 13(8.1%)
Non-epithelial
GCT 7 0 7 (4.4%)
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4.4.5 Cause of Death
The cause of death was scored as ‘0’ if death occurred as a result of the OC or ‘1’ if  other 
causes as shown in the 6 cases below (Table 4.12). Six patients died within 30 days of 
surgery. Thirteen died prior to completing their adjuvant chemotherapy.
Table 4.12: Cause of death if not resulting from ovarian cancer
Other cause o f death N=6
Myocardial Infarction 2
Relapse from breast cancer 2
Unprovoked fatal pulmonary embolus 2
78 women were still alive from both groups when data collection ended in August 2012 as 
shown in Table 4.13
Table 4.13: Status of cohort at the end of data collection
Primary Treatment Total Alive Deceased
NACT 96 19 77
PD 160 59 101
Both 256 78 178
4.4.6 Follow-up
The median follow-up in this group was 1560.5 days implying that one half o f the women 
were followed up for atleast 4.27 years. The minimum duration of follow-up was 396 days 
and the maximum duration was 6251 days (396-6251). Of these, 6 were lost to follow-up 
as they had moved out o f the area and the author was unable to procure any further 
information. Three women were discharged from follow-up after 5 years o f surveillance. 
O f the 178 women who died during this study, median survival time was 522 days (range 
5-3268).
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4.5 Survival Data Analysis
In this section, survival using the above described data is estimated.
4.5.1 Disease Free Survival
Disease free survival (DFS) is calculated from the date when completed chemo OR where 
no chemotherapy taken, date o f operation or date of last primary treatment to date of 
relapse OR where no relapse has been observed, date patient last seen.
DFS has only been calculated in those cases where 6 cycles of chemotherapy and surgery 
was completed in no particular order. DFS is available in 237 cases. In the remaining cases, 
it was unavailable due to the following reasons:
• Patient deceased immediately following surgery (less than 6 weeks) and did not 
commence adjuvant chemotherapy in 6/256 cases.
• 13/256 women commenced adjuvant chemotherapy however did not complete 6 
cycles.
• 19/256 (7.42%) did not complete chemo due to the following reasons and hence 
DFS has not been calculated in such cases.
• Of the remaining 237, 198 (83.5%) suffered disease relapse during this study and 
39(16.5%) remained disease free till last follow- up date as shown in the Table 4.14 
below:
Table 4.14: Relapse versus disease free state by primary treatment
Disease Status NACT
n=90
PD
n=147
Number 
N= 237
Relapse 86 112 198
No Relapse 4 35 39
DFS is tabulated below separately by primary treatment. Table 4.15 below is for patients 
who suffered a relapse while Table 4.16 is for women who did not suffer a relapse.
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Table 4.15 showing disease free survival by primary treatment in relapsed patients
Primary
Treatment
Number Range (in days) Median (in days)
NACT 86 9-1154 225.5
PD 112 0-2421 318.5
Table 4.16 Disease free survival by primary treatment in women without relapse
Primary
Treatment
Number Range (in days) Median (in days)
NACT 4 679-1257 1176.5
PD 35 1-3142 1312
4.5.2 Overall Survival (OS)
Overall survival is calculated from the date o f diagnosis to the date o f death (DOD) or 
survival status last seen in cases still alive and is available in all cases.
Patients were followed up according to a local protocol, three monthly for two years, 6 
monthly for 5 years and thereafter annually for 10 years prior to discharge. Follow-up data 
was rechecked in August 2012 just prior to data analysis and recorded to ensure calculation 
of the most up to date survival dates. OS ranged from 0- 205 months and is shown in Table
4.17 and 4.18.
Table 4.17: Overall Survival by primary treatment in the deceased
Primary
Treatment
Number Range (in days) Median (in days)
NACT 77 5-2098 525
PD 101 10-3268 68&6
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Table 4.18: Overall Survival by primary treatment in patients alive as on August 2012
Primary
Treatment
Number Range (in days) Median (in days)
NACT 19 536-2913 1254
PD 59 396-6251 1734
As previously mentioned, the bulk of residual disease has been reclassified as “0” meaning 
no visible macroscopic disease and “ 1” implying some visible macroscopic disease. The 
median survival is not reported here as there was insufficient number o f cases in Stage 1 & 
2. Table 4.19 shows OS at 1, 2 and 3 years following diagnosis.
The total follow up period was 205 months and during this period 69.5% of women died. 
While the data is available to clarify that not all patients succumbed to the disease, the case 
fatality rate does appear to be higher in this series than the accepted rate o f 65% (Jolies et 
al 1985). Since the known associations with clinicopathological variables and the 
prognostic value of Cyclin E was consistently reproduced in this series, it was decided that 
although the fatality rate was high, the otherwise expected correlations with previous 
studies of EOC survival, allows for its valid use in assessing novel prognostic marker 
expression. In addition, as the markers assessed compared differences in survival within the 
tumour population, any confounding effects on survival would be equally attributable to all 
patients within the cohort.
There are various reasons that might account for this worse survival. Patient factors include 
older aged patients; worse ECOG PS. Disease factors may include more number o f high 
grade and poor prognosis tumours like MMMT and clear cell carcinomas. Treatment 
factors such as delayed diagnosis, inadequate staging and suboptimal treatment prior to 
centralisation of the gynaecological oncology department in our centre may also be 
contributory. Bristow et al in 2006 and a more recently published Cochrane review
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demonstrated better OS in women treated at centres (Bristow et al 2006, Woo et al 2012). 
Similar observations, suggesting that survival rates in the UK for gynaecological cancer 
were poor in comparison with other developed countries, has led to implementation of 
changes to the framework of cancer services. These improvements have been coordinated 
through initiatives such as The NHS Cancer Plan and The Cancer Reform Strategy which 
included centralisation o f services, reducing waiting times, sub-specialisation o f care (NHS 
Plan 2000 and NHS cancer reform strategy 2007).
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Table 4.19: shows Overall Survival at 1 ,2  and 3 years following diagnosis.
V ariable %  surviving a t 
1 year
%  surviving a t 
2 years
%  surviving a t 3 
years
Bulk of residual disease
0 88.4 77.6 65.6
1 64.3 43.4 2 6 2
Patients received chemo as part 
o f primary treatment
Yes (n=233) 77.7 60.8 44.7
Combined chemo (CP) 81.2 63.7 47.2
Single agent (C) 622 45.9 3 2 2
No (n=23) 43.5 34.8 30.4
FIGO stage
18(3.1) 87.5 87.5 87.5
11 9 (3.5) 8&9 66.7 55.6
111 186 (92.9) 76.3 60.1 47.1
IV 53 (20.7) 64.2 47.2 21.5
Histological Grade
Grade 1 90.9 81.8 81.8
Grade 11 78.1 6Z5 526
Grade 111 73.2 56.7 3 9 ^
124
Chapter 4: Results
4.5.3 Survival by treatment type
Disease free survival (by prim ary  treatm ent)
O f the 96 NACT patients, there was no information available in 6 cases. 86 (95.6%) o f the 
remaining 90 women suffered a relapse. O f the 160 PD cases, data was missing in 13 cases. 
112 (76.2%) o f the remaining 147 were diagnosed with a recurrence o f the original OC as 
shown in Table 4.20.
Table 4.20 showing disease free and overall survival by prim ary treatm ent
DFS
Primary
Treatment
Total Missing Remaining Recurrence
NACT 96 6 90 86 (95.6%)
PD 160 13 147 11:2(76/294)
N=256 19 237 233
OS
Primary
Treatment
Total Alive Dead
NACT 96 19 77 (80.2%)
PD 160 59 101 (63.1%)
N=256 78 178
DFS comparing the 90 NACT cases vs 147 PD cases using log rank test shows a p<0.0005 
indicating a highly statistically significant improvement in survival amongst the PD group 
see Kaplan-Meier plot (Figure 4.14).
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Overall Survival by primary treatment
OS comparing all cases in the 2 subgroups (96 vs 160) using a log rank test results in a 
p=0.002 indicating statistically significant improvement in survival among the PD group 
(see Kaplan-Meier plot Figure 4.15).
Figure 4.14: Kaplan-Meier plot showing improved disease free survival with primary
surgery
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Figure 4.15: Kaplan-Meier plot showing improved overall survival following primary
surgery
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4.5.4 Survival by type of chemotherapy
Single agent carboplatin chemotherapy was delivered to 37 women and 191 received 
combination chemotherapy with carboplatin (C) and paclitaxel (CP). When survival was 
compared using log rank test based on the type of chemotherapy to assess if adding 
Paclitaxel to single agent carboplatin provided any additional benefit, no significant 
difference was noted for both DPS and OS. See Kaplan-Meier plots (Figure 4.16&Figure
4.17 respectively).
Of the 228 (89%) women who completed chemotherapy, 37 received single agent 
carboplatin alone while the remaining 191 received combined carboplatin and paclitaxel 
chemotherapy.
Figure 4.16: Kaplan-Meier plot with no difference in disease free survival on
Paclitaxel addition
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A log rank test to compare the type o f chemotherapy (30 C vs 180 CP) and DFS produced a 
p = 0.962 indicating no statistical significance; however, the number of women on single 
agent carboplatin were very small to draw significant conclusions.
The OS using the log rank test in both groups (37 C vs 191 CP) generated a p=0.254 
suggesting no statistical significance implying that CP chemotherapy did not necessarily 
improve survival. However, this test is performed under the assumption that comparing 
both treatment arms of C vs CP have homologous cohorts o f patient population. The 
definitive method of undertaking this comparison is to compare the type of treatment and 
type of chemo while adjusting the possible effect of age at diagnosis, CA-125 at diagnosis, 
bulk of residual after surgery, grade, ECOG PS, FIGO stage and histology. This is done 
using Cox regression models (also known as proportional hazards regression analysis) as 
shown in Figure 4.17.
Figure 4.17: Overall Survival by type of chem otherapy
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4.5.5 Survival and bulk of residual disease after surgery
DFS and OS were significantly better in patients rendered with nil macroscopically visible 
disease. Initially the analysis was performed using 2 parameters only i.e. comparing nil 
visible disease with some disease using a log rank test. A highly statistical significance of 
p<0.0005 was noted for both DFS and OS confirming that patients with nil visible disease 
had better survival than those with disease. DFS when categorised into 2 groups by either 
presence or absence of any disease seen on Kaplan-Meier plot below Figure 4.18. This 
illustrates statistically significant worsening of survival with any macroscopic disease. Log 
rank= p<0.0005.
Figure 4,18: Improved disease free survival with no visible disease following surgery
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Kaplan-Meier plot (Figure 4.19) showing OS when categorised into 2 groups by either 
presence or absence of any disease. This illustrates statistically significant worsening of 
survival with any macroscopic disease. Log rank= p<0.0005.
Figure 4.19 Improved overall survival with no visible disease following surgery
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To further understand if the volume of disease had an influence on survival, residual 
disease was divided into 3 categories as below:
• no disease
• disease<0.5 cm
• disease>0.5 cm
The Kaplan-Meier plot below Figure 4.20showing DFS divided into 3 groups. This 
demonstrated significant reduction in survival with increasing volumes o f residual disease. 
Log rank=p<.0005.
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Figure 4.20 showing improved disease free survival with nil residual disease
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Similar findings with OS when divided into 3 groups as seen in the Kaplan-Meier plot 
belowFigure 4.21. This demonstrated significant reduction in OS with increasing volumes 
o f residual disease. Log rank= p<.005.
Although there are several factors that contribute to the clinical course of women with 
advanced EOC, there are several studies in the literature suggesting that amount of residual 
tumour remaining after initial cytoreduetion is a key determinant of survival (Vergote et al 
2010).
Previously, optimal cytoreduetion was considered to have been achieved if individual 
residual tumour nodules were less than 1cm in size in maximal diameter. Recent evidence 
suggests that even in the optimally cytoreduced patients as defined above, improved 
survival was noted in the subset of women with no visible disease. Today, the benchmark
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for optimal surgical success has been defined as surgical cytoreduetion with no visible 
disease i.e. complete cytoreduetion (Thigpen et al 2011).
Figure 4.21: Significantly more overall survival with minimal residual disease
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4.5.6 Tumour grade analysis
Tumour grade did appear to have prognostic significance on DFS and OS indicating that 
the influence of grade of tumour is independent of other co-variates like stage of disease, 
histological subtype, bulk of residual disease after surgery and response to chemotherapy. 
Figure 4.22 shows the Kaplan-Meier plot of grade and DFS within the EOC IHC database. 
A statistically significant worsening of survival is seen with poorly differentiated (G3) 
compared to moderate and well differentiated (01 and 02) tumours. Log rank= p<0.005.
132
Chapter 4: Results
Figure 4.22: Tumour Grade and disease free survival within the database 
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Figure 4.23 Kaplan-Meier plot of grade within the EOC IHC database with OS. A
statistically significant worsening of survival is seen with poorly differentiated (03)
compared to moderate and well differentiated (G1 and 02) tumours. Log rank= p<0.003.
Figure 4.23: Tumour Grade and overall survival within the database 
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4.5.7 FIGO Stage
Survival by FIGO stage and distribution is shown in the table subsequently (Table 4.21). 
Both in univariate and multivariate analysis, there is a significant association between stage 
and survival. Since stage was clearly an independent prognostic factor it was included in 
Cox’s models for assessment of other markers.
A statistically significant worsening of DFS is seen with increasing stage.
Figure 4.24: Kaplan Meier plot of FIGO stage within the database
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A statistically significant worsening of overall survival is seen with increasing stage. 
Figure 4.25: Kaplan Meier plot of FIGO stage within the database
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The above data may be summarized as below:
- 256 patients are analysed in this eohort.
- Median disease free survival (DFS) in relapsed women was better in the primary 
debulking group as compared to the group who received primary chemotherapy (318.5 vs 
225.5 days).
- Median DFS in women without relapse was also better in the women receiving primary 
surgery (1312 vs 1176.5 days).
- As reflected above the median overall survival (OS) was also improved when primary 
surgery was the first treatment (1734 vs 1254 days).
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- Survival data analysed shows improved DFS and OS when no visible residual disease 
was left behind following surgery.
- Worsening survival (both DFS and OS) was noted with increasing FIGO stage. Stage I 
patients showed improved survival as compared with Stage IV.
The information discussed above relates to the demographics of the cohort o f cases 
included in this study. The above data is useful for data analyses of large chunks o f data. 
However to evaluate the impact on individual patients, biomarkers may be useful and are 
explored with the results of the IHC and the survival data including Cox regression analysis 
discussed next.
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4.6 Immunohistochemistry Results for
In this section, the charaeteristics of the cohort analysed for p57^'^^ expression is first 
tabulated (Table 4.21). The next section analyses the p57*"^  ^ expression with various 
clinical characteristics and finally survival statistics has been described.
4.6.1 Clinicopathological characteristics
All 256 identified cases had archived tissue available. Thus 100% of tumours were 
included in the IHC. Two different scoring techniques have been employed. For the 
purpose o f descriptive statistics, the ‘Quickscore’ is used. This scoring system takes into 
account both the intensity of staining as well as the number of cells stained in any given 
field and categorised as low expression or high expression. For the purpose of survival 
statistics, initially survival data analyses were performed using the low and high 
expressors. However for the purpose o f multivariate analysis using Cox modelling to 
predict both DFS and OS, the ‘H ’ score has been utilised which is described in the relevant 
section.
Table 4.21: Clinicopathological characteristics of cohort analysed for p57kip2
expression
V ariable W hole series n=256
Age n=256
<50 38
50-69 131
>70 87
V ariable W hole series n=256
FIGO  Stage n=256
I 8
II 9
III 186
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Table 4.22: Characteristics of cohort (continued)
V ariable W hole series n=256
O ptim al Debulking n=256
Yes 112
No 140
Missing 4
Variable W hole series n=256
Tum our G rade n=256
1 11
2 32
3 213
Chem otherapy n=256
Platinum based 228
Non- platinum based 5
No chemotherapy 23
Histological Type n=256
Serous 151
Endometrioid 29
Mucinous 22
MMMT 19
Clear Cell 28
Other 7
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4.6.2 IHC and staining
pgvkipigtaining
Staining was seen predominantly within the nucleus. Since three random fields were 
chosen, there was no patient with negative staining in all three fields. In every field there 
was varying distribution of intensity o f staining and number of positively stained cells.
No staining was noted within the negative controls.
Table 4.23: Intensity of nuclear staining with p57kip2
Intensity of Staining N um ber Percentage
No staining 0 0
Mild <25% 73 28.5%
Moderate 25-50% 100 39.0%
Strong >50% 83 32.4%
To evaluate various methods of using the scoring, literature was searched again. One 
technique employed included dividing the p57^‘^  ^ expression into ‘high’ and ‘low’ 
expression based on a cut- off value. This cut- off value was arbitrary and was chosen at 
50%. This meant that if the sum of the staining scores in the two and three plus for a given 
patient was less than 50%, such a patient was classified to be a ‘low expressor’ o f p57^ '^^ .^ 
In this thesis, using the above technique, the following descriptive statistics was found.
4.6.3 Descriptive statistics and Cross tabulations
There were 160 low expressors compared with 96 high expressors o f p57’^ ‘^ .^ The 
descriptive statistics below analyse the p57’^‘^  ^ expression with various demographic 
parameters in the first instance prior to survival data analysis.
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Comparison of p57"^ '^  ^expression by Age at diagnosis
The ehart and table below show the distribution of p57'"'^  ^ expression by low and high
expression. In the women under 50, there were equal numbers of cases in both groups.
However, in the over 50’s low expression of p57'"''^ seemed to predominate with 77 vs 54
in women less than 70 years and 64 vs 23 in women over 70 years of age.
Figure 4.26: p57kip2 expression distributed with patient age at diagnosis
p57kip2 exp ression  by D iagnosis age
High Expression 
Low Expression
50-65 
Age at diagnosis
Table 4.24 showing age distribution and expression of p57kip2 expression
Age All cases Low expression High expression
<50 38 19 19
50- 69 131 77 54
>70 87 64 23
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Comparison of p57*"'’^  expression by Primary Treatment
The distribution of p57""^  ^expression by primary treatment is shown in (Figure 4.27). 
Figure 4.27: Comparison of p57'^ P^  expression by Primary Treatment
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Comparison of p57kip2 expression with bulk of residual disease following surgery
The table below shows the p57^ '"^  ^ expression whieh appears to be indicative of tumour 
bulk following surgery. This is indicated by some visible residual disease in eases o f low 
expression of p57'"^^. Subsequent Cox modelling has been performed to assess if p57‘"''^  ^
can independently predict the possibility of achieving nil residual disease.
Table 4.25 showing p57kip2 expression compared with bulk of residual disease
Residual disease All cases Low expression High expression
Nil visible disease 112 43 69
Some visible disease 140 114 26
141
Chapter 4: Results
Comparison of expression by FIGO stage
To compare p57‘"^  ^ expression with FIGO stage, the distribution is shown in Figure 4.28
below. As expected, the majority of cases were in FIGO stage 3. Further division into low
and high expressors are shown in the Table 4.26
Figure 4.28: The distribution of p57kip2 expression with FIGO stage 
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Table 4.26 showing p57kip2 expression compared with FIGO stage
FIGO Stage All cases Low expression High expression
Stage I 8 1 7
Stage 11 9 4 5
Stage 111 186 113 73
Stage IV 53 42 11
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Comparison of expression by Tumour Grade
As seen subsequently, the grade of tumour appears to be inversely related to the pS?'"''’^  
expression. The high grade tumours appear to have low expression of p57""^  ^as seen in the 
Figure 4.29 and Table 4.27 below.
Figure 4.29 showing expression of p57kip2 by the tumour grade at histology
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Table 4.27 showing p57kip2 expression tabulated with tumour grade
Grade All cases Low expression High expression
Low grade G 1 11 2 9
Intermediate grade G2 32 16 16
High grade G3 213 142 71
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Comparison of p57"^ ^^  expression and histology
p 5 7 kip2  expression was noted to vary with the histological subtype and is shown below in 
Figure 4.30 and Table 4.28.
Figure 4.30 showing expression of p57kip2 by the histological subtype 
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Table 4.28 showing p57kip2 expression tabulated with histology
Histology All eases Low expression High expression
Serous 151 91 60
Endometrioid 29 11 18
Mucinous 22 17 5
Clear Cell 28 24 4
MMMT 19 17 2
Other 7 0 7
As seen above low p57’"^^  expression appears to be associated more with poor prognostic 
tumour like clear cell and MMMT. Unfortunately, this technique of dividing the scoring 
into high and low expression did not appear to be robust. The reason for this was it did not
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take into account the effect of the intensity o f staining. For instance, while comparing the 
cases in the Table 4.29 below, both have scores o f 80 in the 2+ and 3+ fields however the 
intensity of staining is not reflected if  only classifying them as low and high expressors 
based on the number o f cells.
Table 4.29: Exam ple of 2 cases w ith same IHC score bu t varying intensity of
expression
No staining 1+staining 2+ staining 3+ staining Total
Case 1 5 15 10 70 100
Case 2 0 20 30 50 100
As a result of this, the ‘H ’ score which was derived using a validated tool and used for the 
purpose of data analysis in this study as described in chapter 3. (Macdonald et al 2004) and 
all analyses in the next section has been performed using the ‘H ’ score.
4.7 Summary statistics of p57^^  ^H score
IHC staining was available in all cases with no missing data. The mean p57^'^^ H score was 
112.2 (3.33-277).
4.7.1 Comparison of p57"^ ^^  expression and patient 
characteristics
Prim ary Treatm ent
On comparing the ‘H ’ score in the 96 NACT vs 160 PD cases, no statistically
significant difference was found p=0.096 as seen in Table 4.30 below. The MWU test was 
used to derive this.
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Table 4.30: Mann Whitney U Test of p57 ‘H ’ score by Primary treatment
Type p57k.p2 'H ’ score
Mann-Whitney U 6724.500
Wilcoxon W 11380.500
Z -1.666
Asymp. Sig. (2-tailed) .096
a. Grouping variable: Primary Treatment
Bulk of residual disease analysis
Comparing p57’^ ‘^  ^ ‘H ’ score with extent of cytoreductive surgery using spearman’s rank 
correlation test produced (Rho = -.470) with a p<0.0005, which is highly significant. This 
implies that low levels of p57" '^^  ^ are likely to indicate inability to optimally debulk 
individual patients.
Table 4.31: Bivariate Analysis p57^^  ^ ‘H ’ score vs bulk of residual disease
Correlations Bulk o f residual after surgery
Spearman's rho
p57kip2
‘H ’ score
Correlation
Coefficient
-.470
Sig. (2-tailed) .000
N 252
However, to estimate accurately, if p57 expression levels are able to predict feasibility 
of disease resection, the bulk of residual disease will require a continuous variable as the 
outcome and exploration of other variables can be undertaken and is an avenue for future 
research beyond the scope of this study.
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Tumour Grade Analysis
Comparing p5?’^‘P^ ‘H ’ score with extent of cytoreductive surgery performed using 
spearman’s rank correlation test with (Rho = -.207) produced a p<0.001 indicating a highly 
significant correlation with low levels o f p57’"‘^  ^ being more likely to be present in higher 
grades as compared to G1 (Figure 4.29). Again as above, to estimate accurately, grade of 
disease will need to be expressed as a continuous variable (possibly using the Silverberg 
scoring system) and is beyond the scope of this study.
Table 4.32: Bivariate Analysis p57kip2 expression vs grade of disease
Grade
Spearman's rho p57"'P" Correlation -.207
H score Coefficient
Sig. (2-tailed) .001
N 256
Assessment of p57*^ P^  expression by histological subtype 
Mann-Whitney U test
The above test is used to compare each individual histological subtype against p57'"‘P^  
expression. (Table 4.33 a-e)
Comparing the 151 serous EOC vs the 105 non- serous EOC, higher p57^ ^P^  expression was 
noted in the serous group with a p=0.027 (Table 4.33a). The next comparison between the 
22 mucinous EOC vs the 234 non- mucinous EOC suggested a p= 0.011 (Table 4.33b). 
Further correlation with 29 endometrioid vs 227 non- endometrioid EOC case revealed a 
higher p57'^‘P^  expression was noted in the endometrioid group with a p=0.052(Table 
4.33c). In clear cell EOC, when comparing 28 clear cell cases with 228 non- clear cell 
cases, a p value of 0.048 was obtained (Table 4.33d). In the MMMT cohort o f 19 cases as
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compared to 237 EOC, a p value o f 0.0005 suggestive of very low p57^ '"^  ^expression in the 
MMMT group was noted (Table 4.33e).
Table 4.33 a-e showing histological subtype against p57kip2 expression
Grouping Variable: serous
pSV"'’’-' 
‘H ’ score
Mann-Whitney U 6642.500
Wilcoxon W 12207.500
Z -2.205
Asymp. Sig. (2- 
tailed)
.027
b. Grouping Variable: Mucinous
p57"'P^ 
‘H ’ score
Mann-Whitney U 1733.500
Wilcoxon W 1986.500
Z -2.531
Asymp. Sig. (2- 
tailed)
.011
c. Grouping Variable: endometrioid
‘H ’ score
Mann-Whitney U 2561.500
Wilcoxon W 28439.500
Z -1.944
Asymp. Sig. (2- 
tailed)
.052
d. Grouping Variable: clear cell
p57kip2
‘H ’ score
Mann-Whitney U 2460.000
Wilcoxon W 2866.000
Z -1.980
Asymp. Sig. (2- 
tailed)
.048
e. Grouping Variable: MMMT
pjykipi
‘H ’ score
Mann-Whitney U 1104.500
Wilcoxon W 1294.500
Z -3.694
Asymp. Sig. (2- 
tailed)
.000
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FIGO Stage and expression
Comparing p57^'^^ ‘H ’ score by FIGO stage using spearman’s rank correlation test 
produced (Rho = -.254) with a p<0.0005 which is highly significant. This implies that low 
levels of p57^'^^ are present in advanced EOC and redueed/lack of p57*^ ‘^  ^ is indicative of 
poor prognosis. Rho is the Spearman’s rank correlation coefficient. It varies between -1 to 
+1. A negative value is indicative of an inverse relationship between the 2 parameters 
being compared.
Table 4.34 Bivariate Analysis p57^^  ^‘H ’ Score by FIGO stage
Correlations FIGO stage
Spearman's rho p57"'P^ 
‘H ’ score
Correlation
Coefficient
-.254
Sig. (2-tailed) .000
N 256
Having performed the above analysis, the next step was to undertake survival statistics. 
This includes both bivariate and multivariate analyses. Bivariate survival analyses using 
Kaplan Meier plots to compare clinical criteria with p57’"‘^  ^expression were performed as 
shown below.
4. 8 Survival Statistics with
Bivariate analysis of p57"^ '^^  status and clinicopathological criteria is tabulated in Table 
4.35. A significant difference in both the DFS and OS was noticed based on p57^'^^ 
expression. Women with tumours expressing high levels o f the p57^'^^ protein on IHC had 
a greater DFS (p<0.0005) and OS (p<0.0005) as shown in the table and Kaplan-Meier plots 
below (Figure 4.31 and Figure 4.32).
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Table 4.35: p57*^ P^  expression in all the cases included in the final analysis compared
with clinicopathologic parameters
Variable Analysed
cases
N=256
(%)
Low pS7“>’^  
expression
(%)
High p57*^ P^  
expression 
(%)
(p value) Test
used
Age (years) n=256 160 96 0.001 MWU
<50 38 19(11.9%) 19 (19.8%)
50-69 131 77 (48.1%) 54 (56.3%)
>70 87 64(40.0%) 23(24.0%)
FIGO Stage n=256 <0.0005 MWU
I 8 1(0.6%) 7(7.3%)
II 9 4(2.5%) 5(5.2%)
III 186 113(70.6%) 73(76.0%)
IV 53 42(26.3%) 11(11.5%)
Tumour Grade n=256 0.001 MWU
Low 11 2(1.3%)
Intermediate 32 16(10.0%) 16(16.7%)
High 213 142(88.8%)
Primary Treatment 0.008 72
NACT 96 26(27.1%) 70 (43.8%)
PD 160 70 (72.9%) 90 (56.3%)
Optimal debulking n=252 <0.0005 72
Yes 43
(27.4%)
69 (72.6%)
No 114
(72.6%)
26(27.4%)
Histological Subtype <0.0005 72
Serous 151 91 (56.9%) 60 (67.4%)
Mueinous 22 17(10.6%) 5 (5.6%)
Endometrioid 29 11 (6.9%) 18 (20.2%)
Clear Cell 28 24 (15.0%) 4 (4.5%)
MMMT 19 17 (10.6%) 2 (2.2%)
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4.8.1 Survival by expression
Disease Free Survival
Figure 4.31: Kaplan-Meier plot for disease specific survival. High p57kip2 expression 
tumours compared with low expression tumours and Log Rank test for univariate
survival analysis. (n=256).
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Table 4.36 log rank test of DFS showing statistical significance
Overall Comparisons
Chi-Square df Si%.
Log Rank (Mantei- 
Cox)
106.281 1 .000
Test of equality of survival distributions for the different levels of p57''‘‘’^  
expression.
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Figure 4.32: Kaplan-Meier plot for overall survival. High p57kip2 expression 
tumours compared with low expression tumours (n=256) and log rank test for
univariate analysis.
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Table 4.37 log rank test of OS showing statistical significance
Overall Comparisons
Chi-Square df Sig.
Log Rank (Mante 1- 
Cox)
192.219 1 .000
Test of equality of survival distributions for the different levels of p57'"^ ^^  expression.
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4.8.2 Survival by within FIGO stage
Tumour stage is a significant prognostic factor in EOC. In the Cox model, the ‘H’
score was considered an independent prognostic factor of both DFS and OS. To confirm 
this, an analysis of FIGO stage was performed for p57*"’’^  high and low expression. 
Figure 4.33 -Figure 4.36: Kaplan-Meier plots for disease free survival with FIGO 
stage of disease with p57*^ ^^  expression
Figure 4.33 showing disease free survival with FIGO Stage I
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Figure 4.34 showing disease free survival with FIGO Stage II
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Figure 4.35 showing disease free survival with FIGO Stage III
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Figure 4.36 showing disease free survival with FIGO Stage IV
S urv iva l F u n c tio n s  
F IG O  S ta a e  IV
1 .0 -
p57 expression  
—riLO W  P57 <50%  
-riH IG H  P57 >=50%0 .8 -
O
0 .2 -
0 .0 -
800 10006004002000
d isease  free surv iva l days
Figure 4.37 -  F igure 4.40: K aplan-M eier plots for overall survival with FIGO  stage of 
disease, using expression.
Figure 4.37 showing overall survival with FIG O  Stage I 
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Figure 4.38 showing overall survival with FIGO Stage II
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Figure 4.39 showing overall survival with FIGO Stage III
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Figure 4.40 showing overall survival with FIGO Stage IV
Survival Functions ^FIGO Stage IV
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The next step in the analysis was to undertake a multivariate analysis as described in the 
next section.
4.9 Multivariate Analysis
To assess if H score is an independent prognostic marker, backward stepwise Cox
Regression Analysis was carried out to explore the possible role of H score in
predicting DFS and OS. To compute this model, the following other predictors were used:
1. ECOG Status
2. Primary Treatment
3. Grade of tumour
4. FIGO Stage
5. Bulk of residual disease following surgery
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To enable Cox modelling, the following recoding of the above mentioned predictors were 
performed:
ECOG PS was reclassified from a 6 point scale to a 2 point scale where “0” indicates active 
and able to self care and work including “0,1 & 2” and “ 1” indicates limited self care and 
unable to work including “3 &4” from the previous ECOG PS.
Grade of tumour has three categories. To retain these 3 categories, the Cox model has 
enabled fitting of parametric testing. However, a linear worsening relationship has been 
assumed with high grade being the most adverse feature.
FIGO stage was used with only Stages I, II, III & IV with no further subdivision.
Bulk of residual disease was reclassified as ‘0’ if there was no visible disease and ‘E if 
there was visible disease.
4.9.1 Disease Free Survival
The first step in this process is a straightforward comparison of primary treatment for DFS 
time using the log rank test shows a highly significant improved survival in women 
undergoing primary surgery as shown in the Kaplan Meier plot. (Figure 4.41)
Figure 4.41: Kaplan Meier plot for disease free survival with primary treatment
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Table 4.38 showing log rank test of disease free survival of primary treatment
Overall Comparisons
Chi-Square df Sig.
Log Rank (Mantel-Cox) 29.548 1 .000
Test of equality of survival distributions for different levels of Primary treatment.
Backward stepwise Cox regression modelling was then performed using the previously 
mentioned predictors above as well as the p57^'^^ ‘H ’ score. The table below shows all the 
variables in the model for DFS.
Table 4.39 Step 1 all significant variables in the Cox model
B Sig. Exp(B)
95.0% Cl for Exp(B)
Lower Upper
Step 1 PD/NACT -.208 .200 .812 .590 1.117
Grade 3 .871
Grade 1 -.191 .669 .826 .344 1.981
Grade 2 -.092 .715 .912 J5 8 1.492
Residual disease .087 .591 1.091 .794 1.499
ECOG status -.104 .542 .901 .646 1.258
FIGO Stage 4 .021
FIGO Stage 1 -2.072 .007 .126 .028 .565
FIGO Stage 2 -1.232 .056 .292 .083 1.030
FIGO Stage 3 -.209 .267 .811 .560 1.174
p57‘"‘’^  
‘H ’ score
-.017 .000 .983 .979 .987
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The final Cox model was applied as shown below, FIGO stage and ‘H ’ score
emerge as being highly significant. (Table 4.40)
Table 4.40: Step 2 M ultivariate analysis using Cox regression model dem onstrating 
p57^^^ expression predicts a positive disease free survival advantage independently of 
other accepted independent prognostic factors.
95.0% Cl fbrExp(B)
B Sig. Exp(B) Lower Upper
Step 2 FIGO Stage 4 .000
FIGO Stage 1 -2.157 .004 .116 .027 .495
FIGO Stage 2 -1.451 .016 .234 .072 .766
FIGO Stage 3 -.267 .135 .766 .539 1.086
H score
-.017 .000 .983 .980 .986
The non- significant variables are  shown below (Step 3 Table 4.41)
V ariables not in the Equation®
Score df Sig.
Step 3 PD/NACT 2.068 1 .150
Grade 3 .285 2 .867
Grade 1 .179 1 .672
Grade 2 .071 1 .789
Residual disease .334 1 .563
ECOG status .263 1 .608
a. Residual Chi Square = 3.038 with 6 df Sig. = .804
As seen in the models above, p57‘^‘^  ^ ‘H ’ score expression retains the power to 
independently predict DFS (p=0.0005) with (95% Cl 0.980-0.986).
160
Chapter 4: Results
Upon inspeetion, a plot of partial residuals for p57""^ '^  ‘H’ score against DFS time rank, it 
produced evenly distributed points over time showing evidence the assumption of 
proportional hazards is upheld. However, there was one noticeable outlier belonging to 
patient no. 82 whose DFS time was heavily overestimated by the model. This patient was 
diagnosed with a Stage 3c clear cell carcinoma following a PD and subsequently received 6 
cycles of CP chemotherapy. However, she did not have a disease free interval and 
commenced chemotherapy at the National Cancer Institute, Bethesda, USA immediately 
following treatment at our centre.
4.9.2 Cox model- Overall Survival
As previously, the first step in this process is a straightforward comparison of primary 
treatment for overall survival time using the log rank test shows a highly significant 
improved survival in women undergoing primary surgery as shown in the Kaplan Meier 
plot. (Figure 4.42)
Figure 4.42 showing the Kaplan Meier plot for OS with primary treatment
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Table 4.42 showing log rank test of overall survival by primary treatment
Overall Com parisons
Chi-
Square df Sig.
Log Rank (Mantel-Cox) 9.648 1 .002
Test of equality of survival distributions for different levels of 
Primary treatment.
When the Cox model is applied for overall survival, the following results emerge.
Table 4.43 shows the different variables in the equation. (Step 1)
B Sig. Exp(B)
95.0% CIforExp(B)
Lower Upper
Step 1 PD/NACT -.186 .259 .830 .601 1.147
Grade 3 .673
Grade 1 .336 .536 1.399 .484 4.048
Grade 2 .189 .468 1.208 .725 2.014
Residual disease .337 .066 1.401 .978 2.008
ECOG status .196 .250 I.2I6 .871 1.697
FIGO Stage 4 .611
FIGO Stage 1 -.442 .571 .643 .140 2.960
FIGO Stage 2 -.171 .764 .843 .275 2.579
FIGO Stage 3 .172 .371 1.188 .814 1.733
p57Kip2
‘H ’ score
-.026 .000 .974 .970 .979
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When the Cox model was applied as shown below, bulk o f residual disease following 
surgery and p57^'^^ ‘H ’ score emerge as being highly significant.
Table 4.44 Step 2 Multivariate analysis using Cox regression model demonstrating p57" '^^  ^
expression predicts a positive overall survival advantage independently of other accepted 
independent prognostic factors.
Table 4.44 shows the significant variables emerging in the Cox model
B Sig. Exp(B)
95.0% ClforExp(B )
Lower Upper
Step 2 Residual
disease
.402 .020 1.495 1.067 2.095
‘H ’ score
-.027 .000 .974 .970 .977
As compared to bulk of residual disease and p57^'^^ H ’ score, the other variables not 
significant are shown below:
Table 4.45 Variables not significant in the Cox model
V ariables not in the Equation*
Score df Sig.
Step 3 PD/NACT .888 I .346
Grade 3 .140 2 .933
Grade 1 .055 I .814
Grade 2 .071 1 .790
ECOG status 1.209 1 .271
FIGO Stage 4 1.537 3 .674
FIGO Stage I .786 1 .375
FIGO Stage 2 .235 1 .628
FIGO Stage 3 1.003 1 .316
a. Residual Chi Square = 4.736 with 8 d f Sig. = .785
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As seen above, p57^'^^ ‘H ’ score expression retains the power to independently also predict 
OS (p=0.0005) with (95% Cl 0.969-0.977). Upon inspection of a plot of partial residuals 
for p57^'^^ ‘H ’ score against OS time rank, it produced evenly distributed points showing 
evidence the assumption o f proportional hazards is upheld. However, there were 3 
noticeable outliers for whom the OS time was substantially overestimated by the model. 
The 3 cases are described individually below:
Case 1: A 60 year old lady with CA-125 of 1599 at diagnosis. She had NACT followed by 
IDS after 3 cycles. Her CA-125 dropped to 122 prior to surgery and she was optimally 
debulked. She was diagnosed with a FIGO stage 3c grade 2, serous ovarian 
adenocarcinoma. Despite having high p57'"'^^ ‘H’ score of 193, she relapsed 9 months after 
completing treatment and died 843 days after diagnosis of disease while the model 
estimated her being alive.
Case 2: A 70 year old lady with a CA-125 at diagnosis o f 743 underwent PD and was 
optimally debulked. She was staged as having a FIGO stage 3c grade 2, serous ovarian 
adenocarcinoma. Her p57^'^^ ‘H ’ score was 207. She relapsed 10 months following 
treatment and died 874 days later. Again the model overestimated her survival. Her poor 
performance may be explained by a high Cyclin E score of 218.
Case 3: This 79 year old lady had a previous hysterectomy for fibroids at the age o f 40. 
She underwent PD and CA-125 at diagnosis was 343. She was optimally debulked and 
staged as having a FIGO stage 3c grade 3, mucinous ovarian adenocarcinoma. She 
survived 661 days. Her p57'^‘P^  ‘H ’ score was 185. The poor performance in this case may 
also be explained by her high Cyclin E score of 230.
The above models suggest that a more exhaustive explanation is produced by the p57^'^^ 
‘H ’ score and remains consistent for DFS and OS. In the DFS model FIGO stage also plays
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a significant role however the bulk of residual disease is more significant for overall 
survival.
4.10 Immunohistochemistry Results for Cyclin E
In this section, the characteristics of the cohort analysed for Cyclin E expression is 
mentioned. The next section analyses the Cyclin Eexpression with various clinical 
characteristics and finally survival statistics has been described.
4.10.1 Clinicopathological characteristics
All 256 identified cases had archived tissue available. Thus 100% of tumours were 
included in the IHC. As for p57"^ '^  ^ for descriptive statistics purposes, quickscore is used 
and ‘H ’ score for Cox models unless specified otherwise.The same cohort (Table 4.21 and 
4.22) was analysed for Cyclin E expression
4.10.2 Cyclin E staining
Staining was seen predominantly within the nucleus. Since three random fields were 
chosen, there was no patient with negative staining in all three fields. In every field there 
was varying distribution of intensity of staining and number of positively stained cells.
Table 4.46showing Intensity of nuclear staining w ith Cyclin E
Intensity of Staining N um ber Percentage
No staining 0 0
Mild <25% 49 19.1%
Moderate 25-50% 59 23.0%
Strong >50% 148 57.8%
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4.10.3 Descriptive statistics and Cross tabulations
The Cyclin E expression used to divide the cohort into low and high expressors and 
revealed low expression in 92 cases (35.9%) and high expression in 164 cases (64.9%). As 
for p5V'^ ‘P^ , the ‘H ’ score was derived and used.
Comparison of Cyclin E expression by Age at diagnosis
The chart and table below show the distribution of Cyclin E expression by low and high 
expression.
Figure 4.43: Cyclin E expression distributed with patient age at diagnosis 
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Table 4.47: Distributed by patients’ age cross tabulation below
Age Low Cyclin E 
expression
High Cyclin E 
expression
Total
<50 18 20 38
50-69 49 82 131
>70 25 62 87
Total 92 164 256
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Comparison of Cyclin E expression by Primary Treatment
The distribution of Cyclin E expression by primary treatment is shown in the graph below 
(Figure 4.44)
Figure 4.44: Comparison of Cyclin E expression by Primary Treatment 
Primary Treatment and Cyclin E expression
c 80
m m #
PD NACT
Primary Treatment
E3 Low Cyclin E expression M High Cyclin E expression
Comparison of Cyclin E expression with bulk of residual disease following surgery
The table below shows the Cyclin E expression which appears to be indicative of tumour 
bulk following surgery. This is indicated by some visible residual disease in cases o f high 
expression of Cyclin E. Subsequent Cox modelling has been performed to assess if Cyclin 
E can independently predict the possibility of achieving nil residual disease.
Table 4.48 showing Cyclin E expression compared with bulk of residual disease
Residual disease All cases Low expression High expression
Nil visible disease 112 58 54
Some visible disease 140 31 109
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FIGO Stage
Comparison of Cyclin E expression by FIGO stage
To compare Cyclin E expression with FIGO stage, the distribution is shown in the Figure 
4.45 below. As expected, the majority of cases were in FIGO stage 3. Further division into 
low and high expressors are shown in the Table 4.49.
Figure 4.45: The distribution of Cyclin E expression with FIGO stage
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Table 4.49showing Cyclin E expression compared with FIGO stage
FIGO Stage All cases Low expression High expression
Stage I 8 7 1
Stage 11 9 5 4
Stage 111 186 68 118
Stage IV 53 12 41
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Comparison of Cyclin E expression by Tumour Grade
As seen subsequently, the grade of tumour appears to be directly related to the Cyclin E 
expression unlike p57’^‘*’^ . The high grade tumours appear to have high expression o f Cyclin 
E as seen in the Figure 4.46 and Table 4.50 below.
Figure 4.46 showing expression of Cyclin E by the tumour grade at histology
Expression of Cyclin E by Tumour Grade
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Table 4.50showing Cyclin E expression tabulated with tumour grade
Grade All cases Low expression High expression
Low grade G1 11 9 2
Intermediate grade G2 32 17 15
High grade G3 213 66 147
Comparison of Cyclin E expression and histology
Cyclin Eexpression was noted to vary with the histological subtype and is shown in Figure 
4.47 and Table 4.51.
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Figure 4.47showing expression of Cyclin E by the histological subtype
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Table 4.51 Cyclin E expression amongst various histological subtypes
Histology Low Cyclin E 
expression
High Cyclin E 
expression
Total
Serous 7 1 8
Endom etrioid 5 4 9
Mucinous 68 118 186
Clear cell 12 41 53
M MM T 0 19 19
O ther 7 0 7
Total 92 164 256
Converse to p 5 e x p r e s s i o n  seen previously high expression appears to be associated 
more with poor prognostic tumour like clear cell and MMMT. Unfortunately, this 
technique of dividing the scoring into high and low expression did not appear to be robust.
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The reason for this was it did not take into account the effect o f the intensity of staining and 
hence the ‘H ’score is used below.
4.10.4 Summary statistics of Cyclin E ‘H’ score
IHC staining was available in all cases with no missing data. The mean Cyclin E ‘H ’ score 
was 171 (23.33-273.33).
Comparison of Cyclin E expression and clinical characteristics
Prim ary Treatm ent
On comparing the Cyclin E expression in the 96 NACT vs 160 PD cases, no statistically 
significant difference was found p=0.466. The MWU test was used to derive this.
Table 4.52: M ann W hitney U Test of Cyclin E ’H ’ score by P rim ary treatm ent
Test Statistics*
Cyclin E ‘H ’ score
Mann-Whitney U 7262.000
Wilcoxon W 20142.000
Z -.729
Asymp. Sig. (2-tailed) .466
a. Grouping Variable: Primary treatment
Bulk of residual disease and Cyclin E
Comparing Cyclin E ’H ’ score with extent of cytoreductive surgery using spearman’s rank 
correlation test produced (Rho = -.365) with a p<0.0005 which is highly significant. This 
implies that high levels of Cyclin E are likely to indicate inability to optimally debulk 
individual patients (Table 4.53). However to estimate accurately, if Cyclin E expression 
levels are able to predict disease resectability, the bulk o f residual disease will require a
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continuous variable as the outcome and exploration of other variables can be undertaken 
and is an avenue for future research beyond the scope of this study.
Table 4.53: B ivariate Analysis Cyclin E ‘H ’ score vs bulk  of residual disease
Correlations
Grade
Bulk o f 
residual after 
surgery FIGO
Spearman’s rho Cyclin E 
‘H ’ score
Correlation
Coefficient
.263 365 .256
Sig. (2-tailed) .000 .000 .000
N 256 252 256
T um our G rade and Cyclin E (Bivariate Analysis Cyclin E ‘H ’ score vs grade of 
disease)
Comparing Cyclin E ‘H ’ score with extent o f cytoreductive surgery performed using 
spearman’s rank correlation test with (Rho = .263) produced a p<0.005 indicating a highly 
significant correlation with high levels o f Cyclin E being more likely to be present in 
higher grades as compared to grade 1 as seen in the table above (Table 4.54). Again as 
above, to estimate accurately, grade o f disease will need to be expressed as a continuous 
variable (possibly using the Silverberg scoring system) and is beyond the scope o f this 
study.
Table 4.54: Bivariate Analysis Cyclin E H ’ expression vs grade of disease
Grade
Spearman's rho Cyclin E Correlation -.207
‘H’ score Coefficient
Sig. (2-tailed) .001
N 256
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Assessment of Cyclin E ‘H ’ score by histological subtype 
Mann-Whitney U test
The above test is used to compare each individual histological subtype against Cyclin E ‘H ’ 
score. (Table 4.55 a-e)
Comparing the 151 serous EOC vs the 105 non- serous EOC, lower Cyclin E expression 
was noted in the serous group with a p=0.001 (Table 4.55 a). The next comparison between 
the 22 mucinous EOC vs the 234 non- mucinous EOC suggested a p= 0.013 (Table 4.55 b). 
Further correlation with 29 endometrioid vs 227 non- endometrioid EOC case revealed a 
lower Cyclin E expression in the endometrioid group with a p=0.004 (Table 4.55 c). In 
clear cell EOC, when comparing 28 clear cell cases with 228 non- clear cell cases, a p 
value of 0.005 was obtained with significantly high levels of Cyclin E (Table 4.55 d). In 
the MMMT cohort o f 19 cases as compared to 237 EOC, a p value o f 0.0001 suggestive of 
very high Cyclin E expression in the MMMT group was noted (Table 4.55 e).
Table 4.55a-e showing histological subtype against Cyclin E H ’ score
a: Grouping Variable: 
Serous
Cyclin E 
‘H ’ score
Mann-Whitney U 6067.500
Wilcoxon W 17543.500
Z -3.192
Asymp. Sig. (2- 
tailed)
.001
b: Grouping Variable: 
mucinous
Cyclin E 
‘H ’ score
Mann-Whitney U 1753.500
Wilcoxon W 29248.500
Z -2.471
Asymp. Sig. (2- 
tailed)
.013
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c: Grouping Variable: 
Endometrioid
Cyclin E 
‘H ’ score
Mann-Whitney U 2215.000
Wilcoxon W 2650.000
Z -2.867
Asymp. Sig. (2- 
tailed)
.004
d: Grouping Variable: 
clear cell
Cyclin E 
‘H ’ score
Mann-Whitney U 1399.000
Wilcoxon W 27505.000
Z -4.849
Asymp. Sig. (2- 
tailed)
.000
e: Grouping Variable: 
MMMT
Cyclin E 
‘H ’ score
Mann-Whitney U 1249.000
Wilcoxon W 29452.000
Z -3.228
Asymp. Sig. (2- 
tailed)
.001
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FIGO Stage
Comparing Cyclin E ‘H ’ score by FIGO stage using spearman’s rank correlation test 
produced (Rho = .256) with a p<0.0005 which is highly significant. This implies that high 
levels o f Cyclin E are present in advanced EOC and is indicative of poor prognosis. Rho 
is the Spearman’s rank correlation coefficient. It varies between -1 to +1. A negative value 
is indicative of an inverse relationship between the 2 parameters being compared.
Table 4.56: B ivariate Analysis Cyclin E H  score by FIG O  stage
Test Statistics*
FIGO Stage
Mann-Whitney U 6092.500
Wilcoxon W 10370.500
Z -3.276
Asymp. Sig. (2- 
tailed)
.000
Having performed the above analysis, the next step was to undertake survival statistics. 
This includes both bivariate and multivariate analyses. Bivariate survival analyses using 
Kaplan Meier plots to compare clinical criteria with Cyclin Eexpression were performed as 
shown below.
4.11 Survival Statistics
Bivariate analysis o f Cyclin E status and clinicopathological criteria is tabulated in (Table 
4.57). A significant difference in both the DFS and OS was noticed based on Cyclin 
Eexpression. Women with tumours expressing low levels of the Cyclin Eprotein on IHC 
had a greater DFS (p<0.0005) and OS (p<0.0005) as shown in the table and Kaplan-Meier 
plots below Figure 4.48 and Figure 4.49.
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Table 4.57: Cyclin E  expression of all cases included in the final analysis. This 
includes bivariate analysis of Cyclin E status and clinicopathological criteria.
Clinicopathological
Variable
Analyse 
d cases 
(%)
Low Cyclin E 
expression (%)
High Cyclin 
E expression 
(%)
(p value) Test
used
Histology 0.0005 X2
Serous 151 63 (74.1%) 88 (53.7%)
Mucinous 22 3 (3.5%) 19(11.6%)
Endometrioid 29 18(21.2%) II  (6.7%)
Clear Cell I (1.2%) 27 (16.5%)
MMMT 0 19(11.6%)
Prim ary T reatm ent 0.083 %2
NACT 96 28 (30.4%) 68(41.5%)
PD 160 64 (69.6%) 96 (58.5%)
Age (years) n=256 0.022 MWU
<50 38 18(19.6%) 20 (12.2%)
50-69 131 49 (53.3%) 82 (50.0%)
>70 87 25 (27.2%) 62 (37.8%)
Optim al debulking 0.0005
Yes 112 58 (65.2%) 54 (33.1%)
No 140 31 (34.8%) 109 (66.9%)
FIGO  Stage n=256 0.001 MWU
I 8 7 (7.6%) I (0.6%)
II 9 5 (5.4%) 4 (2.4%)
III 186 68 (73.9%) 118(72.0%)
IV 53 12(13.0%) 41 (25.0%)
Tum our G rade n=256 MWU
I II 9(9.8% ) 2(I.2% 0
2 32 17(18.5%) 15 (9.1%)
3 213 66 (71.7%) 147 (89.6%)
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Survival by Cyclin E expression
A significant difference in both the DFS and OS was noticed based on Cyclin E 
expression. Women with tumours expressing high levels of the Cyclin E protein on IHC 
had a significantly reduced DFS (p<0.0005) and OS (p<0.0005).
Figure 4.48: K aplan-M eier plot for disease specific survival showing highly significant 
relation between expression and survival. Log rank  test of p<0.0005.
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Figure 4.49: K aplan-M eier plot for OS showing high significance of correlation 
between Cyclin E expression and OS. Log rank  test of p<0.0005.
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Survival by Cyclin E within FIGO stage
Tumour stage is a significant prognostic factor in EOC. In the Cox model, the Cyclin E ‘H’
score was considered an independent prognostic factor of both DFS and OS. To confirm
this, an analysis of FIGO stage was performed Cyclin E expression.
Figure 4.50-Figure 4.53 Kaplan-Meier plots for disease free survival with FIGO stage of
disease with Cyclin E expression
Figure 4.50 showing disease free survival with FIGO Stage I
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Figure 4.51: Disease free survival with Stage II
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Figure 4.52: Disease free survival with Stage III
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Figure 4.53: Disease free survival with Stage IV 
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Overall survival
Cyelin E expression significantly affects both disease free survival and overall survival and 
high expression is associated with poor prognosis.
Figure 4.54- 4.57 show the Kaplan- Meier plots for overall survival with FIGO stage using
Cyclin E expression (n=256) shows significant association with survival.
Kaplan-Meier plots for overall survival with FIGO stage of disease
Figure 4.54: Overall survival with FIGO Stage I 
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Figure 4.55: Overall survival with Stage II
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Figure 4.56: Overall survival with FIGO Stage III 
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Figure 4.57: Overall survival with FIGO Stage IV
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The next step in the analysis was to undertake a multivariate analysis as deseribed in the 
next section.
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4.11 Multivariate Analysis
To assess if  Cyclin E ‘H ’ score is an independent prognostic marker, Cyclin E ‘H ’ score 
along with other known clinicopathological variables like grade and stage o f disease, 
primary treatment as well as type of chemo and bulk o f residual disease following surgery 
were included in the Cox regression analysis. This model was used to identify independent 
prognostic markers o f both DFS and OS.
Table 4.58: Step 1 Multivariate analysis using Cox regression model
B Sig.
95.0% Cl for Exp(B)
Lower Upper
Step 1 Grade 3 .747
Grade 1 -.349 .457 .281 1.770
Grade 2 -.066 .793 .572 1.532
Chemo type -.396 .207 .364 1.245
Residual disease .089 .584 .795 1.504
ECO G status -.112 .511 .641 1.248
FIGO Stage 4 .014
FIGO Stage 1 -2.207 .005 .024 .507
FIGO Stage 2 -1.305 .044 ,076 .967
FIGO Stage 3 -.219 .246 .555 1.163
Cyclin E ‘H ’ score -.017 .000 .979 .987
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Table 4.59 Step 2 showing Cyclin E ‘H ’ score and FIGO  stage to be independent
indicators of prognosis
95.0% C lforE xp(B )
B Sig. Lower Upper
Step 2 FIGO Stage 4 .000
FIGO Stage 1 -2.157 .004 .027 .495
FIGO Stage 2 -1.451 .016 .072 .766
FIGO Stage 3 -.267 .135 J3 9 1.086
Cyclin E 
‘H ’ score
-0.17 .000 .970 .977
Cyclin E ‘H ’ score expression retains the power to independently also predict overall 
survival with a p<0.0005 (95% Cl 0.969-0.977) as seen in the model below:
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Table 4.60: Step 1 & Step 2 Multivariate analysis using Cox regression model 
demonstrating Cyclin E ‘H ’ score predicts a negative OS advantage independently of 
other accepted independent prognostic factors.
B Sig.
95.0% Cl for Exp(B)
Lower Upper
Step 1 Grade 3 .324
Grade 1 -.510 .374 .195 1.847
Grade 2 ^93 .261 .804 2.237
Chemo type -1.548 .000 .115 393
Residual disease .349 .061 .984 2.044
ECOG status .163 .341 .842 1.646
FIGO Stage 4 ^66
FIGO Stage 1 -1.111 .182 .064 1.685
FIGO Stage 2 -.498 389 .196 1.887
FIGO Stage 3 .133 .494 .781 1.669
Cyclin E ‘H ’ score -.027 .000 469 478
Step 2 Chemo type -1.129 .000 .190 .549
Residual disease .469 .008 1.130 2.261
Cyclin E ‘H ’ score -.027 . .000 .969 .977
As seen in the models above, Cyclin E ‘H ’ score expression retains the power to 
independently predict OS p<0.0005 (95% Cl 0.980-0.986) demonstrating Cyclin E 
expression predicts a negative OS advantage independently of other accepted independent 
prognostic factors.
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Combined Cox model
From above analyses both are independently able to predict survival in an inverse manner 
to each other i.e. high p57 '^^  ^predicting better survival advantage while high Cyclin E 
levels predicting poor survival. A combined Cox regression analysis was undertaken to 
explore the ability of both p57" ‘^^  ^and Cyclin E.
4.11.1 DFS
When combining p57^'^^ and Cyclin E ‘H ’ scores along with the clinicopathologic
variables, Cyclin E does not retain its independent prognostic ability for both DFS and OS
as demonstrated below:
Table 4.61: Step 1 & 2 Cox regression model and both p57kip2 and Cyclin E
expression
B Sig. Exp(B)
95.0% Cl for 
Exp(B)
Lower Upper
Step 1 Primary treatment -.208 .200 .812 .590 1.117
Grade 3 .871
Grade 1 -.191 ^69 326 .344 1.981
Grade 2 -.092 .715 .912 .558 1.492
Residual disease .087 .591 1.091 .794 1.499
ECOG status -.104 .542 .901 .646 1.258
FIGO Stage 4 .021
FIGO Stage 1 -2.072 .007 .126 428 .565
FIGO Stage 2 -1.232 .056 392 .083 1.030
FIGO Stage 3 -.209 367 .811 .560 1.174
p57 H score -.017 .000 483 .979 .987
Cyclin E H score -.001 .694 499 496 1.003
Step 2 FIGO Stage 4 .000
FIGO Stage 1 -2.157 .004 .116 .027 .495
FIGO Stage 2 -1.451 .016 .234 .072 .766
FIGO Stage 3 -.267 .135 .766 .539 1.086
p57kip2 score -.017 .000 483 .980 486
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Backward stepwise Cox regression modelling performed using the previously mentioned 
predictors above as well as the p57^ '^^  ^ ‘H ’ and Cyclin E ‘H ’ score. The table shows all the 
variables in the model for DFS. (Table 4.61 Step 1 and 2)
The final Cox model was applied as shown below and FIG O  stage and p57*^ **^  ‘H ’ 
score emerge as being highly significant for DFS while Cyclin E ‘H ’ score did not 
prove to be significant. (Table 4.62 Step 3)
Table 4.62 Step 3: The non- significant variables are  shown below
Variables not in the Equation*
Score df
Step 3 Grade 3 1.318 2 .517
Grade 1 1.102 1 394
Grade 2 .297 1 386
ECOG status 1.071 1 .301
FIGO Stage 4 4.077 3 353
FIGO Stage 1 2.030 1 .154
FIGO Stage 2 1.212 1 .271
FIGO Stage 3 1.494 1 322
Cyclin E ‘H ’ Score .566 1 .452
Residual Chi Square = 10.032 with 8 d f Sig. = 363
4.11.2 Combined Cox model- Overall Survival
When the combined Cox model is applied for OS, the following model emerges. Table 
4.46 below shows the different variables in the equation. (Table 4.63 Step 1)
Bulk of residual disease following surgery and p57^^^ ‘H ’ score emerge as being 
highly significant while Cyclin E is not significant. (Table 4.64 Step 3)
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Table 4.63 Step 1 and 2: Multivariate analysis using the Cox regression model for OS.
B Sig. Exp(B)
95.0% Cl for 
Exp(B)
Lower Upper
Step 1 Primary treatment -.186 359 .830 .601 1.147
Grade 3 .673
Grade 1 336 336 1.399 .484 4.048
Grade 2 .189 .468 1.208 .725 2.014
Residual disease 337 .066 1.401 .978 2.008
ECOG status .196 .250 1.216 .871 1.697
FIGO Stage 4 .611
FIGO Stage 1 -.442 .571 .643 .140 2.960
FIGO Stage 2 -.171 .764 .843 .275 2.579
FIGO Stage 3 .172 .371 1.188 .814 1.733
p57 H score -.026 .000 .974 .970 .979
Cyclin E H Score .001 .555 1.001 .997 1.005
Step 2 Residual disease .402 .020 1.495 1.067 2.095
p57kip2 ‘H ’ score -.027 .000 .974 .970 .977
Cyclin E and other variables is not in the equation as shown below in Table 4.64 
Table 4.64 showing Cyclin E and other variables as not significant
Variables not in the Equation*
Score df Sig.
Step 3 Primary
treatment
.888 1 .346
Grade 3 .140 2 ^33
Grade 1 .055 1 .814
Grade 2 .071 1 .790
ECOG status 1.209 1 .271
FIGO Stage 4 1.537 3 .674
FIGO Stage 1 386 1 .375
FIGO Stage 2 335 1 .628
FIGO Stage 3 1.003 1 .316
Cyclin E ‘H ’ 
Score
.451 1 .502
a. Residual Chi Square = 4.736 with 8 df Sig. = .785
Unlike the p57^^^, Cyclin E does not emerge as being a significant m arker of either 
DFS o r OS. As a result o f the mixed outcome from the m arkers, statistical modelling 
was explored.
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4.12 Predictive Modelling
Statistical modelling was attempted to predict DFS and OS using ‘H ’ score.
Predictive model for overall survival was developed using bulk of residual disease, FIGO 
stage and p57^'^^ ‘H ’ score which were confirmed on the Cox regression analysis to be 
highly significant. Having taken into account the above mentioned variables, the model 
calculated the probability o f survival (OS) at 1, 2 and 3 years post diagnosis in each case. 
This was then tested against the true OS previously calculated. In 71.6% cases, the model 
was able to accurately predict the probability of survival. However, in 17.8% of cases, the 
model predicted a better survival i.e. it suggested that the likelihood of that patient being 
alive was very high at the various endpoints while the true OS suggested that patient may 
have already deceased. These cases are identified as substantial ‘under performers’. In 
another 10.6% cases the model predicted a worsening survival i.e. it suggested the 
likelihood of that patient being alive at the various endpoints was unlikely while the true 
OS showed the patient to be still alive and these cases have be considered_as ‘over 
performers.
Predictive model for DFS was developed using histology, FIGO stage and p57'"‘‘’^  ‘H ’ 
score. Using the above mentioned variables, the DFS calculated the probability of being 
disease free at various intervals. This was compared to the true DFS computed earlier. The 
model accurately predicted DFS in 74.8% of cases. This model has proved to be more 
challenging than the OS model and is still being tested.
In conclusion, extensive data analyses o f the cohort independently, as well as combined 
with p57^'^^ and Cyclin E as undertaken above has offered significant data and this is 
summarized on the next page.
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4.13 Summary of Main Findings
• Database o f 256 cases with clinical and p57' '^'’^  and Cyclin E IHC staining data.
• Primary treatment with surgery and chemotherapy was noted in 160 and 96 cases 
respectively,
• Complete cytoreduction with nil visible disease at the end of surgery was noted in 
43.75% (112) cases.
• At histology, 213/256 patients were noted to have grade 3 (high grade) disease.
• 186 women had FIGO Stage IV disease and the remaining stages I, II and IV had 8, 9
and 53 cases respectively.
• 151/256 cases were noted to have serous adenocarcinoma on histology and the 
remaining subtypes included endometrioid (29), clear cell (28), mucinous (22), MMMT 
(19) and non-epithelial granulosa cell tumours in 7 cases.
• Follow-up in this study ranged between 396- 6251 days and during this period, 178/256
were noted to be deceased at the end of the study period with 6 women dying o f causes 
unrelated to the EOC.
• 237/256 women were recorded as having disease relapse and disease free survival was 
calculated in these cases.
• The disease free survival ranged from 9-1154 days (median 225.5) and 0-2421 days 
(median 318.5) in the NACT and PD patients respectively.
• The overall survival appeared to be improved in women who received primary surgery.
• Addition of paclitaxel chemotherapy did not appear to improve survival
• Absence of residual disease significantly improved survival (DFS and OS p<0.0005).
• Worsening survival was noted with increasing FIGO stage and high grade tumours.
• p57^'^^ expression was noted to be low in 160 cases and high in the remaining 96 cases.
• 142/213 high grade tumours expressed low levels of p57^'^^.
• Low p57^'^^ expression appeared to be associated more with poor prognostic tumours 
like clear cell and MMMT.
• Women with tumours expressing high levels o f the p57' '^^  ^protein on IHC had a greater 
DFS (p<0.0005) and OS (p<0.0005) and a p57"^ '^  ^positive correlation with DFS and OS 
implying that increased expression is associated with better prognosis.
• Using the p57’^‘^  ^ ‘H ’ score resulted in no statistically significant difference was noted 
when comparing primary surgery versus primary chemotherapy (p=0.096) however
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comparing the p57’"^^  ‘H ’ score with bulk o f residual disease (p<0.0005), tumour grade 
(p<0.001), histological subtype (page 158) and FIGO stage (p<0.0005) were all statistically 
significant.
• A multivariate analysis using the Cox regression model using the p57""^^ ‘H ’ score for 
both DFS and OS was highly significant demonstrating that high levels of p57^'^^ ‘H ’ score 
predicted an independent positive DFS advantage (p=0.0005) and OS (p=0.0005).
• High Cyclin E expression was noted in 164 cases and the remaining 92 tumours 
demonstrated low levels.
• Using the Cyclin E ‘H ’ score resulted in no statistically significant difference was noted 
when comparing primary surgery versus primary chemotherapy (p=0.466).
• High Cyclin E ‘H’ score were noted in advanced FIGO stage (p<0.0005), in cases were 
complete cytoreduction was not achieved (p<0.0005) and in higher grade tumours 
(p<0.0005) and were all noted to be statistically significant.
• High Cyclin E ‘H ’ scores appeared to be associated more with poor prognostic tumours 
like clear cell and MMMT.
• Women with tumours expressing high levels of the Cyclin E protein on IHC had a 
significantly reduced DFS (p<0.0005) and OS (p<0.0005) and a Cyclin E negative 
correlation was noted with DFS and OS suggesting that high levels of expression are 
associated with poor prognosis.
• A multivariate analysis using the Cox regression model using the Cyclin E ‘H ’ score for 
both DFS and OS was highly significant demonstrating that high levels o f Cyclin E ‘H ’ 
score predicted an independent negative DFS advantage (p=0.0005) and OS (p=0.0005).
• In the combined Cox model for DFS, using both the p57^'^^ and the Cyclin E ‘H ’ score, 
FIGO  stage and p57^^  ^ ‘H ’ score emerge as being highly significant while Cyclin E 
‘H ’ score did not prove to be significant.
• In the combined Cox model for OS, using both the p57^'^^ and the Cyclin E ‘H ’ score, 
bulk of residual disease following surgery and p57^P  ^ ‘H ’ score emerge as being 
highly significant while Cyclin E ‘H ’ score did not prove to be significant.
The above results are used to answer some key clinical questions and are discussed in the 
next chapter.
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5.1 Rationale for Study
Epithelial ovarian cancer is an important health issue in the UK and worldwide with its 
rising incidence and significant contribution to the cancer mortality figures. There have 
been several studies following clinical trials discussing the role of primary treatment in 
EOC. While awaiting results from the UK clinical trial CHORUS it appears that in 
advanced EOC, the sequence of primary treatment does not matter as long as no residual 
disease is left behind following surgery which can be PD or IDS (Vergote et al 2010).
It then becomes a significant priority to identify those patients in whom complete 
cytoreduction can be achieved and along with imaging, biomarkers may play a role in this. 
Chemotherapy along with surgery has remained the mainstay of EOC treatment. While 
initial tumour response is good, in a significant proportion of patients, eventual 
development of drug resistance is frequent heralding disease recurrence, progression, 
metastasis and death. There is a significant advantage for both health care professionals as 
well as patients to discern which patients are likely to respond to treatment- who is likely to 
remain disease free? In which patient are we likely to achieve optimal disease 
cytoreduction at surgery? - and which cohort of patients are likely to perform poorly with 
no clear survival advantage? Such key clinical information is likely to have benefit as 
selected patients may benefit from other adjuvant therapies including newer 
chemotherapeutic agents, targeted biological therapies while offering crucial information to 
the patient to engage them in decision making around their health. While there are several 
clinical trials ongoing to identify newer chemotherapy drugs and regimes, there are small 
pockets of research into prognostic biomarkers in EOC. There is a strong clinical need for 
biomarkers and the following discussion explores the results o f the investigated markers 
(p^?kip2  Cyclin E) in answering some of these key questions.
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5.2 Answers to Study Questions
Are the biomarkers identified in the present study able to recommend 
which primary treatment offers better prognosis? Standard treatment for 
advanced EOC has been a staging laparotomy followed by platinum based chemotherapy. 
There have been several studies in the literature over the years debating the role o f PD 
versus NACT as some investigators could not demonstrate maximal benefit from PD for 
women with large disease volumes (Hoskins et al 1992; Van der Burg 1995 and Vergote et 
al 1998). In 1998 Vergote introduced the concept of treating women depending on the 
extent o f disease burden and performance status with either PD or NACT. This has been 
followed with an RCT which is discussed later on in this chapter (Vergote et al 2010). 
From this thesis, when independently analysed, it appears that women undergoing PD 
have a better prognosis (both DFS and OS) as compared to those undergoing NACT. 
When directly comparing the biomarkers with primary treatment, both pSV'^ ^^  and 
Cyclin E measurements demonstrate that primary debulking confers a survival 
advantage (Figure 4.14 and Figure 4.15). However, on multivariate analysis, primary 
treatment does not emerge as having a significant influence on survival suggesting 
that the sequence of treatment is less important as compared to other factors (Table 
4.41 and Table 4.45, Table 4.62 and Table 4.64). This compares favourably with the 
literature which has suggested that where complete cytoreduction at PD is unlikely to 
be achieved, NACT may be considered and is not inferior. (Bristow et al 2007 and 
Schwartz et al 2009) It is also in agreement with the RCT from Vergote et al which 
concluded that the timing of surgery in the treatment of EOC is less important. 
(Vergote et al 2010) The aim of surgery irrespective o f the timing remains complete 
cytoreduction which is vital to improving DFS and OS in this group.
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Are IHC biomarker levels able to predict residual disease volumes 
following surgery? As mentioned previously following surgery (PD or IDS) various
studies have evaluated that the key factor in prognosis is the volume of residual disease 
remaining after surgery. The goal o f surgery (PD or IDS) remains complete cytoreduction 
of all visible macroscopic disease (Onda et al 2010). Various meta-analyses have 
concluded that survival positively correlates with the extent of debulking achieved (Hunter 
et al 1992, Allen et al 1995 and Bristow et al2002). The extent of debulking that can be 
achieved may depend on the tumour biology which is likely to dictate the pattern o f spread. 
Tumour that have spread to the upper abdomen, chest and above are less likely to be 
optimally debulked despite ultra-radical surgery (Ang et al 2011). Studies suggest that 
resectability of the tumour depends on several variables including patient’s age, medical 
co-morbidities, ECOG status, volume of disease and skill o f the surgical team (Kehoe 
1994, Chi 2010 and Vergote et al 2011b). One overriding factor is the tumour biology 
though an analysis of three RCTs by du Bois et al suggested that surgical debulking may 
overcome tumour biology albeit partially (du Bois et al 2009). The above has to be 
considered in the changing context of what constitutes ‘optimal’ debulking. While in the 
1980’s residual disease greater than 2 cm was considered acceptable today ‘optimal’ 
cytoreduction constitutes nil visible macroscopic disease (Thigpen et al 2011). Meta­
analyses conclude that optimal cytoreduction tends to be achievable at PD. During IDS, 
response to chemotherapy is often reflected as fibrosed disease which is often not easily 
resectable. In our study, a statistically significant difference (p<0.01) was noted between 
the two groups with the NACT cohort having a higher residual disease following IDS 
likely due to difficulties encountered at IDS from chemotherapy induced fibrosis.
Several methods have been evaluated to predict bulk of residual disease. These include 
using clinicopathologic variables (Gemer et al 2001, Bristow et al 2010), imaging (Dowdy
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et al 2004, Axtell et al 2007 and Gemer et al 2009), a combination of the two (Ibeanu et al 
2010) and more recently an initial laparoscopy is being evaluated for this role (Fagotti et al 
2008) . In this study, low p57"^ ^^  and high Cyclin E levels were associated with some 
residual disease volume at surgery. The author along with the statistician is currently 
developing a model which incorporates the bulk of residual disease as one variable to 
predict survival. The author attempted to use the retrospective data to derive a 
scoring method of predicting disease bulk following surgery prior to subjecting a 
patient to surgery. This however only uses ECOG status, CA-125 and age. Ideally, 
levels of p57‘^ P^  and Cyclin E in serum collected for routine tests including CA-125 or 
tissue biopsy may be required and is an avenue to explore for future research. Several 
statistical first order interactions needed to be explored involving these biomarker levels 
which are beyond the scope of this thesis but form the basis o f a submitted mathematical 
grant for further extensive data analysis.
Is variable IHC expression of the study markers noted with histology?
Previously EOC was considered a single entity with all patients receiving standard 
treatment. It was subsequently reported that certain patient subgroups performed better than 
others. While some of this may be attributed to patient characteristics, in recent years, the 
heterogeneity of EOC has been recognised and is now well accepted (Gaudet et al 2012). 
Several markers are currently being investigated by study groups worldwide (Duncan et al 
2008, Duncan et al 2010, Hetland et al 2012, Li et al 2012 and He et al 2012). At present 
there is no consensus on predictive biomarkers in EOC. As the data presented in the 
literature, this thesis also had very small numbers of non- EOC. (Khouja et al 2007). Our 
data demonstrates an inverse relationship between the two markers p57""P^  and 
Cyclin E. Consequently, higher levels of p57"^ ^^  are noted in endometrioid type EOC 
as compared to clear cell or MMMT and conversely, higher levels o f Cyclin E are
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noted in clear cell and MMMT as compared to the more common and less aggressive 
endometrioid subtype.
Our cohort o f cases do include a higher proportion o f G3 cases (83.2%) than reported in the 
literature at less than 50% (Heintz et al 2001). This may be due to a true difference between 
the 2 populations. However it may represent the difficulty that has been well documented 
in the reproducibility o f the grading system between observers for all the histological 
subtypes (Hernandez et al 1984, Jolies et al 1985 and Silva et al 1998). Some variability 
may also exist on EOC grading by individual pathologists. Grading is altered by some 
depending on the histological subtype (for ex. MMMT are automatically graded to be G3) 
and some grade all EOC with standard grading systems. The grading systems commonly 
employed are the WHO and FIGO grading which is based on the ratio of 
glandular/papillary growth versus solid growth. Silverberg grading has also been used in 
the past which is a more complex and uses three parameters -  architectural pattern, nuclear 
pleomorphism and mitotic activity (Kommoss et al 2009 and Yamamoto et al 2011). This 
makes comparisons between studies complex and inconclusive. Higher levels of 
also appear to be associated with low grade tumours and appear to be related to 
better prognosis. Conversely, low levels of Cyclin E appear to suggest better 
prognosis as noted by their decreased presence in low grade tumours and presence of 
high levels in the more aggressive tumours such as clear cell malignancies and 
MMMT concur with the current literature (Sui et al 2002).
Do the IHC markers have an influence on adjuvant treatment in Stage I 
ovarian malignancies?
Epithelial ovarian cancer often presents as an advanced stage disease with fewer than 30% 
of patients presenting with FIGO stage I and II (Jemal 2008). Patients with early stage EOC 
are offered surgery with a view to removal of disease as well as accurate staging and
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studies have shown that accurate staging offers better prediction of individual case 
outcome. More significantly, it can be an independent prognostic factor of survival in stage 
I disease (Zanetta 1998, Trimbos 2003). Though some reports suggested good outcomes 
including the option of fertility sparing surgery for very early disease, the recurrence rate 
has been noted to be 30% across some studies (Takada 2012). In the UK, the NICE 
guideline on ovarian cancer management recommends that adjuvant chemotherapy not be 
offered to women with stage I (low risk disease- stage la or Ib and grade 1/2) if  optimally 
staged and discussed with those suboptimally staged (NCCC OC 2011). The challenge that 
remains in this group is to identify the ‘high risk women’ who would not usually be offered 
adjuvant chemotherapy. While practices vary biomarkers such as those explored in this 
thesis may have a role in determining this. The rationale behind offering chemotherapy was 
based on the results o f the 2 trials ICON 1 and ACTION 2003 suggesting a treatment 
benefit from adjuvant chemotherapy (Colombo 2003, Trimbos 2003).
In this study, there were 8 cases of Stage I ovarian malignancy all of who underwent 
primary surgery. Following surgery, 4/8 were noted to have stage la disease and the 
remaining stage Ic disease. O f the 4 stage la, only one had grade 2 disease and the other 3 
were noted to have grade 3 disease on histology with one serous, one endometrioid and two 
mucinous subtypes. Of the 4 stage Ic patients, only one had grade 1 and grade 2 disease 
while the remaining 2 were noted to have grade 3 disease with 3 mucinous and one clear 
cell tumour noted on histology. All patients were offered chemotherapy irrespective o f 
their stage, grade or histological subtype. Two patients declined chemotherapy while the 
third died after 2 cycles. All the remaining 5 patients completed 6 cycles o f atleast single 
agent carboplatin with 2 patients receiving paclitaxel in addition. On review o f their ‘H ’ 
scores, very high p57^'^^ ‘H ’ scores (284 and 295) were noted in the two patients who 
declined chemotherapy and remained free of relapse. In the two women who received
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single agent carboplatin, p57*"^  ^ ‘H ’ scores were noted to be above 250 whereas in the three 
women who received combined carbotaxol chemotherapy, p57*^ *^  ^ ‘H ’ scores were between 
175 and 225.
While the sample size is minute (n=8) for stage I cancers in this study with multiple 
variables, a flowchart that may be put forward is to explore the role of p57’^ ‘^  ^ ‘H ’ scores in 
determining adjuvant chemotherapy in this group of patients as shown on the next page 
(Figure 5.1). This requires large sample sizes as well as an RCT to identify a cutoff value, 
an algorithm of any true benefit. It is however remains an interesting question to 
investigate in future studies.
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Figure 5.1: Flow chart of the potential role of in Stage I ovarian cancer
Stage I ovarian cancer
Surgical
stagingStaged completely*.
YES
P57'^ 'P^  ‘H’ score
Low score with 
predetermined 
cut-off value
High score with 
predetermined cut­
off value
Offer adjuvant 
chemotherapy
Discuss benefits 
and risks of 
surveillance vs 
adjuvant 
chemotherapy
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Are the IHC markers predictive of disease free survival? Management of 
advanced EOC involves surgery +/- platinum based chemotherapy with or without the 
addition o f paclitaxel (Morrison 2007). Although this treatment results in complete 
remission in at least 75% of patients, (Thigpen 2004), 75% of these will relapse with 18 to 
28 months (Stuart 2003). O f these, 20-40% will survive beyond five years (Kikuchi 2005). 
DFS is critical to patient management and such information early in the treatment pathway 
can help with decision making involving primary treatment, chemotherapy +/- maintenance 
drugs to prolong DFS. An approach to improving DFS was to increase the number of 
chemotherapy cycles. There is conclusive evidence to show that more than 6 cycles of 
chemotherapy did not improve DFS but worsened toxicity and quality o f life (Lambert 
1997).
Some studies also suggested that maintenance chemotherapy with platinum may improve 
DFS (Markman 2003). Meta- analysis from 6 RCTs did not show any evidence that 
maintenance chemotherapy with platinum or doxorubicin improved DFS (Picart 2003, 
Sorbe 2003, Placido 2004, Nicoletta 2004, Bolis 2006 and Cheng 2006).
Angiogenesis has been a focus of interest for several years in EOC and VEGF is key in 
angiogenesis stimulation. Bevacizumab (Avastin) is a monoclonal antibody that binds 
VEGF preventing its binding to VEGF receptors and inhibits VEGF receptor activation 
thus slowing down angiogenesis and tumour progression. This was the basis of two clinical 
trials (GOG 0218 and ICON 7). Results from these trials show that women who received 
Bevacizumab concurrently and as maintenance treatment had longer DFS (Burger 2010, 
Perren 2010).
From  the data  presented in this thesis, p57‘^ P^  and Cyclin E are  able to independently 
predict DFS. These results have been confirmed using m ultivariate analysis and Cox 
modelling. However, when p57'"P^ and Cyclin E are  combined into a Cox model.
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p 5 ?kip2  ,.g„jains a significant predictor of DFS while Cyclin E does not emerge as a 
significant variable (Chapter 4). The finding of p57*^ P^  in this thesis is in contrast to 
the two studies previously described which concluded that p57^^  ^ offered no 
prognostic information (Rosenberg et al 2001 and Khouja et al 2007). Both these studies 
had smaller number of cases in comparison to the current study and this may explain the 
lack of any prognostic information. Using tumour histology, FIGO  stage and p57*^ ^^  a 
prognostic model for DFS has been derived. This model has predicted DFS 
accurately in 74.8% of cases in our cohort. The model is currently being refined and 
validated as part of our ongoing work.
Are the IHC markers predictive of overall survival?
Following completion of primary treatment, most women with advanced EOC eventually 
develop recurrences with a median DFS of 18 months (Burke et al 994, Munkarah et al 
2004 and Ozols et al 2006). Once a patient develops recurrence the disease is incurable. 
Efforts have thus been made to delay the development of recurrence and prolong the DFS. 
Maintenance chemotherapy has been considered as one option and options such as 
platinum based chemotherapy as well as doxorubicin were tried in RCTs (Picart et al 2003, 
Sorbe et al 2003, Placido et al 2004, Nicoletta et al 2004, Bolis et al 2006, Cheng et al 
2006) and each showed no OS benefit while toxicity levels were considered severe. 
Management of recurrence also depends on the DFS period. Evidence of disease 
progression during first line chemotherapy (platinum refractory) or within 6 months of 
completing primary treatment (platinum resistant) renders these women in a poor 
prognostic category. Further chemotherapy is only considered to be palliative and no other 
treatment option (e.g. secondary cytoreduction) is considered (Eisenkop et al 2000, 
Scarabelli et al 2001 and Tebes et al 2007). Secondary cytoreductive surgery is reserved for 
those cases where disease recurrence is beyond six months (platinum sensitive) and where
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complete tumour resection is deemed feasible, recent literature supports the view that 
complete secondary cytoreduction for recurrent EOC prolongs OS (Bristow et al 2007).
To address the question of OS, this thesis evaluated whether p57^^  ^and Cyclin E are 
able to independently predict OS. Both p57'^ P^  and Cyclin E predict OS independently 
and on multivariate analysis using Cox regression modelling along with other 
variables. However, should the two IHC markers be combined into a single model, 
p5 7 kip2  power to predict OS while Cyclin E loses out. Using FIGO stage,
bulk of residual disease following surgery and p57^^  ^ H ’ scores, an OS predictive 
model has been developed which has accurately predicted the OS in 71.6% of cases. 
In 17.8% of cases the model ‘underperformed’ and reported a worsening survival 
than the actual survival whilst in the remaining 10.6% of cases the model 
‘overperformed’ by reporting a better survival outcome for the patients than 
recorded survival and date of death. This model is being refined further to be 
validated and tested using other patient cohorts.
5.3 Study Strengths
This study was undertaken using IHC techniques which are easily reproducible, cost- 
effective and can be undertaken in most histopathological laboratories with existing 
equipment and minimal investment (antibodies). Like most studies using multiple markers, 
p^ 7 kip2  warrants further investigation and adaptation into the next phase using serum 
etc while Cyclin E has shown to be of limited prognostic value.
This is the largest study of p57'^ 'P^  in epithelial ovarian cancer currently and will make 
a significant contribution to existing knowledge on the role of this cell cycle regulator.
Robust clinical dataset with minimal missing data has resulted in a valuable resource for 
ongoing work. Using retrospective patient cohort implied availability of mature data and 
outcomes and since the study only used IHC techniques, it did not influence the study.
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5.4 Study Limitations
IH C technique: The entire study is based on IHC. This is a subjective staining assessment 
and this is subject to bias.
Levels of In ter-observer variability: The other limitation of this study is that while there 
was an extremely high level of inter- observer agreement for the IHC scoring, the double­
scoring was not performed in all cases and random selections of slides only were dual 
scored. While literature suggests that kappa scores >0.6 are sufficient to support suitable 
levels of agreement between independent scores, this work while not forming part o f the 
thesis is currently underway to dual score all the IHC work undertaken (Viera et al 2005).
5.5 Avenues for future research
This thesis has raised the possibility of using p57^'^^ as a potential marker o f prognosis in 
EOC. There are several conceivably tandem routes for the continuation of the work that has 
been done in this project.
Firstly while IHC sits at the heart o f this study, further validation o f results needs to be 
carried out using concurrent serum and tissue. While it has become very clear that p57'^ *^  ^
has proved value as a prognostic marker and further studies are needed to evaluate its role, 
these studies need to include sequential serum samples in the women with a baseline 
sample at diagnosis and subsequent samples at varying stages throughout their treatment 
(i.e prior to commencing chemo, surgery etc).
Secondly, the predictive ability o f the model generated in this project needs to be tested and 
improved upon. In order to do this, the predictions made using this model must be applied 
to and tested experimentally in further sets of databases and these results to be fed back 
into the model in an iterative fashion. The current model has been generated using only 
p^ 7 kip2  following the Cox regression model rendering it ‘naïve to other cell cycle
markers. The quantitative modelling is also being reviewed to identify if  a scoring
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methodology can be derived which then needs to be tested in several other cohorts. Tissue 
microarray is also being explored as an alternative with incorporating p57^'^^ in this setup 
as part o f routine practice.
Furthermore, as discussed previously the role o f p57^‘^  ^in stage I ovarian cancers where the 
role of chemotherapy continues to be debated may be explored in much more detail to 
answer this crucial question o f adjuvant treatment following surgery in this cohort and a 
grant application is being prepared to address this further.
Other avenues to explore include platinum sensitivity in this group. There is now further 
analysis being undertaken to explore if the markers Cyclin E) can predict platinum
sensitivity. While outside the scope of this thesis, this correlation is being explored in 
detail.
5.6 Conclusion
This thesis addresses various aspects of the tumour biology including prognosis which is of 
utmost significance in any disease state including cancer through the use of IHC 
techniques. The work in this thesis illustrates that EOC is a heterogeneous disease and 
variations in expression of certain protein markers (biomarkers) can help to distinguish 
tumour biology as well as predict tumoral behaviour. Limited success with 
chemotherapeutic agents in the treatment of EOC is likely due to the heterogeneous nature 
o f the disease and a “same drug for all disease subtypes” approach which has been adopted 
to date. The future o f EOC treatment needs to involve individualised treatment based on 
the histological subtype and molecular behaviour o f each tumour as determined through 
simple and reproducible tests such as IHC (Macdonald et al 2004). Ongoing clinical trial 
work on novel treatments needs to be encouraged and will need to include simultaneous 
biomarker investigation to determine the pathways being targeted, response to treatment to 
establish which patients are most likely to benefit from a certain treatment. This thesis has
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demonstrated that tumours expressing high and low Cyclin E levels are associated
with improved survival rates and prognosis. Consistent with the literature the prognostic 
value of Cyclin E is limited in concluding that high Cyclin E levels confer a poor prognosis 
while failing to provide further meaningful survival data.
Below is a flowchart designed from the author’s perspective of the role of if
translated to the clinical setting with the current knowledge. There queries indicate the gaps 
in knowledge but suggest possible options for its use.
Figure 5.2: Flowchart on possible uses of p57^^  ^in the clinic
Early stage with
p57kip2 ,|_|> ggQ|.g
(Figure 5.1)
Ovariam Cascer
? role o f adjuvant 
chemotherapy 
prognostic information
Advanced stage 
with p57^ 'P^  ‘H’ 
score
1. Ability to achieve complete
cytoreduction at primary
surgery '
r I. Prognostic information
3. ? platinum sensitivity
>
Though ideal, a single protein marker is unlikely to provide all answers during a patient’s 
treatment journey; targeted therapies based on a panel of IHC markers are likely to pave 
the way forward in the long awaited future of personalized medicine.
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APPENDIX A: Ovarian Tumours
WHO Classification of Ovarian tumours
Modified WHO scheme of classification of Ovarian Tumours 1995
a. Surface epithelial tumours
1. Serous tumours
(a)Benign
i. Cystadenoma and papillary cystadenoma
ii. Surface pailloma
ill. Adenofibroma and cystadenoflbroma
(b) Borderline malignancy (low malignant potential)
i. Cystic tumour and papillary cystic tumour
ii. Surface papillary tumour
ill. Adenofibroma and cystadenoflbroma
(c) Malignant
i. Adenocarcinoma, papillary adenocarcinom and papillary 
cystadenoma
ii. Surface papillary adenocarcinoma
iii. Adenocarcinofibroma and cystadenoflbroma.
(2) Mucinuous tumours (endocervical like and intestinal type)
(a) Benign
i. Cystadenoma
ii. Adenofibroma and cystadenoflbroma
(b) Malignant
i. Adenocarcinoma and cystadenocarcinoma 
ii Adenocarcinofibroma & cystadenocarcinofibroma
(3) Endometrioid tumours
(a) Benign
i. Cystadenoma with squamous differentiation
ii. Adenofibroma and cystadenoflbroma
iii. Adenofibroma and cystadenoflbroma with squamous 
differentiation
(b) Malignant
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i. Adenocarcinoma and cystadenocarcinoma
ii. Adenofibroma and cystadenoflbroma with squamous 
differentiation
iii. Adenocarcinofibroma & cystadenocarcinofibroma
iv. Adenocarcinofibroma & cystadenocarcinofibroma 
with squamous differentiation
(c) Epithelial (endometrioid) stromal and (endometrioid) stroma
i. Adenosarcoma, homologous and heterologous
ii. Mesodermal (Mullerian) mixed tumor (carcinosarcoma) 
homologous and heterologous
iii. Stroma sarcoma.
(4) Clear cell tumour
(a) Benign
i. Cyst adenoma
ii. Adenofibroma and cystadenoflbroma
(b) Malignant
i. Adenocarcinoma
ii. Adenocarcinofibroma and cystadenoflbroma
(5) Transitional cell tumours
(a) Brenner tumour
(b) Brenner tumour o f borderline malignancy/ proliferating
(c) Malignant Brenner tumour
(d) Transitional cell carcinoma (non-Brenner type)
(6) Squamous cell tumour
(7) Mixed epithelial tumour (specific types)
(a) Benign
(b) Of borderline malignancy/ or low malignant potential
(c) Malignant
(8) Undifferentiated carcinoma
(9) Unclassified
b. Sex-cord Stromal Tumours
(1) Granulosa cell tumour
(a) Juvenile
(b) Adult
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c. Germ cell tumours
(1) Dysgerminoma
(a) Variant with syncytiotrophoblast cells
(2) Yolk sac tumour (endodermal sinus tumor)
(a) Variant Polyvesicular vitelline tumor
(b) Hepatoid
(c) Glandular
(3) Embryonal carcinoma
(4) Polyembryoma
(5) Choriocarcinoma
(6) Teratoma
(a) Premature
(b) Mature
i. Solid
ii. Cystic (dermoid cyst)
iii. With secondary tumour formation (specify types)
iv. Fetiform (Homunculus)
(c) Monodermal and highly specialized
i. Strauma ovary
ii. Ariant with thyroid tumour (specify type)
iii. Carcinoid
iv. Insular
V . Trabecular
vi. Strauma carcinoid
vii. Mucinous carcicoid
viii. Neuroectodermal tumours
ix. Sebaceous tumours 
X. Others
(7) Mixed (speeify types)
(a) Gonadoblastoma
i. Variant with dysgerminoma or other germ cell tumor
(b) Tumours of rete ovari
i. Adenoma and cystadenoma
ii. Carcinoma
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(c) Mésothélial tumours
i. Adenomatoid tumour
ii. Others
(d) Tumours of uncertain origin
i. Small cell carcinoma
ii. Tumour of probable Wolffian origin
iii. Hepatoid carcinoma
iv. Oncocytoma
(e) Gestational trophoblastic diseases
(f) Soft tissue tumours specific to ovary
(g) Malignant lymphomas
(h) Unclassified tumours
(i) Secondary (metastatic) tumours 
(j) Tumour like lesions
i. Solitary follicle cyst
ii. Multiple follicle cyst (polycystic disease)(sclero cystic ovaries)
d. Large solitary leuteivized follicle cysts of pregnancy and puerperium
e. Hyper-rectio luteinalis (multiple
leutinized folliclecysts) ^variant with corpora lutea.
(1) Corpus luteum cyst
(2) Pregnancy luteoma
(3) Ectopic pregnancy
(4) Hyperplasia of stroma
(5) Stromal hyperthecosis
(6) Massive edema
(7) Fibromatosis
(8) Fibromatosis
(9) Endometriosis
(10) Cyst, unclassified (simple eyst)
f. Inflammatory lesions
(1) Xanthogranuloma
(2) Malakoplakia
(3) Other
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Staging of Carcinoma of the Ovary (FIGO 1988)
FIGO Extent of Disease
I Growth limited to the ovaries.
la Growth limited to one ovary; no ascites present containing
malignant cells. No tumour on the external surfaee; capsule 
intact.
Ib Growth limited to both ovaries; no ascites present
containing malignant cells. No tumour on the external 
surfaces; capsules intact.
Ic Tumour either stage la or Ib, but with tumour on surface of
one or both ovaries, or with capsule ruptured, or with ascites 
present containing malignant cells, or with positive 
peritoneal washings.
II Growth involving one or both ovaries with pelvic extension.
Ha Extension and/or métastasés to the uterus and/or tubes.
Ilb Extension to other pelvic tissues.
lie Tumour either stage Ha or Hb, but with tumor on surface of
one or both ovaries, or with capsule(s) ruptured, or with 
ascites present containing malignant cells, or with positive 
peritoneal washings.
III Tumour involving one or both ovaries with histologically 
confirmed peritoneal implants outside the pelvis and/or positive 
regional lymph nodes. Superficial liver métastasés equals stage 
III. Tumour is limited to the true pelvis, but with histologically 
proven malignant extension to small bowel or omentum.
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Ilia
mb
IIIc
IV
Tumour grossly limited to the true pelvis, with negative 
nodes, but with histologically confirmed microscopic 
seeding o f abdominal peritoneal surfaces, or histologic 
proven extension to small bowel or mesentery.
Tumour of one or both ovaries with histologically confirmed 
implants, peritoneal metastasis o f abdominal peritoneal 
surfaces, none exceeding 2 cm in diameter; nodes are 
negative.
Peritoneal metastasis beyond the pelvis >2 cm in diameter 
and/or positive regional lymph nodes.
Growth involving one or both ovaries with distant 
métastasés. If pleural effusion is present, there must be 
positive cytology to allot a case to stage IV. Parenchymal 
liver metastasis equals stage IV.
F ig u re  A p p e n d ix  A1: F low chart on m a n a g e m e n t of su sp ic io u s  pelvic m a s s e s
yes
Follow-up
Complete 6 cycles 
of chemotherapy
Follow-up & 
discharge
Benign disease confirmed
MDT confirms benign disease
Surgery with frozen section
Borderline/Malignancy confirmed- 
Surgical staging
Pelvic mass suspicious o f ovarian 
malignancy
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Figure Appendix A2: Flowchart on management of advanced ovarian
cancers
MDT
Siiitahle; fnr TDS
NACTPS
Follow-up
Complete 6 cycles 
of chemotherapy
MDT following 3 or 4 cycles
Complete remaining of 
chemotherapy
Not suitable for IDS- 
continue with 
chemotherapy
Clinical and or radiological e/o pelvic mass and extra-pelvic métastasés 
(FIGO Stage III/IV) EOC/PP at presentation
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APPENDIX B: Study Documents
STUDY DOCUMENTATION FOR OVARIAN CANCER 
BIOMARKER RESEARCH PROJECT
The Royal Surrey County Hospitall
NHS Trust 
St. L uke’s C ancer C entre
Egerton Road 
Guildford 
Surrey 
GU2 7XX 
Tel: 01483 571122
Patient Information Sheet
PATTENT INFORM ATION SHEET
Name of Studv: The identification of new prognostic indicators and m arkers of drug 
resistance for the managem ent of ovarian cancer
Name of Researchers: Mr Simon Butler-Manuel
Mr. Anil Tailor
Dr Helen M Coley
Dr. Thumuluru Kavitha Madhuri
You are invited to take part in a research study involving your doctors at the Royal Surrey
County Hospital and a group of cancer scientists at the University o f Surrey. Before you decide
whether you will take part or not, it is important for you to understand why the research is being
carried out and what it will involve. Please take time to read the following information carefully
and discuss it with others if you feel the need to. You are welcome now and at any stage o f the
research study to ask us (i.e. your hospital doctors or the scientists at the university) about
anything that is not clear, or if you require more information. It is important that you take time to
decide whether or not you wish to take part.
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How may I be involved in the study?
Samples of ovarian tissue will be removed by your surgeon as part of the routine diagnosis and 
treatment o f your condition. We are asking if  a small part o f these samples can be used in our 
research study. Please be reassured that we are not taking additional tissue as what we are taking 
for our study is surplus material left over from that taken in the course of your normal clinical 
care. The samples for our research will only be taken once all material for diagnostic and 
therapeutic purposes have been obtained. These will be taken to the Postgraduate Medical 
School at the University of Surrey. The samples will be given a unique identification number for 
laboratory analysis. It may be appropriate in some cases to take a number o f samples from you 
over a period of time i.e. over many months, if you agree to this. Again, these samples will only 
be taken in the course of your routine treatment.
What is the purpose of the study?
Since scientists have had the opportunity to access the whole o f the human genetic code as a 
result of the “Human Genome Project”, a new technique called “microarray” has been 
developed. This enables us to look at hundreds if not thousands of genes within a sample of 
tissue. We want to find out which genes, or groups of genes, are increased in response to drug 
therapy and also which of those genes is relevant to the type of ovarian cancer you have. The 
differences we see in the so-called “gene expression profiles” between patients who respond 
differently to their drug therapies and/or the specific type of cancer will provide us with 
information that may in the future be used to choose the appropriate types o f therapy to be used 
to treat a particular patient. In addition, the information should provide us with information as to 
why some ovarian cancers develop drug resistance.
So far in the earlier study we have conducted we were able to look at tissue obtained from over 
30 cases of ovarian cancer as these patients were kind enough to give us their consent to take 
part in this initiative. We were able to identify at least two genes that appeared to be associated
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with ovarian cancer and the way that patients responded to their therapy. These genes are called 
“Met” and “p57kip2”. Using your tissue we wish to continue using the microarray technique to 
search for other genes of interest but in addition we now wish to study in more depth the role of 
“Met” and “p57kip2” genes using a process called immunohistochemistry. If  any cells remain 
from your sample we would also like to seek permission from you to store these for use in future 
studies that may lead on from the work we plan to carry out now. Your sample will be stored in 
a secure deep freezer at the University o f Surrey and may be used for other analyses in addition 
to microarray. At the present time it is impossible to be precise what the methodology will 
involve as we want to allow for any new changes that may arise in the way that scientists 
analyse tissue samples in the near future. Hence we wish to make the most o f the valuable 
resource of your tissue and therefore would like to include your tissue sample in any new 
initiative we undertake that will help us to develop a better understanding of ovarian cancer. For 
any future new research initiative that we undertake that may involve your stored tissue our 
proposal will be submitted for the scrutiny o f a Research Ethics Committee. For completeness 
we would also like to ask for a small sample of blood from you that will be included as part of 
the research analysis. This sample will be destroyed if any remains after we have completed the 
study described herein.
The objective of this study is designed to build up a large amount of data that will be examined 
over the next 3 years or more. It is true to point out that what we find will not impact on your 
treatment or obviously gain any benefit for you directly. However, if you take part in this study 
you will be contributing enormously to the research and the long term benefit to ovarian cancer 
sufferers could be considerable. At any stage it is accepted that you retain the right to ask us to 
destroy the material held in the research laboratories at the University of Surrey. 
Confidentiality
We would also like to ask your permission to allow senior members o f the scientific team in 
addition to the medical team at the RSCH to access your medical notes in order to collect
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clinical information regarding your case. This would include information such as a description 
of your condition in terms o f the type o f tumour, the drug therapy given and the way your 
tumour responded. You will be given a unique registration number which will ensure that you 
will not be identified outside the confines of the trial.
What will happen to the results of the research study?
All data will be stored confidentially, both electronically and as hard copy. The results from our 
research studies will be reported in scientific and medical journals and thus will increase our 
understanding of the biology and treatment o f ovarian cancer.
What will happen to me if I agree to take part in this study?
Please be assured that in agreeing to take part in our study this will in no way delay the normal 
course of your treatment and there will be no additional risk attached to the sampling procedure.
Do I have to take part?
Your involvement is entirely voluntary and greatly appreciated. If you do decide to take part you 
will be given this information sheet to keep, asked to sign a consent form which you will be 
given a copy of once it is signed. As already stated, your identity will be protected by a 
numbering system and all health information is subject to absolute confidentiality.
Contact for further information:-
Thank you for taking time to read this. If you require further information please do not hesitate 
to contact:-
Mr Simon Butler-Manuel/ Mr. Anil Tailor 
Consultant GynaeOncologists 
Royal Surrey County Hosptital 
01483 571122 extn 2176
VERSION 5 
17.10.07
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The Royal Surrey County Hospitall
NHS Trust 
St. L uke’s C ancer C entre
Egerton Road 
Guildford 
Surrey 
GU2 7XX
Tel: 01483 571122
WRITTEN PATIENT CONSENT TO PARTICPATE IN 
A RESEARCH STUDY
Title of Study: The identification o f new prognostic indicators and markers o f drug
resistance for the management of ovarian cancer
Name of researcher(s): Mr Simon Butler-Manuel
Mr. Anil Tailor
Dr Helen M Coley
Dr Thumuluru Kavitha Madhuri
Contact details: Mr Simon Butler-Manuel/Mr. Anil Tailor
Consultant Gynaecological Oncologists
01483-571122 extn 2176
1 .1 have read the attached patient information sheet on the above
project and have been given a copy to keep. I have had the 
opportunity to ask questions about the project and understand 
why the research is being carried out.
2 .1 agree to give a sample(s) o f my tissue and blood for research
on the above project. I understand that you are only using 
tissue that will be removed as part of my operation.
□
□
3. I agree that the sample I have given can be stored for possible use in future projects as 
mentioned in the Information Sheet.
□
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4. I understand that the project and any future research using the sample I give may include 
genetic research but I also understand that the results of these research investigations are 
unlikely to have any implications for me personally.
□
5 .1 give permission for senior members of the scientific team, in addition to the medical team at 
the Royal Surrey County Hospital, to access my medical records to collect clinical information 
relevant to the study. I understand that the information will be kept confidential at all times.
□
6 .1 know how to contact the Research Team if I need to. □
Name o f Patient (BLOCK CAPITALS) Date Signature
Name o f Person taking consent if  Date Signature
Different from researcher
Name o f Researcher Date Signature
Version 3
Copy 1 : Trial folder 
Copy 2: Patient 
Copy3: Medical notes
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Study Protocol
Title
Study to evaluate the utility o f biomarkers at the gene and protein level in their role as new 
prognostic indicators and/or new drug targets to assist in the treatment and management of 
ovarian cancers.
Background
Ovarian cancer remains the most lethal o f the gynaecological cancers with some 7,000 new 
cases reported annually in the UK. Patients with ovarian cancer are usually treated with a 
combination o f cytoreductive surgery and systemic treatment with platinum and paclitaxel. 
Although initial response to chemotherapy may be good (70-80%) responders, nearly 80% 
relapse and need further systemic chemotherapy due to drug resistance development. Patients 
who relapse with platinum free interval o f 6months or less are considered as platinum 
refractory/resistant individuals and the chances of achieving complete response is rare and 
sustained remission to any known chemotherapy leading to survival benefit is unclear. Second 
line chemotherapy is then aimed at improving quality of life rather than survival.^Ovarian 
tumours of different histotypes have distinct genetic characteristics that may predict response to 
chemotherapy^. Currently, no specific prognostic factors exist, that predict outcome following 
treatment with paclitaxel and platinum. Moreoever, there are no methods for defining a 
particular cohort o f patients who may, or may not, respond to a particular therapy. There is an 
obvious and urgent need for new therapies designed to target particular molecular features of 
ovarian cancers and there is currently considerable interest in finding molecular markers of 
prognosis to enable use of appropriate therapies in the treatment o f the disease.
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Ovarian cancer is characteristic of a tumour that succumbs to acquired drug resistance despite 
the initial good response but relapsing subsequently in spite of further second and third line 
therapy. A number of mechanisms have been shown to be implicated in platinum-refractory 
disease -  for example, méthylation of the M LH\ gene which has been identified as a factor 
contributing to poor response to carboplatin based therapy.^ More recently growth factor 
receptor over expression has been shown to be associated with acquired drug resistance in 
cancer cell line models, including ovarian cancer.
Thus, it is likely that several genes are involved in drug resistant ovarian cancer -  although to 
date those identified have failed to result in significant therapeutic advances -  such as the 
identification of new targets or new prognostic indicators. Hence, it is now imperative that the 
search be broadened to seek out critical genes involved in ovarian cancer. A recent and 
potentially exciting approach is to use gene expression data generated by DNA microarray 
technology. This approach can involve both tumour cell lines and patient biopsy material and a 
number of publications have recently appeared which address the problem of ovarian cancer 
using microarray technology.^’^  Further, it has been suggested that genes that are attenuated by 
prolonged exposure of cancer cell lines to drugs in the in vitro environment may not necessarily 
be relevant to the problem of clinical drug resistance.^
The foundation for this project is based on a number of studies carried out in thelaboratory o f Dr 
Coley and her collaborators into drug resistance in ovarian cancer. One of these studies 
comprised a pilot study investigating gene expression profiles of ovarian cancer specimens taken 
from a group of 20 women, which was recently carried out in the Faculty of Health and Medical 
Sciences (FHMS), UniS in conjunction with the our department o f Gynaecological Oncology, St 
Luke’s Cancer Centre, Royal Surrey County Hospital. We aim to look at a cohort of 
approximately 200 cases of epithelial ovarian cancer of varying histological subtypes and
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disease stages all o f which will have reached maturity before the close o f the study. A 
comprehensive database o f patient clinical information has already been accrued -  and will 
continue to be collated by myself (Dr.Madhuri)- with the assistance o f the collaborating 
Consultant Gynaecological Oncologist (Mr Simon Butler- Manuel) and his team as required. 
The database, similar in format to that used for the SCOTROC trial in ovarian cancer, is already 
set up for the first cohort of 40 patients in the initial pilot study where we used extracted RNA 
for gene expression profiling.
The cohort o f patients in the pilot included both chemo-naive patients and those who had been 
previously treated. All patients were given carboplatin with paclitaxel post-operatively. Patients 
were given an information sheet and all fresh tumour samples taken in the operating theatre were 
snap-frozen following the patients consent (along with their blood samples). All processes were 
carried out under the auspices o f the local Surrey Ethics committee. The microarray pilot study 
included ovarian cancer cell lines models with acquired drug resistance which were also 
subjected to genetic profiling. Further in depth gene expression profiling on a wide range of our 
in-house derived drug resistant ovarian cancer cell lines was then carried out at the CRUK 
microarray facility at the Institute of Cancer Research in collaboration with Dr Tim Crook, 
Section of Cancer Genetics and Epigenetics. Data obtained from these analyses has then 
provided the rationale for more recent laboratory investigations which includes the assessment 
o f a number of genes and their protein products as potential prognostic indicators and markers of 
drug resistance.
Literature Review
Alteration of cell cycle regulators shows co-relation with survival in epithelial ovarian cancer 
was a study that was carried out in 107 patients for pl6-cyclin D1 pathway. Othersmaller 
studies than the one we propose to run have been carried out in ovarian cancer patients -  for all
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of the parameters apart from snk/PLK2. Our study will validate some of the previous work of 
others (on MET, cyclin E, p57^®& BRK^). The PLK2/snk is totally unique for evaluation as a 
biomarker and stems from work that Dr. Coley has carried out in conjunction with Dr. Tim 
Crook.
Biomarkers are molecules that exist naturally in the body that can help predict or reflect the 
presence of a disease, the risk of relapse o f the disease, and/or response to treatment.
Successfully translating research on biomarkers from the laboratory to patients involves five 
phases:
Discovery phaseis Phase 1 which includes exploratory studies to identify potentially useful 
biomarkers.
Phase 2 is where biomarkers are studied to determine their capacity for distinguishing between 
people with cancer and those without. The validation phase
Phase 3 determines the capacity of a biomarker to detect pre-clinical disease by testing the 
marker against tissues collected longitudinally from research cohorts.
Phase 4 includes prospective screening studies.
Phase 5 is when large-scale population studies evaluate not just the role o f the biomarker for 
detection of cancer, but the overall impact of screening on the population and whether this 
screening impacts survival.
Our study on biomarkers will revolve around Phase 1 & 2 where following identification o f the 
useful biomarkers, we will validate their role in identifying cancer patients at various treatment 
phases and response states.
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Aims
1. To evaluate the utility o f measuring gene protein products relating to epigenetic modification 
and signal transduction pathways to examine their role as possible new prognostic indicators in 
the management of epithelial ovarian cancer
2 .T0  examine the role of the chosen markers in the molecular pharmacology studies to be carried 
out in drug resistant ovarian cancer cell lines.
Contribution to Clinical Practice
This study will provide information and a more clear rationale on the use o f biomarkers 
associated with epigenetic changes and signal transduction processes in terms o f their utility as 
prognostic indicators and/or potential new drug targets in the management of ovarian cancers.
Biology of gene protein products
Based on evidence obtained from microarray analysis and further molecular evaluation into the 
role o f particular factors in the chemo- responsiveness o f ovarian cancers, we will look at the 
following two areas:
1. Epigenetic silencing (looking particularly at cell cycle regulation and mitotoic regulation ) :-
and cyclin E, snk/PLK2, epigenetically modified in ovarian cancer &
2. Signal transduction pathways
BRK tyrosine kinase, hepatocyte growth factor receptor MET and it activated form -  signal 
transduction pathways.
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Rationale for choice of parameter measurement
P57/cvclinE:
It is now well established that abnormally regulation o f the cell cycle is a hallmark of human 
carcinogenesis. Cell cycle control is held under stringent regulation through groups o f protein 
kinases known as the cyclin-dependent kinases (CDKs) and by their inhibitors the CDKIs. 
p57^‘P^  is a member of the cip/kip CDKI family (which includes p2U'^^ and p27 p57^'^^
plays a key role in embryogenesis and is also associated with the promotion of cell death. The 
findings o f the microarray study of ovarian cancer cell line models, indicated that p57'"^^was 
associated with response to chemotherapy as very low levels were detected in drug resistant 
versus drug sensitive lines. Further analysis (using a technique o f microarray méthylation 
reversal expression analysis) has clearly shown that epigenetic méthylation silencing of the 
p 5 7 kip2  gene |g ^ feature o f our ovarian cancer cells that have acquired resistance to platinum 
agents (manuscript in preparation). Moreover, in the pilot microarray study we saw significantly 
higher levels of p57kip2 in patients who gave a complete response compared with those who 
gave a partial or no response. This result was confirmed by real-time PCR looking at the mRNA 
expression of p57kip2 in those same biopsies -  CR mean level 18.3(3.4) versus PR/NR mean 
level 3.8 (3.6), p = 0.008 (units are relative expression compared with actin). These data will be 
firmed up by further analysis of RNA from snap frozen tissue from surgically excised samples 
on ovarian cancer patients (as under the current ethics application granted for this study).
We will also look at the expression of the protein levels o f p57kip2 in our cohort of ovarian 
cancer patients. Two previous studies have looked at p57kip2 in ovarian cancer and they 
comprised of 53 and 103^  ^ cases respectively. The former study also incorporated 
immunohistochemical measurement of cyclin E levels and there was some indication that this 
could be used as a predictive marker of chemo-responsiveness. Given the close relationship
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between cyclin E and p57kip2 (in S-phase progression) in cell cycle regulation these 2 
parameters will be looked at in conjunction with one another in our larger ovarian cancer patient 
cohort.
This part o f the MD will also involve some basic laboratory science which will be carried out 
within the FHMS, UniS. The effects o f silencing of the p57kip2 gene will be carried out by a 
process o f RNAi in a panel o f ovarian cancer cell lines and their sensitivity to cytotoxic drugs 
will examined. The effects of any changes in cell cycle regulation will also be examined by flow 
cytometric analysis for DNA content. This part o f the work will be supervised by Dr Coley, and 
the methods are already established in her laboratory.
SNK/PLK2
Snk/Plk2 has a role in development and is involved in cell cycle progression. The protein is 
required for centriole duplication near the G l-S  transition of the cell cycle. Recent studies 
carried out by Dr.Coley in conjunction with Dr.Crook has shown that with méthylation 
reversal/micro-array analysis (in the same way as for p57kip2), demonstrated in paclitaxel and 
platinum resistance in ovarian cancer is influenced by methylation-dependent transcriptional 
down-regulation o f the Polo-Like Kinase Snk/Plk2.^^ Importantly, these findings were also 
borne out by similar analysis of ovarian cancer tissue obtained from a cohort of 50 patients using 
real-time PCR analysis for levels of PLK2/snk mRNA.^^ The MD studies will involve the 
analysis of protein expression levels of PLK2/snk using immuno-histochemistry and levels of 
PLK2/snk mRNA in snap-frozen tissue samples in our ovarian cancer patient cohort.
BRK ( protein kinase-6f
Implicated in breast cancer where increases in BRK activity has been demonstrated in a large 
number of cases.M oreover, BRK has been described as a potential new target for cancer
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therapy. More recently BRK has been reported to be a potential new prognostic indicator in 
ovarian cancer and its expression is absent from normal surface ovarian epithelium.^ 
Interestingly, a recent collaboration with Dr.Harvey (Brunei University) has revealed that there 
is increase in BRK expression in paclitaxel-resistant ovarian cancer cell lines (derived by Helen 
Coley, unpublished data). These novel findings will be followed up in more laboratory studies at 
UniS -  particularly considering there is evidence for interaction o f BRK with the EGFR 
pathway. The PEOl panel o f drug resistant lines have been shown to overexpress EGFR'^and the 
effects of co-expression of BRK will be examined following treatment of cells with tyrosine 
kinase inhibitors e.g. gefitinib and lapatinib. Effects on signal transduction pathways will be 
examined using western-immunoblotting of treated cell lines.
Henatocvte Growth Factor Receptor -M ET
There is now a large body o f evidence that suggests MET/HGF signalling plays a significant role 
in tumour development and malignant progression. MET is a receptor tyrosine kinase and along 
with BRK (above) these are two relatively new areas for consideration in the aetiology of 
ovarian c a n c e r s . I n  the case of ovarian malignancies, it is reported that MET is often expressed 
in tumours where it has been associated with a poor prognosis. Moreover, there are a small 
number o f small-molecule inhibitors of MET available, all at preclinical stage of development. 
Hence, MET is under consideration as a potential prognostic indicator and as a new therapeutic 
target. Recent data obtained by Dr.Coley’s group has shown that the activated form o f MET -  
the phosphorylated form p-MET is markedly upregulated in carboplatin-resistant ovarian cancer 
cell lines. This is a novel finding and will be explored in the present proposal in two ways :
(1). MET and phosphorylated-MET will be assessed for their expression levels in our cohort of 
ovarian cancer patients using immunohistochemistry. There are reliable antibodies available for 
these procedures to be successfully carried out. To date, there are no studies that look at
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expression o f p-MET in ovarian cancer and those studies that have looked at MET expression 
alone have comprised 41 patients and 138 patients.
(2). A developmental small molecule inhibitor of MET (given under conditions o f an MTA by 
UCB Celltech) will be assessed in in-vitro experiments to look at the effects o f MET inhibition 
on reversing carboplatin resistance in drug resistant ovarian cancer cell lines. This will be done 
by carrying out the MTT assay for chemosensitivity assessment in the absence and presence of 
the MET inhibitor.
Time Scale
1 intend to devote between 3 -4 days a week towards this project. Any extra time (i.e.
evenings & weekends) will help in quicker completion of the project. Backdate from October 
2007 as 1 have already spent considerable time on sample collection, database collation and 
learning laboratory techniques e.g. cell culture.
Study Population
All consenting patients are registered under the care o f Dept, o f Gynaecological Oncology, St 
Luke’s Cancer Centre. A sub-set o f these patients (c. 20) will be assessed in a longitudinal 
manner over a period of time using sequential samples taken from interval debulking 
procedures. Tissue sections from this cohort will be examined for all parameters using the same 
immunohistochemistry procedures to be used for the entire sample cohort.ln addition, a sub-set 
of borderline or benign ovarian cyst samples (c. 10-20) will be assessed in the same way as for 
all the ovarian cancer samples.
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Sample Size
Statistical opinion was obtained from Dr D Lovell, Reader in Medical Statistics, PGMS, UniS, 
regarding the possible need for further patient recruitment, in order to increase the power of the 
study. Using the statistical software ‘Minitab’ it has been calculated that we would require 
between 109 and 244 patients in each group designated as ‘poor prognosis’ versus ‘good 
prognosis’ using a 2-sided test at p= 0.05. This will give a power calculation of 0.8-0.9.
Control selection
Age matched controls will be selected from the population base with presentations suspicious of 
ovarian malignancy. Patients with benign and borderline ovarian disease i.e. free of ovarian 
cancer will be analysed for the same markers to reflect the levels.
Data Analysis
All statistical evaluation of the immunohistochemistry (i.e. comparison of different patient 
cohorts such as pre-treated versus chemo-naive) and all other analyses will be carried out under 
the supervision of Dr David Lovell.
Work already carried ont
1. Ethical Approval
2. Database creation and updating
3. obtaining consent and sample collection-ongoing
4. Pilot study being written up
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Ethical Consent
Ethical approval has been already obtained from the Surrey Ethics Committee for analysis and 
processing o f stored paraffin blocks. Informed consent obtained from patients, following a 
discussion about the study and written detailed information material provided to them. It has 
been clearly mentioned in the patient information leaflet given to all the subjects, that tissue 
samples may be used for further analysis and tests if  necessary.
Database
I have created an ovarian cancer database from all patients treated for Ovarian Cancer at the 
Royal Surrey County Hospital since 2003 following their identification through the 
histopathology database. All relevant clinical details are being collected on the patients since 
presentation. These are in line with a similar database used for the SCOTROC trials which are 
large multi-centric studies into ovarian cancer treatments
Study Strengths
Large sample size and tissue availability.
Access to complete clinical data
Originality of scientific rationale due to novel drug resistant cell lines and robust microarray 
analysis for hypothesis development.
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APPENDIX D
IHC Reagents 
TRIS BUFFERED SALINE
Tris (Hydroxymethyl) Methylamine 6g
Sodium Chloride 81g
IN HCL 38ml
TWEEN 20 . 10ml
Adding distilled water to dissolve solids (approx 800mls). 10 litres volume is made up 
with distilled water.
ENDOGENOUS PEROXIDASE BLOCK
(obtainedfrom DAKO UK Ltd, E ly , UK)
Ready to use DAKOREAL HRP block solution (HP) 10 mis per 10 well tray.
HIGH pH  9 BUFFER
Concentrated solution-DAKO high pH target retrieval solution.Diluted 1:10 to 
use.SOmls of buffer in 450mls of distilled water.
CITRATE BUFFER pH  6.0
(Obtained from  Vector Laboratories Ltd, Peterborough, UK) Concentrated solution- 
Vector Labs- 15mls concentrate to 1600mls distilled water.
PROTEOLYTIC ENZYME
(Obtainedfrom Sigma Aldrich, Poole, UK) Enzyme Proteinase K 
360pl of proteinase K concentrate in 54mls of proteinase K buffer 
Place in coplin jar and heat in the oven to 37° C for 18 minutes.
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DAB
Diaminobenzidine tetrahydrochloride
This is supplied as part of the DAKO ChemMateTM Detection Kit in 2 bottles; 
substrate solution and chromogen. The working solution (CHROM) is used with 
780pl per individual well.
Disposal o f DAB
DAB is disposed by adding 5 parts o f 30% hydrogen peroxide to 1 part o f DAB to 
enable neutralisation and discarded down the sink followed by steady flow o f copious 
amounts of water.
Washing Buffers
Supplied ready to use. (BUT 1,2,3)
Water wash (H2 O) BUT 4. 20mls per 10 well tray.
Primary Anitbodies
Made up in ready to use antibody diluents (A Bl) at the rate of 8 drops per individual 
well (400pl).
Link Reagents
Part o f the detection kit; 8 drops per individual well (400pl)
Link, Biotinylated Secondary Antibodies -  (AB2) Bottle A in this kit 
Streptavidin Peroxidase- (HRP)- Bottle B  in this kit
HAEMATOXYLIN
{Ohtained jrom  Amber Scientific, Australia) Supplied ready to use. (HEMA) Filtered 
before use at the rate of lOmls per 10 well trays.
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Envision (ENV)
Part o f the envision detection kit, supplied by DAKO; 8 drops per individual well 
(400pl).
Primary Antibodies
1. Monoclonal Antibody to p57^'^^. ((500 pi purified anti-human mouse 
monoclonal IgG), (Clone 57P06), Imgenex®)+ 2079 pi PBS).
Product Code: IMG -80201, ohtained from  Cambridge Bioscience Ltd, Cambridge, 
UK
2. Mouse Monoclonal Antibody to Cyclin E. (500 pi purified anti-human mouse 
monoclonal IgGl (Clone HE 12), Abeam®) + pi PBS
Product Code: ab95I7, obtained from  Abeam, Cambridge,UK)
Counterstaining Solutions
1. Haematoxylin; (HEMA)
2. 100 % ethanol. (BDH, VWR UK)
3. 70 % ethanol.
4. Histo-clear®, (Fisher Scientific Ltd, Loughborough, UK)
5. Scotfs Tap Water: 1 in 10 dilution in distilled water of Surgipath® Scotfs Tap 
Water substitute, Peterborough, UK.
6. Acid alcohol: 10 ml concentrated HCl (specific gravity 1.16 g/ml -  approximately 
33 %) + 990 ml ethanol.
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